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Abstract 
Bovine respiratory disease (BRD) is the principal cause of morbidity and mortality among feedlot cattle.  
Mannheimia haemolytica is consistently implicated in this condition, but treatment options are 
diminishing with the rise of antimicrobial resistance and intensifying consumer pressure to reduce 
reliance on conventional therapies.  Thus, sustainable alternatives like vaccination are required.  In this 
study, the phenotypic and genotypic diversity of BRD pathogens were examined with the objective to 
identify vaccine targets using reverse vaccinology, an innovative approach to identify antigens via 
genomic sequence.  Preliminary surveillance confirmed M. haemolytica serotype 2 isolates were 
predominant in healthy animals (75.5%) while serotypes 1 (70.7%) and 6 (19.5%) were common in 
diseased animals.  Pathogens of BRD, including M. haemolytica, Pasteurella multocida and Histophilus 
somni were also isolated from North American BRD mortalities, and compared using pulsed-field gel 
electrophoresis and antimicrobial susceptibility.  Concurrently, polymerase chain reaction detection of 
bacterial and viral agents confirmed that M. haemolytica with bovine viral diarrhea virus were the most 
prevalent.  Whereas isolates from live cattle were found to have a relatively low level of resistance, 
several pathogens from the mortalities were found to contain integrative conjugative elements (ICE) 
conferring resistance to seven antimicrobial classes.  These ICEs were transferred via conjugation to 
other bacterial species, emphasizing the need for alternative antimicrobial therapies.  Collectively, data 
from these investigations informed the selection of 11 diverse M. haemolytica strains for whole genome 
sequencing and comparative analyses.  Several bacteriophage associated genes and CRISPR-Cas 
regulated gene expression systems were identified and are likely contributing to virulence in M. 
haemolytica.  Coding sequences across all genomes were screened using pan-genome analysis, 
identifying 291 candidates with cell-surface associated signatures.  Using a cell-free translation system 
and enzyme-linked immunosorbent assay the candidates were screened against serum from cattle 
challenged with serovar 1, 2 or 6 of M. haemolytica, and ranked according to immunogenicity.  The top 
five vaccine candidates included Ssa1, ComE, a solute binding protein, an outer membrane protein, and 
the periplasmic component of an ABC transporter.  With further characterization, these unique 
antigenic candidates could be developed into a vaccine to effectively reduce the dependence on 
antimicrobial therapies. 
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1 
1 Literature review 
1.1 Introduction to bovine respiratory disease and the North American cattle industry 
1.1.1 Occurrence and economics  
Bovine respiratory disease (BRD) is the most common and costly disease in North American 
feedlots. In spite of extensive study the condition is still  responsible for up to 80% of morbidities and 
50% of feedlot cattle mortalities (Sanderson et al., 2008), costing global beef production 3 billion USD$ 
annually (Watts and Sweeney, 2010), with 1 billion US$ of this loss occurring in the North America 
(Griffin, 2010; Taylor et al., 2010; Watts and Sweeney, 2010).  Economic losses occur primarily through 
reduced carcass yield, the cost of preventative treatment or direct therapy and death (Griffin, 2010; 
Loneragan et al., 2001).   
Bovine respiratory disease can refer to both acute and chronic infection of the respiratory tract 
of cattle.  When observed in newly received calves within 60 days of arrival at the feedlot (Gagea et al., 
2006), it is also called shipping fever.  Although variable in severity, typical symptoms include 
depression, anorexia, fever, increased heart rate and rhinitis resulting in mucosal discharge or a dry 
encrusted muzzle, lacrimation and cough (Zecchinon et al., 2005).  Early stages of infection show 
increased respiration followed by dyspnea (Zecchinon et al., 2005).  Although BRD can occur throughout 
the year, shipping fever varies seasonally, typically peaking in recently weaned calves in the fall or early 
winter (Dabo et al., 2007; Loneragan et al., 2001; Ribble et al., 1995). 
1.1.2 Bovine respiratory disease complex 
Bovine respiratory disease is a complex condition, comprised of multiple factors including host status, 
environmental influences and microbial agents.  Stressors associated with weaning, marketing and 
transport often lead to viral infections in predisposed or immune supressed animals.  These infections 
further compromise natural clearance mechanisms in the respiratory tract and lead to bacterial 
infection in the lower lungs. 
1.1.2.1 Viral agents of BRD 
1.1.2.1.1 Bovine herpes virus 1 (BHV-1) 
Multiple viral agents are associated with BRD, the most common being bovine herpes 1 (BHV-1), 
bovine viral diarrhoea virus (BVDV), bovine parainfluenza 3 virus (BPI3V) and bovine respiratory syncytial 
virus (BRSV).  Bovine herpes virus 1 is a double stranded DNA virus responsible for infectious bovine 
rhinotracheitis, characterized by acute inflammation with erosion and ulcers in the upper respiratory 
tract (Ellis, 2009; Yates, 1982).  First documented in Canada in the late 50’s, BHV-1 is now ubiquitous, 
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highly contagious and in addition to BRD can cause conjunctivitis, abortions, encephalitis and systemic 
infections.   
Infections with BHV-1 typically occurs 2-7 days post exposure and uncomplicated cases do not 
manifest as pneumonia unless accompanied by a secondary bacterial infection (Yates, 1982).  The 
presence of BHV-1 down regulates type 1 interferon and expression of both major histocompatibility 
complex (MHC) I  and MHC II molecules, reducing the ability of the immune system to clear infected 
cells and display antigens (Ellis, 2009).  BHV-1 can also enhance the pathogenesis of Mannheimia 
haemolytica during co-infection as the presence of the virus has been shown to increase the expression 
of the β2 integrin CD11a/CD18 on bovine leukocytes (Ellis, 2009), which target leukotoxin secreted by 
the bacterium (Lawrence et al., 2008).   
1.1.2.1.2 Bovine respiratory syncytial virus (BRSV) 
Bovine respiratory syncytial virus is a single stranded RNA virus that can induce 
bronchointerstitial pneumonia, independent of a secondary bacterial infection (Taylor et al., 2010; 
Valarcher and Taylor, 2007).  It can be responsible for 70% of respiratory disease in cattle with 
mortalities ranging from 2-20% (Gershwin, 2007).  Infection doesn’t advance beyond the respiratory 
epithelium (Ellis, 2009) and viral shedding begins 3 days after infection, with the vi0rus typically being 
undetectable after 10 days (Gershwin, 2007).  The development of effective vaccines against BRSV is a 
challenge as the virus induces cytokine responses that result in the activation of the humoral or 
antibody mediated immune responses.  This T helper 2 response targets extracellular parasites, bacteria, 
allergens and toxins rather than the desired T helper1 responses that activates the bactericidal activity 
of macrophage and is effective against intracellular pathogens, including viruses.  As seen with BHV-1, 
the presence of BRSV contributes to the pathological effects of M. haemolytica by enhancing secretion 
of proinflammatory cytokines (Ellis, 2009) and enhancing leukocyte recruitment.      
1.1.2.1.3 Bovine parainfluenza 3 virus (BPI3V) 
Bovine parainfluenza 3 virus is a single stranded RNA virus of the Paramyxoviridae family that is 
endemic to cattle worldwide.  Infection is common and generally subclinical (Ellis, 2009).  Typically with 
BRD, BPI3V infections are coupled with a secondary bacterial agent.  Acute infection results in loss of 
ciliated cells but also includes a marked reduction in the cytotoxic capabilities of infected macrophage 
(Ellis, 2010).  Current epidemiological data is largely absent for BPI3V as it is endemic and difficult to 
detect through isolation (Henrickson, 2003).  It is considered a catalyst to BRD and is already included in 
many BRD combination vaccines (Ellis, 2010).   
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1.1.2.1.4 Bovine viral diarrhoea virus (BVDV) 
Bovine viral diarrhoea virus is a single stranded, RNA pestivirus responsible for respiratory 
infection and reproductive disorders in cattle (Ridpath, 2010). Infection is spread largely by persistently 
infected animals, often as a result of infection of the fetus in early gestation (Lanyon et al., 2014).  
Bovine viral diarrhoea virus is divided into two genotypes, BVDV1 and BVDV2, based on antigenic and 
genetic differences and further into cytopathic and non-cytopathic (ncp) biotypes based on a strains 
ability to induce cell death in cell culture (Vilcek et al., 2005).  Cytopathogenicity is not necessarily an 
indicator of virulence as many disease-causing strains are ncp, with only the ncp biotype is able to 
establish persistent infection in the fetus (Peterhans et al., 2010).  Both acute and postnatal BVDV 
infections can contribute to BRD, mainly by facilitating secondary infection through immunosuppression 
and synergism with other pathogens (Ridpath, 2010).  Acute infection results in damage to the epithelial 
surface in respiratory tract and depletion of lymphoid tissues, however, 70-90% of cases of BVDV 
infection are considered subclinical (Ridpath, 2010). 
1.1.2.2 Bacterial agents of BRD 
1.1.2.2.1 Mycoplasma bovis 
Multiple bacteria can contribute to BRD, the most common being Mycoplasma bovis, Histophilus 
somni, Pasteurella multocida and Mannheimia haemolytica.  Mycoplasma bovis is a member of the class 
Mollicute and is associated with respiratory disease, mastitis, and arthritis in cattle (Caswell et al., 2010).  
First isolated in the USA in 1961, it is now detected worldwide (Horwood et al., 2014) with incidence 
ranging from complete absence to involvement in 90% of cases (Griffin, 2010). However, it is often 
found in the deep respiratory system and is typically only detected using serological methods (Griffin, 
2010).  Although acknowledged to contribute to acute respiratory disease it is often associated with 
chronic bronchopneumonia (Horwood et al., 2014), which is characterized by a caseonecrotic 
pneumonia that differs from the acute fibrinous pneumonia seen with classical BRD.  Much about the 
etiology of M. bovis virulence is unclear, as the mechanisms by which it causes tissue damage are not 
well understood (Caswell and Archambault, 2007).  Variable surface proteins (VSP) are the most 
characterized virulence factors, consisting of  a family of lipoproteins with varied expression profiles that 
allow this bacterium to both adhere to different cell types and to evade host antibody responses 
(Caswell and Archambault, 2007; Caswell et al., 2010).  Other virulence factors include production of a 
polysaccharide toxin, hydrogen peroxide, heat shock proteins and biofilms (Caswell and Archambault, 
2007).      
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1.1.2.2.2 Histophilus somni 
Histophilus somni is a bacterium from the Pasteurellaceae family, responsible for multiple 
syndromes in cattle including thromboembolic meningoencephalitis, arthritis, pneumonia and 
reproductive disorders (Corbeil, 2007; Pérez et al., 2010).  Pneumonic isolates are capable of inducing 
respiratory infection after intra-tracheal inoculation, but preputial and encephalitic strains fail to do so 
(Pérez et al., 2010).  A commensal in the respiratory and genital tract, H. somni survives better in the 
bronchoalveolar areas than in nasal mucosa (Pérez et al., 2010) and is capable of surviving phagocytosis 
by macrophage, persisting within polymorphonuclear leukocytes for brief periods of time (Corbeil, 
2007).  Histophilus somni pneumonia is typically fibrinous suppurative and contributes to 
bronchopneumonia through a chronic progression as it does not disseminate rapidly through the lung as 
does M. haemolytica (Pérez et al., 2010).  Multiple virulence factors have been identified in H. somni 
including lipooligosaccharide, immunoglobulin binding proteins, outer membrane and major outer 
membrane proteins and exopolysaccharides (Corbeil, 2007). 
1.1.2.2.3 Pasteurella multocida 
Pasteurella multocida is also a member of the Pasteurellaceae family and is associated with 
several diseases in animals including cholera in birds, atrophic rhinitis in swine, septicaemia in rabbits 
and pneumonia in cattle (Blackall and Miflin, 2000; Wilson and Ho, 2013).  Its role in bovine respiratory 
disease is more apparent with enzootic calf pneumonia in diary calves (Dabo et al., 2007), although the 
proportion of fatal BRD cases in feedlots associated with P. multocida is increasing (Welsh et al., 2004). 
Of the five serogroups and sixteen serovars described, serogroup A causes the majority of BRD 
infections with serotype A3 being isolated from approximately 35% of BRD cases in the USA (Wilson and 
Ho, 2013).  Pasteurella multocida may have synergism with Mycoplasma spp. as they are commonly 
isolated together (Dabo et al., 2007).  However, P. multocida has been shown to inhibit the growth of M. 
haemolytica (Wilson and Ho, 2013). Pasteurella multocida harbors multiple virulence factors including a 
lipopolysaccharide (LPS) that confers resistance to serum complement, a cytotoxin, iron acquisition 
proteins, and filamentous hemagglutinin (Wilson and Ho, 2013).    
1.1.2.2.4 Mannheimia haemolytica 
Mannheimia haemolytica, also a member of the Pasteurellaceae family, is the bacterium most 
commonly isolated from newly received calves suffering from pleuropneumonia (Confer, 2009). As a 
result, it is often considered the primary bacterial agent of BRD (Rice et al., 2008).  Of the 12 capsular 
serotypes identified, serotype 1 (S1) and serotype 6 (S6) are the most prevalent in BRD (Al-Ghamdi et al., 
2000; Rice et al., 2007).  Serotype 2 (S2) is found frequently as a commensal in the upper respiratory 
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tract of healthy animals (Klima et al., 2011), but is associated with respiratory disease and causes high 
mortality in wild and domestic sheep (Lawrence et al., 2010).  
Mannheimia haemolytica has several virulence factors.  These include multiple fimbriae, 
adhesions, outer membrane proteins (OmpA) and surface lipoproteins (Lpp1) that assist in adherence 
and colonization (Confer, 2009).  Neuraminidase and O-sialoglycoprotein endopeptidase also support 
attachment, modifying the cell surface and reducing respiratory mucosal viscosity and facilitating access 
to host epithelial cells (Griffin, 2010).  Other factors like transferrin-binding proteins assist in scavenging 
iron for bacterial growth.  The capsular polysaccharide of M. haemolytica can also protect against 
phagocytosis (Rice et al., 2007). 
Lipopolysaccharide is a major component of the Gram-negative cell wall, contributing to the 
structural integrity of bacteria, but it is also an important virulence factor in M. haemolytica.  As an 
endotoxin, LPS can induce inflammatory cytokine responses and expression of the β2 integrin leukotoxin 
receptor on bovine leukocytes (Gioia et al., 2006).  In addition, it forms complexes with leukotoxin that 
may help enhance its cytotoxicity (Rice et al., 2007). Mannheimia haemolytica serotypes are virtually 
clonal for LPS, with most of the minor variation occurring in the lipid A and oligosaccharide region 
(Davies and Donachie, 1996).    
Leukotoxin (Lkt) is the primary virulence factor of M. haemolytica (Dassanayake et al., 2009).  It 
is a pore forming cytotoxin of the RTX family that has affinity for the CD18 β subunit of β2 integrins on 
bovine leukocytes (Griffin, 2010).  Actively secreted by all serotypes during log phase growth (Rice et al., 
2007), Lkt activity is responsible for the lung lesions observed during M. haemolytica infection (Fedorova 
and Highlander, 1997; Tatum et al., 1998).  Sequence diversity occurs between serovars, with S1 and S6 
Lkts similar and S2 Lkts more variable (Davies et al., 2001; Rice et al., 2007).  Low concentrations of Lkt 
enhance the inflammatory response, inducing cells to release free radicals, cellular proteases and 
proinflammatory cytokines (Confer, 2009; Griffin, 2010; Rice et al., 2007).  At high concentrations Lkt, 
impairs leukocyte function by inducing osmotic swelling, pore formation and necrosis (Confer, 2009; 
Griffin, 2010).  Mannheimia haemolytica pneumonia is characterized by acute cranioventral fibrinous to 
fibrinopurulent pleuropneumonia (Confer, 2009), with lesions that are lobar and anteroventrally 
distributed (Zecchinon et al., 2005) with neutrophil and fibrin accumulation in the lungs (Rice et al., 
2007).   
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1.2 Management of BRD 
1.2.1 Preconditioning 
Current management strategies for BRD consist of preconditioning programs, vaccination and 
antimicrobial therapies.  Preconditioning is used to prepare calves to enter the feedlot and can include 
castration, dehorning, weaning, administration of antimicrobials, vaccination, and adaptation to dry 
feed and water troughs prior to transport (Schumacher et al., 2012).  Preconditioned calves often have 
better performance with lower morbidity and mortality than those that have been weaned and 
immediately shipped to a feedlot.  Preconditioned calves can be worth over $7/cwt US$ more than 
unconditioned calves with an added $2.37/cwt US$ if the health program is third party certified 
(Schumacher et al., 2012).  
1.2.2 Vaccination 
Vaccination is an important tool in the management and prevention of BRD.  The majority of 
cattle entering feedlots receive viral vaccination.  In the USA a reported 95.1% of calves are vaccinated 
against BVDV, 93.2% against BHV-1, 61.4% against BRSV and 55.1% against BPI3V (Theurer et al., 2015).   
Despite a current lack of data to support the effectiveness of these products in a commercial settings, 
there is a consensus among most veterinarians that vaccination at arrival against BHV-1, BVDV  BRSV 
and BPI3V (Theurer et al., 2015).   
There are three major types of vaccines: inactivated, modified-live and subunit vaccines 
containing purified components of the infectious agent (Bambini and Rappuoli, 2009).  Viral vaccines for 
BRD are usually modified-live vaccines (MLV) or contain inactivated virus antigens.  Modified-live 
vaccines typically induce cell-mediated and humoral responses by activating T lymphocytes, generating 
an adequate immune response with one vaccination, while inactivated vaccines stimulate the humoral 
response to encourage B cell activity and antibody generation and thus require a booster (Theurer et al., 
2015).  There are many viral vaccines available either targeting single, multiple or all viral agents 
associated with BRD (Bowland and Shewen, 2000).    
There are multiple commercial vaccines available against M. haemolytica, P. multocida, H. somni 
and M. bovis (Bowland and Shewen, 2000).  These typically contain bacterins, or killed whole bacterium, 
with M. haemolytica vaccines typically supplemented with Lkt.  Meta-analysis of data published 
surrounding the effectiveness of these vaccines indicates that there may be some benefit for vaccination 
against M. haemolytica and P. multocida, but at this stage there is no solid evidence supporting 
vaccination against H. somni (Larson and Step, 2012).  However, the outcomes of these studies vary 
greatly, some reducing BRD morbidity, some showing no significant difference from controls, and others 
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potentially increasing the risk of morbidity (Larson and Step, 2012).  Although natural M. bovis infection 
has been shown to elicit a robust immune response and both commercial and autogenous vaccines have 
been produced, there is also no evidence of their efficacy under field conditions (Caswell et al., 2010).  
Vaccination against bacterial agents in feedlots is less frequent than against viruses with approximately 
66% of feedlots in the USA vaccinating against H. somni and M. haemolytica and 21.8% vaccinating 
against M. bovis (Neibergs et al., 2014). 
1.2.3 Antimicrobial Use 
Antimicrobials are a primary tool used against bacterial pneumonia in feedlots, either as 
preventatives or direct therapies, being administered in-feed or through injection.  Shown to reduce 
BRD morbidity by 50% and mortality by 30-50% (Miles and Rogers, 2014), 20-50% of calves receive 
injectable antibiotics upon arrival at the feedlot (Checkley et al., 2010; Hilton, 2014).  With over 80% of 
the antimicrobials licenced for use in cattle being used to control BRD (Bowland and Shewen, 2000), it is 
clear these therapies must be efficacious  if  the current intensive feedlot beef production systems in 
North America are to remain viable. 
Unfortunately, even with the use of antibiotics, best management practices and vaccination 
programs, the prevalence of BRD has not fallen (Neibergs et al., 2014), but appears to actually be 
increasing (Hilton, 2014; Miles and Rogers, 2014). A likely contributor to this is the recent emergence of 
pan-antibiotic resistant M. haemolytica (Eidam et al., 2015; Lubbers and Hanzlicek, 2013) and P. 
multocida in beef cattle (Michael et al., 2012).  Some of these isolates have been shown to harbour self-
transmissible conjugative elements with extended multidrug resistance gene arrays (Michael et al., 
2012) conferring resistance to the entire suite of drug therapies currently used to treat BRD, with the 
exception to ceftiofur (Lubbers and Hanzlicek, 2013; Michael et al., 2012; Miles and Rogers, 2014).  The 
development of antimicrobial resistance on this scale is not only of concern for maintaining current 
therapies, but also poses a potential hazard to human health if these elements transfer into zoonotic 
pathogens. 
With the extent of multidrug resistance occurring in BRD pathogens, new solutions to prevent 
and treat bacterial agents will need to be found either through altering management practices, the 
development of new drugs and/or the design of more effective vaccines.  The development of 
antibiotics has declined substantially over the last thirty years (Prescott, 2014) with only three new 
drugs approved by the USDA between 2005 and 2009 (May, 2014).  The current global market for 
antibiotics is low and with no incentive for development many pharmaceutical companies have shut 
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down pipelines and bowed out of antimicrobial production entirely (May, 2014), despite there being   
few alternatives to existing antibiotics.    
1.3 Using the Genome for Vaccine design 
While drug development has stalled, vaccine design has been transformed by advancements in genomic 
technologies.  Whole genome sequencing and bioinformatics have allowed for rapid identification of 
novel antigen candidates previously unidentifiable by convention methods (Figure 1.1).  This includes 
antigens that are less abundant, not expressed in vitro or not very immunogenic during infection 
(Bertholet et al., 2014). Genome mining is a step up from the classical approach of isolation, infection 
and injection with the causative agent as it has the potential to identify all of the proteins produced by 
an organism, including their cellular location and predicted function (Rappuoli, 2001). By combining in 
silico analysis of genome sequences with recombinant DNA technologies and structural and function 
genomics, targeted vaccines can be rapidly developed.  A good example of this approach was witnessed 
with the emergence of severe acute respiratory syndrome (SARS) in 2003, where sequencing and 
bioinformatic analysis of the responsible coronavirus identified a protective vaccine antigen candidate in 
less than a month (Bambini and Rappuoli, 2009).   
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Figure 1.1 Reverse vaccinology vs conventional vaccine design. Reproduced with permission from 
Rappuoli, 2000 © Elsevier. 
 
1.3.1 Reverse vaccinology 
The strategy to design vaccines starting from the genome rather than the organism, termed 
reverse vaccinology (RV), was first applied to Neisseria meningitidis serogroup B (MenB) (Pizza et al., 
2000).  The causative agent of meningitis and severe sepsis, N. meningitidis is a challenge for 
conventional vaccine design as it displays strain variation and the capsular polysaccharide is both poorly 
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immunogenic and can induce autoimmunity (Rappuoli, 2001).  To examine potential candidate proteins 
for vaccine use, the whole genome of a single N. meningitidis strain was sequenced and the coding 
genes examined for protein motifs that were exported to the cell surface, or embedded within the lipid 
bilayer (Pizza et al., 2000).  A total of 600 candidate proteins were identified with 350 being expressed in 
E. coli and used to immunize mice (Pizza et al., 2000). The serum generated was used to identify surface 
expressed proteins that were conserved across strains and induced a bactericidal response (Pizza et al., 
2000).  The resulting five antigen candidates were combined to produce the multicomponent 
meningococcal serogroup B vaccine called 4CMenB (Bexsero®) which  has now completed clinical trials 
(Donati and Rappuoli, 2013) and is approved for use in over 30 countries (Doolan et al., 2014) including 
the EU, USA and Canada (Medini et al., 2015).   
Because the incidence of invasive meningococcal disease (IMD) is low, there is little available 
data to support the efficacy of the 4CMenB vaccine (Dwilow and Fanella, 2015).  However, several 
clinical studies have examined its immunogenicity through surrogate markers, including serum 
bactericidal activity assays and a novel Meningococcal Antigen Typing System, all of which support the 
vaccine’s effectiveness (Dwilow and Fanella, 2015; Gorringe and Pajón, 2012; Medini et al., 2015).  
Current measures used to determine the cost-effectiveness of its inclusion in national vaccine programs 
is hindering the adoption of 4CMenB (Dwilow and Fanella, 2015) with authorities in Canada 
recommending that only high risk individuals such as those that have contacted IMD-infected patients 
be vaccinated.  This policy may change if the vaccine was demonstrated to have an effect on carriage or 
herd immunity, information that only could be garnered after its widespread use (Dwilow and Fanella, 
2015).    
Since its first application, reverse vaccinology has been used to identify vaccine protein antigens 
against several important pathogens including Streptococcus pneumoniae, Chlamydia pneumoniae, 
Bacillus anthracis, Porphyromonas gingivalis, Mycobacterium tuberculosis, Helicobacter pylori, 
Streptococcus agalactiae, E. coli, Leishmania major and Leishmania infantum (Bambini and Rappuoli, 
2009; Donati and Rappuoli, 2013).  Not previously applied to agents contributing to BRD, the RV 
approach has the potential to identify novel antigens candidates that could be used to formulate 
protective vaccines against respiratory pathogens in cattle.  
1.4 Comparative genomics 
The advent of comparative genomics has improved upon the original RV approach.  The genetic 
diversity of strains within a species can be substantial, due largely to horizontal gene transfer by mobile 
genetic elements (Bambini and Rappuoli, 2009). To develop a vaccine capable of providing broad 
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coverage, an understanding of the population structure of a pathogen is required (Donati and Rappuoli, 
2013).  Sequence comparison of pathogenic and non-pathogenic strains can assist in identifying those 
factors that contribute to virulence and enable the design of vaccines that target those strains that 
specifically cause disease.   
1.4.1 Pan and core genome 
Comparative genomics is employed to examine a range of features including overall sequence 
similarity, gene arrangement and gene transfer, but delineation of the pan and core genomes are key to 
using this approach in vaccine design.  The pan-genome was first defined by Tettelin et al. (2005) as the 
global compliment of genes in a species that codes for the complete repertoire of proteins it can 
produce.  Once identified, candidate proteins in the pan-genome can be analyzed using bioinformatic 
approaches for markers that export them to the cell surface, and are thus most likely to serve as targets 
for the host immune system.  The core genome consists of the set of genes shared by all strains, and 
likely encodes for functions related to basic biology and phenotype and can provide a great deal of 
information about the evolution and lifestyle of a bacterial species (Donati and Rappuoli, 2013).  
Comparison of the core and pan-genome identifies vaccine candidates that can be used as antigens to 
provide protection against all strains within a species or against a subset of particularly virulent strains.  
Determining if the pan-genome is open or closed allows for evaluation of the minimal number of strains 
required to reasonably represent the species (Tettelin et al., 2008).  An open pan-genome occurs where 
the addition of new strains to the dataset will contribute new genes to the database.  A closed pan-
genome occurs when the addition of new strains results in the number of strain specific genes 
converging at zero, at which point the dataset encompasses the number of genome sequences required 
to sufficiently characterize the species (Medini et al., 2005).    
1.4.2 Mobile genetic elements  
Approximately three quarters of all genes in bacterial genomes have been acquired through 
horizontal gene transfer of mobile genetic elements (MGE) (Juhas, 2015).  These include plasmids, 
phage, genomic islands and genomic modules that transmit horizontally through conjugation, 
transduction or transformation (Wozniak and Waldor, 2010).  Mobile genetic elements, including 
bacteriophage and integrative conjugative elements, can promote pathogenesis through the provision 
of virulence factors, so identification of these elements within genomes is important to understand the 
mechanisms of virulence and to identify targets for vaccine design in pathogenic strains.   
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1.4.2.1 Bacteriophage 
Phages are the most abundant organisms on the planet, and those that infect bacteria and 
integrate into  the host chromosome can play key roles in diversification and the evolution of pathogens 
(Boyd and Brüssow, 2002).  The horizontal transfer and acquisition of virulence factors through 
prophage is a major driving force in the emergence of pathogenic isolates not only through the provision 
of toxins, but also through factors that regulate virulence gene expression, adhesion, colonization and 
invasion (Wagner and Waldor, 2002).  Phage-derived virulence factors are utilized by many important 
pathogens including E. coli, Salmonella spp., Vibrio cholera, Pseudomonas aeruginosa, Listeria spp., 
Streptococcus spp. and Staphylococcus spp. (Boyd and Brüssow, 2002), and are frequently responsible 
for the zoonotic phenotype of these bacteria (Penades et al., 2015).   
1.4.2.2 CRISPR-Cas systems 
To protect against bacteriophage predation many bacterial species employ a CRISPR-Cas 
(clustered regularly interspaced short palindromic repeats/CRSIPR associated proteins) system.  An 
adaptive and inheritable prokaryotic immune system, CRISPR-Cas is widespread, present in 40-70 % of 
bacteria (Deveau et al., 2010) and 90% of archaea (Sorek et al., 2008).  Although not likely to be a direct 
target for vaccine development, CRISPR-Cas systems influence virulence by preventing bacteriophage 
from integrating into the genome and by regulating prophage and gene expression within the host.   
CRISPRs are the most abundant family of noncoding sequences in prokaryotic genomes 
(Szczepankowska, 2012) and although first described in 1987 (Ishino et al.), it wasn’t until 2005 that 
CRISPR-Cas systems were proposed to mediate immunity against extrachromosomal agents (Sorek et al., 
2008) such as  phages and plasmids (Makarova et al., 2011). Three major types and ten subtypes of 
CRISPR-Cas systems have been identified (Makarova et al., 2011), all consisting of a CRISPR arrays next 
to a series of 4 to 20 CRISPR associated (Cas) genes.  The CRISPR array consists of a leader sequence (20-
534 bp) followed by numerous conserved direct repeats (21-48 bp) that are interspersed with variable 
sequences called spacers (21-72 bp) (Sampson and Weiss, 2013; Szczepankowska, 2012).  Spacers are 
typically derived from foreign genetic material within phage or plasmids and can number in the 
hundreds within an array (Barrangou and Horvath, 2012; Horvath and Barrangou, 2010; 
Szczepankowska, 2012).  Approximately 50% of CRISPR containing genomes have more than one CRISPR 
locus with additional arrays often lacking Cas genes in their proximity (Swarts et al., 2012).  
The CRISPR-Cas mechanism employs spacer acquisition in a process known as adaptation.   In 
the type I and II systems, adaptation relies on CRISPR-Cas machinery to identify, bind and cleave 
invading nucleic acids that are incorporated as spacers into the CRISPR array (Makarova et al., 2011).  
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The selection of proto-spacers (spacer precursors) from the invading nucleic acid is dependent on the 
presence of a proto-spacer-associated motif (PAM), a short nucleic acid sequence located either 
downstream or upstream of the proto-spacer.  Proto-spacer-associated motifs are not incorporated into 
the spacer itself, enabling the CRISPR-Cas system to distinguish between target proto-spacer and the 
host CRISPR array (Szczepankowska, 2012).  Spacers are typically inserted sequentially, adjacent to the 
leader of the array, but occasionally spacer acquisition has been shown to occur internally within the 
array (Westra and Brouns, 2012).  
The mechanism for CRISPR interference first requires transcription and processing of the array 
into a long precursor CRISPR RNA or pre-crRNA (Maraffini and Sontheimer 2010; Jore et al., 2011).  The 
pre-crRNA is cleaved within the repeat sequences by a complex of Cas proteins called Cascade (CRISPR-
associated complex for antiviral defense) to produce small crRNA that are further trimmed to generate 
mature crRNA (Maraffini and Sontheimer 2010; Jore et al., 2011).  The complex of mature crRNA and 
Cascade, together with a Cas protein with nuclease activity, targets and cleaves invading viral or plasmid 
DNA with complementarity to the spacer sequence (Jore et al., 2011; Marraffini and Sontheimer, 2010).         
The CRISPR-Cas system is widely recognized as a defense mechanism against foreign invasive 
plasmids and phage, but its role in gene expression and regulation of cellular processes including biofilm 
formation, lysogenization, spore formation, replicon maintenance and segregation, and DNA repair-
recombination are also being examined (Szczepankowska, 2012).  CRISPR spacers have been found to 
target chromosomal genes, and are thought to regulate transcription of host factors and in some cases 
influence virulence.  A recent example has been described for Francisella novicida, a bacterium 
responsible for tularemia, where CRISPR down regulated an immunostimulatory bacterial lipoprotein 
(BLP) enabling the bacterium to avoid immune detection in the host (Sampson and Weiss, 2013).  
Although CRISPR itself is not a target for vaccine design, examination of those genes it targets can point 
towards candidates that may be central to virulence in pathogenic bacteria.  
1.4.2.3 Integrative Conjugative Elements 
Arguably, one of the most important families of mobile genetic elements in bacteria are 
integrative conjugative elements (ICEs).  These elements are unique in that they are self-transmissible, 
encoding all of the mechanics required for integration, excision and transfer (Wozniak and Waldor, 
2010).  Acquisition of ICEs allows bacteria to rapidly adapt to changing environmental conditions and 
colonize new niches (Burrus and Waldor, 2004) by mediating the transfer of accessory genes that alter 
phenotype, including antimicrobial resistance and virulence (Wozniak and Waldor, 2010).  As a result, 
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they are key contributors to bacterial pathogenicity and the shaping of bacterial genomes (Burrus and 
Waldor, 2004).   
In the past ICEs were described as transposons, conjugative transposons, genomic islands and 
plasmids as they share characteristics in common with all of these elements (Seth-Smith et al., 2012).  As 
the key components of ICEs are often found independently as components of other MGE, it can be 
difficult to identify them through bioinformatic approaches (Wozniak and Waldor, 2010).  For example, 
T4SS can be found on the chromosome of bacteria not involved in conjugation but associated with 
protein transport.  And, integrases are present in both transposons and prophage.  However, with the 
continuing accumulation of whole genome sequencing data, it is now clear that ICEs are far more 
abundant than first anticipated (Seth-Smith and Croucher, 2009) and more prevalent than conjugative 
plasmids (Guglielmini et al., 2011).   
All ICEs contain three modules ensuring their maintenance, dissemination and regulation (Burrus 
and Waldor, 2004).  Maintenance modules contain an integrase that promotes integration, the majority 
belonging to the tyrosine recombinase family, although serine recombinases and DD[E/D]-transposases 
have also been described (Wozniak and Waldor, 2010).  Excision requires the integrase gene, but also a 
recombination directionality factor (RDF) that is used to bias activity towards excision over integration 
(Wozniak and Waldor, 2010).  Integrative conjugative elements can be lost if excision occurs during cell 
division or the element doesn’t properly integrate back into the host after replication.  As a result, some 
ICEs also encode mechanisms to ensure their stability, as is the case with toxin-antitoxin systems.     
Toxin-antitoxin systems are small genetic modules that consist of a stable toxin and a liable, 
neutralizing antitoxin as its counterpart.  When co-expressed, these form a stable complex which 
inhibits the toxin’s activity.  However, if this co-expression stops either through element loss or arrest of 
expression, the unstable antitoxin degrades while the toxin persists, resulting in cell death.  Toxin-
antitoxin systems are widespread in prokaryotes, and employed by MGE including plasmids, phage or 
genomic islands to ensure their maintenance.  They also function within the bacterial genome to 
prevent the spread of phage through a mechanism called abortive infection (Yamaguchi et al., 2011).   
During phage infection host protein expression can be slowed or arrested.  During this time, if toxin-
antitoxin systems are active on the host chromosome, the antitoxin will degrade without replacement 
and the toxin will kill the infected cell.  In this manner, the spread of the phage throughout the bacterial 
population is prevented. 
Integrative conjugative elements disseminate through conjugation, using a model similar to that 
proposed for plasmids.  A relaxase is required to nick DNA at the origin of transfer and to interact with 
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the coupling protein responsible for targeting the nucleoprotein complex to the mating pore for transfer 
(Wozniak and Waldor, 2010).  A single stranded copy of the ICE is transferred into the recipient where it 
becomes a template for polymerase to rebuild the double stranded circular element (Wozniak and 
Waldor, 2010).  However, some ICEs have been shown to undergo rolling circle replication and be 
transferred as double stranded DNA, while others are capable of autonomous replication (Leaves et al., 
2000; Lee et al., 2010a; Lee et al., 2010b; Wozniak and Waldor, 2010).   
To transfer ICE DNA, the majority of Gram-negative bacteria employ a conjugation apparatus 
similar to the type 4 secretion system (Wozniak and Waldor, 2010).  In Proteobacteria this consists of an 
ATPase and mating pair formation genes, which code for a membrane spanning channel and an 
extracellular pilus that attaches to the recipient cell (Guglielmini et al., 2012).  Based on recent 
phylogenetic analysis, T4SS in Proteobacteria can be characterized into one of four groups (Guglielmini 
et al., 2012) MPFT (modeled from the T-DNA conjugation system of A. tumefaciens plasmid Ti), MPFF 
(modeled from the plasmid F), MPFI (modeled from the IncI plasmid R64), and MPFG (modeled from 
ICEHIN1056) (Smillie et al., 2010).  Less is understood about the conjugation systems used to transfer 
ICEs in Gram-positive bacteria although it has been shown that the T4SS is not needed to facilitate ICE 
transfer in Streptomyces ambofaciens (Wozniak and Waldor, 2010). The transfer system of ICEs can be 
hijacked by other MGE (Burrus and Waldor, 2004) and as a result ICEs can play a secondary role in 
facilitating the spread of virulence factors carried on transposons, genomic islands and plasmids.   
Many ICEs are not host specific and can be transferred to a wide range of species (Garriss et al., 
2009), but the factors determining host range have not been explored in detail (Wozniak and Waldor, 
2010).  Like other mobile genetic elements, ICEs have been identified that use entry exclusion systems 
to prevent host cells from obtaining other closely related elements (Wozniak et al., 2009).  Integrative 
conjugative element regulation mechanisms are also largely undefined but those that have been 
characterized are diverse (Burrus and Waldor, 2004).  Some ICEs are regulated through a repressor 
similar to that found in lambda phage.  For these ICEs, DNA-damaging agents that induce an SOS-like 
response, such as exposure to mitomycin C and quinolones will increase their transfer rates (Wozniak 
and Waldor, 2010).  Other ICEs appear to be stimulated by sub-inhibitory concentrations of tetracycline 
(Bellanger et al., 2014; Burrus and Waldor, 2004) or through quorum sensing (Wozniak and Waldor, 
2010).  
In addition to the functional modules necessary for ICE mobility and persistence, many of these 
elements carry accessory cassettes that encode virulence factors including genes that can biosynthesize 
antimicrobials, degrade toxic aromatics and confer resistance to antimicrobials, heavy metals or phage 
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(Burrus and Waldor, 2004).  Integrative conjugative elements have also been found that enhance 
colonization, fix nitrogen and promote biofilm formation (Wozniak and Waldor, 2010).  Accumulation of 
accessory cassettes in ICEs can be mediated by transposons or by homologous recombination (Wozniak 
and Waldor, 2010). 
Integrative conjugative elements have been identified in M. haemolytica, P. multocida (Eidam et 
al., 2015; Michael et al., 2012) and H. somni (as described in Chapter 2) and in addition to having 
important implications for antimicrobial resistance (AMR), genes coding for the extracellular 
components forming the pilus of the T4SS are possible targets for vaccine design as they are linked to 
enhanced virulence and are readily accessible by the host immune system.  As more ICEs are identified, 
classification schemes are being designed with sequence similarities in integrase genes, integration site 
and organization of T4SS arrays, proposed as a means of describing element relationship (Guglielmini et 
al., 2011).  A common identification scheme will likely assist in characterizing the movement of genes 
coding for antibiotic resistance among bacterial communities.  
1.5 Vaccines and Evaluation of Vaccine Candidates 
Vaccination is one of the most efficient and cost-effective approaches to controlling infectious 
diseases (Doolan et al., 2014; Rappuoli and Aderem, 2011).  Although RV and advancements in “omics” 
technologies have revolutionized vaccine design, evaluations of the specific immune responses induced 
by antigens is still required to determine the efficacy of vaccines.  A step in this process is determining 
which arm of the adaptive immune responds to the selected antigen.  
1.5.1 The two arms of the immune response 
 The immune system can be divided into two main subsystems, the innate and the adaptive.  
Detailed reviews of each system can be found elsewhere (Kennedy and Poland, 2011; Luckheeram et al., 
2012; McVey and Shi, 2010), so the main cellular components are only briefly described here and 
presented in Figure 1.2.  The innate immune system is the first line of defence against pathogenic agents 
and encompasses multiple protective measures including anatomical and physiological barriers, the 
compliment pathway, and the activities of mononuclear phagocytes and granulocytic cells that induce 
inflammatory responses.  Innate responses are not specific to a particular agent, but are induced by 
conserved molecular patterns found on all microorganisms and as a result it can act rapidly.  The innate 
system may eradicate pathogens independently or it may stimulate the adaptive system to become 
active in controlling the infection.  
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Figure 1.2 Cells of the innate and adaptive immune systems.  The innate system is comprised of multiple 
anatomical and physiological barriers and compliment (not shown) along with numerous cells whose 
function is to respond quickly to infection, induce inflammation and/or activate adaptive immunity. The 
adaptive system is divided into two branches, humoral and cell-mediated.  The humoral system is 
characterized by antibody production by B cells. Cell-mediated immunity encompasses T cell activities 
that regulate innate and humoral responses or that function against cancers and intracellular pathogens.  
T cells differentiate from CD4+ or CD8+ cells upon exposure to antigens displayed on MHC II or MHC I 
molecules, respectively, of antigen presenting cells (APC) .  Differentiation of T cell is driven by cytokines 
resulting in T cell subset each producing its own unique effector cytokine profile.  Cross-talk through 
cytokine signalling occurs between the innate and adaptive system and within the adaptive system. 
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The adaptive immune system targets specific antigens and thus takes time to develop.  
However, it exhibits immunological memory and will respond more rapidly upon subsequent exposure.  
The adaptive immune system has two arms: the humoral immune response and cell-mediated 
immunity.  Humoral immunity typically acts against extracellular pathogenic agents and includes all 
activities related to antibody production and is largely mediated by B lymphocytes and T helper 2 cells.  
Cell-mediated immunity does not involve the generation of antibodies, but employs phagocytes and 
cytotoxic T lymphocytes, which primarily target intracellular pathogens. 
T cells facilitate cell-mediated immunity through regulating immune responses or by directly 
attacking infected cells.  T cells are classified based on their function and surface markers, with the 
majority being classified into two main types; CD4 and CD8, based on the types of glycoproteins 
expressed on their surfaces.  The CD8+ T cells are called cytotoxic T lymphocytes; their role is to destroy 
any cell that threatens host integrity.  They do so by recognizing antigens displayed by major 
histocompatibility complex (MHC) I molecules on host cells that are infected with viruses or bacteria.  T 
cells that express CD4+ are called T helper lymphocytes and recognize antigens displayed on the MHC II 
molecules of antigen presenting cells.  T helper cells are responsible for modulating both cell mediated 
and humoral responses through the production of signaling molecules called cytokines.    
There are multiple subsets of T helper cells, each secreting a specific cytokine profile.  These are 
described in greater detail elsewhere (Luckheeram et al., 2012), with the primary profiles summarized 
here.  T helper 1 (TH1) cells promote cell-mediated responses that eliminate intracellular pathogens and 
are most commonly associated with secretion of interferon ɣ (INFɣ) and interleukin 2 (IL-2)(Raphael et 
al., 2014).  T helper 2 (TH2) cells promote humoral responses that target extracellular parasites and play 
a major role in asthma and allergic reactions.  Key effector cytokines for TH2 responses include IL-4, IL-5, 
and IL-13 (Raphael et al., 2014).  T helper 17 (TH17) cells are responsible for enhancing anti-microbial 
responses at epithelial and mucosal barriers and produce the effector cytokines IL-17, IL-22, IL-21, IL-25 
and IL-26.  T helper 22 (TH22) cells are associated immunopathology of skin diseases and produce 
predominantly IL-22 (Raphael et al., 2014).  T helper 9 (TH9) cells produce IL-9, IL-10 and IL-21 and are 
involved in promoting mucus production and activating mast cells and eosinophils (Kaplan et al., 2015; 
Raphael et al., 2014). Regulatory T cells (Treg) are immune regulators that play an important role in 
immunological tolerance, and are defined by their expression of FoxP3 producing the main effector 
cytokines IL-10 and transforming growth factor beta (TGF-β).  Lastly, follicular helper T cells (TFH) reside 
in the B cell follicles and play a role in humoral immunity through interactions with B-lymphocytes and 
primarily produce IL-21(Luckheeram et al., 2012; Zhu and Paul, 2010).  
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1.5.2 Measuring Immune Responses 
Multiple assays exist to measure both humoral and cell-mediated responses to antigens.  To 
measure the magnitude of humoral responses, ELISA is commonly employed to determine both overall 
antibody titre, but also to examine isotypes of the sera generated, thus the class or subclass of antibody 
produced.  There are several assays that can be employed to measure cellular immunity, or T cell 
responses.  Older methods include delayed type hypersensitivity (DTH), chromium release assays, and 
limiting dilution assays (LDA) (Hobeika et al., 2005).  Newer assays include intracellular cytokine assays, 
peptide: MHC tetramers and ELISPOT (Hobeika et al., 2005). Conventional assessment of immune 
responses has typically focused on the frequency, magnitude or quantity of the immune response, 
although quality of response is also a critical component (Doolan et al., 2014). Quality of antibody 
responses can be assessed be examining affinity, avidity, diversity and biological function and subclass, 
while quality in T cell response can be accessed via cell phenotype, differentiation state, cytokine 
profiles, T-cell receptor avidity and diversity (Doolan et al., 2014).   
Almost all of the currently licenced vaccines rely on the induction of functional antibodies 
against the target pathogen (Doolan et al., 2014).  There are no vaccines that are designed to specifically 
induce cellular immune responses (Doolan et al., 2014), although these responses play a critical role in 
the targeting and destruction of pathogen-infected cells or through the activation of i B cell expansion 
and differentiation, class switching, and affinity maturation of the responses (Sette and Rappuoli, 2010).  
Although RV can be used as a means to enhance the rate of vaccine design, one of the most challenging 
steps is to evaluate not only the response to antigen exposure, but the quality of that response and how 
it translates into vaccine functionality.  Further, the identification of suitable antigens is only one step in 
vaccine design while vaccine development requires investments in vaccine formulation, proof of 
principal challenge studies, large scale clinical trials, patenting, licencing   regulatory approval, and 
marketing.   
1.6 Conclusion 
Bovine respiratory disease is one of the principal health concerns for the North American beef 
production industry.  Understanding the epidemiological aspect of viral and bacterial agents 
contributing to this condition is necessary to highlight strategies for its management.  As a major 
bacterial agent of BRD, M. haemolytica is of particular interest for study.  Comparative analysis between 
whole genome sequences of pathogenic and commensal serovars of this bacterium allows for the 
examination of virulence mechanisms that have not been phenotypically defined.  This analysis can also 
be applied to identify novel antigens for vaccine development that were previously unknown in this 
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species.  Antimicrobial are the primary means for prevention and treatment of bacterial agents involved 
in BRD in feedlot cattle and the development of widespread antimicrobial resistance could prove to be 
economically devastating to the cattle industry.  The availability of efficacious vaccines against bacterial 
agents of BRD will aid in reducing dependencies on antimicrobial therapies to control these organisms in 
the feedlot setting.  Reverse vaccinology offers an alternative strategy to conventional methodologies 
used for vaccine design against agents of BRD.  
The intent of this project was to examine populations of pathogens associated with BRD cases 
collected from a wide range of geographical locations.  Mannheimia haemolytica was targeted for whole 
genome sequencing and comparative genomic analysis of pathogenic and non-pathogenic serovars in an 
effort to identify antigen candidates that could be explored further for vaccine development.  The 
immunoreactivity of the identified candidates was also to be evaluated.  To pursue this, multiple 
objectives were defined, as outlined below.        
1.7 Hypothesis: 
Reverse vaccinology and comparative genomics of M. haemolytica isolates of varying virulence and a 
diverse geographic origin can be used to rapidly identify novel protein candidates for vaccine 
development.  
1.8 Objectives: 
1. To examine M. haemolytica collected from healthy cattle and those with BRD to better 
characterize populations associated with respiratory disease in feedlot cattle. 
2. To examine BRD mortalities from feedlots in North America for the occurrence of viral and 
bacterial agents associated with disease and to characterize their antimicrobial resistance 
profiles and any associated mobile genetic elements conferring resistance genes. 
3. To undertake comparative genomic analysis on 11 strains of M. haemolytica representing 
serotypes 1, 2 and 6 from healthy cattle or cattle that were morbid or succumbed to  BRD in an 
effort to better understand the genes contributing to virulence in this species.   
4. To use a RV approach to identify antigen candidates that may be components of a vaccine 
designed against M. haemolytica and develop a high throughput method to screen antigens for 
immunoreactivity. 
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2.1 Introduction 
 Bovine respiratory disease (BRD) is a considerable health problem in cattle within confined 
feeding facilities in North America. In western Canada, 10% to 30% of all auction derived cattle are 
treated for BRD, with 5% to 10% of those expected to succumb to the disease (Booker et al., 2008).  
Typically manifesting as severe pneumonia, BRD is usually observed in cattle within 2 months of arrival 
at the feedlot (Gagea et al., 2006).  Economic losses from the condition are primarily due to treatment 
costs and associated animal handling expenditures, reductions in carcass quality, and death (Snowder et 
al., 2007). 
Causation of BRD is linked to environmental stressors that predispose cattle to viral and 
bacterial infection (Taylor et al., 2010) by various agents including bovine viral diarrhea virus (BVDV), 
bovine respiratory syncytial virus (BRSV), parainfluenza-3 virus (PI3V), bovine herpesvirus (BHV-1)/(BHV-
4), Pasteurella multocida, Mycoplasma bovis,  Histophilus somni, and Mannheimia haemolytica.  
Mannheimia haemolytica is the bacterium most commonly associated with the gross pathology of the 
acute fulminating bronchopneumonia, typically seen within the first few weeks that cattle are on feed 
(Confer, 2009).  This, coupled with the systematic detection of M. haemolytica in BRD cases (Rice et al., 
2007), has resulted in M. haemolytica being considered one of the predominant bacterial pathogens 
associated with respiratory disease in cattle. 
Although recognized as a contributing factor to illness, M. haemolytica is also found as a 
commensal bacterium in the upper respiratory tract of healthy ruminants (Confer, 2009).  Virulence is 
strongly associated with capsular serotype; serotypes 1 and 6 are most commonly associated with BRD 
(Rice et al., 2007).  Extensive work focusing on the characterization of virulence factors in M. 
haemolytica (Highlander, 2001; Zecchinon et al., 2005) and the recent sequencing of the M. 
haemolytica genome (Gioia et al., 2006; Lawrence et al., 2010) has helped elucidate much of the genetic 
basis for its pathogenesis.  However, most of these studies have focussed on serotype 1 isolates or are 
limited to only a few strains.  Comparisons of epidemiological isolates from healthy cattle and those 
diagnosed with BRD may also provide important information on bacterial factors that contribute to the 
development of BRD.  The objective of this study was to examine M. haemolytica collected from healthy 
cattle and those with BRD in an effort to develop a better understanding of the characteristics of M. 
haemolytica populations associated with respiratory disease in feedlot cattle. 
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2.2 Materials and methods 
2.2.1 Bacterial Isolates 
 Mannheimia haemolytica used in this study were isolated as part of longitudinal surveillance 
program of commercial beef feedlots in western Canada (Klima et al., 2011).  Samples were collected 
from the nasopharynx of beef cattle using commercially available deep-guarded culture swabs with a 
Cary-Blair agar reservoir for transport (BD Canada, Mississauga, Ontario) and processed for isolation 
of Mannheimia haemolytica as previously described (Klima et al., 2011).  Randomly selected isolates 
that were collected from fall-placed calves with a known history of respiratory health were categorized 
into 2 groups: i) those isolated from healthy cattle (not treated for BRD while placed in feedlots, n = 49) 
and ii) those isolated from cattle treated for BRD (n = 41).  Isolates from healthy cattle were collected 
when they arrived (n = 27) or when they exited feedlots (n = 22).  Healthy cattle were placed in feedlots 
for a minimum of 60 days.  Mannheimia haemolytica from cattle with BRD were isolated at the time of 
initial treatment.  Trained animal health feedlot staff identified the calves as sick and then removed 
them from their pen.  The rectal temperature of these calves was measured and if it was > 40°C, they 
were swabbed and treated as per the feedlot’s protocol.  All isolates were identified as M. 
haemolytica by biochemical and polymerase chain reaction (PCR) tests as previously described 
(Alexander et al., 2008). 
2.2.2 Serotyping  
 Serotyping was performed using the rapid plate agglutination procedure as described by Frank 
and Wessman (Frank and Wessman, 1978).  Rabbit antisera were raised against reference strains of M. 
haemolytica as previously described (Klima et al., 2011). 
Pulsed-field gel electrophoresis (PFGE) 
Molecular typing was performed by pulsed-field gel electrophoresis (PFGE) according to 
methods previously reported (Klima et al., 2010).  Macro-restriction digest was conducted on all M. 
haemolytica isolates using SalI restriction enzyme.  The resulting PFGE patterns were assessed using 
BioNumerics V5.1 software (Applied Maths, Austin, Texas, USA).  Dendrogram and minimum spanning 
tree (MST) analysis was based on similarity matrices generated from UPGMA clustering of Dice 
coefficient values.  Optimization and position tolerance settings for dendrogram analysis were defined 
at 1.00% and 1.50%, respectively.  Simpson’s diversity indices were calculated using the online script 
tools available for BioNumerics V5.1 software. Bin size for MST was set to 3.0% and complexes were 
generated with a maximum neighbor distance of 2. 
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2.2.3 Sensititre 
 Antimicrobial susceptibility testing was performed by broth microdilution using a commercially 
available panel (Bovine/Porcine with Tulathromycin MIC Format, Sensititre; Trek Diagnostic Systems, 
Cleveland, Ohio, USA).  A list of the antimicrobials utilized and the range of concentrations tested are 
presented in Table 2.1.  In addition to these, sulphadimethoxine and trimethoprim/sulfamethoxazole 
were included in the panel , but at single breakpoint concentrations containing 256 μg/mL 
sulphadimethoxine and 2/38 μg/mL trimethoprim/sulfamethoxazole, respectively.  Plates were read 
manually by visual assessment and assignment of growth was defined according to recommendations 
provided in the Clinical and Laboratory Standards Institute (CLSI) document M31-A3 (CLSI, 2008).  At the 
time of experimentation, (CLSI) breakpoints were not available for clindamycin, neomycin, penicillin, 
tiamulin, sulphadimethoxine, trimethoprim/sulfamethoxazole, or tylosin tartrate.  Therefore, 
susceptibility designations for these drugs were not assigned. Exceptions to this are cases in which 
isolates exhibited a high MIC for neomycin (MIC 32 μg/mL) or penicillin (MIC 8 μg/mL) and harbored the 
corresponding antimicrobial resistance gene determinant, aphA-1 and blaROB-1, respectively.  In these 
instances the isolates were classified as neomycin- or penicillin-resistant.  The Fisher’s exact test was 
used to compare differences in the prevalence of antimicrobial resistant M. haemolytica isolated from 
treated and untreated cattle. 
  
  
Table 2.1 Frequency distribution of MICs of 88 Mannheimia haemolytica collected from the nasopharynx of feedlot cattle 
Antibiotic 
Number of isolates (%) showing a MIC (µg/ml) of:
a
 
0.12 0.25 0.5 1 2 4 8 16 32 64 
Ampicillin
b
 
 
83 (94.3) - - - - - 5 (5.7) 
  
Clindamycin
c
 
  
- - 3 (3.4) 33 (37.5) 40 (45.5) 12 (13.6) 
  
Chlortetracycline
b
 
  
49 (55.7) 23 (26.1) 13 (14.8) 3 (3.4) 
    
Danofloxacin
b
 88 (100) - - - 
      
Enrofloxacin
b
 88 (100) - - - - 
     
Florfenicol
b
 
 
5 (5.7) 73 (83.0) 10 (11.4) - - - 
   
Gentamicin
b
 
   
41 (46.6) 46 (52.3) 1 (1.1) - - 
  
Neomycin
c
 
     
54 (61.4) 21 (23.9) - 13 (14.8)* 
 
Oxytetracycline
b
 
  
51 (58.0) 20 (22.7) - 1 (1.1) 16 (18.2) 
   
Penicillin
c
 67 (76.1) 14 (15.9) 2 (2.3) - - - 5 (5.7)* 
   
Spectinomycin
b
 
      
- 48 (54.5) 39 (44.3) 1 (1.1) 
Tiamulin
c
 
  
- - - - 22 (25.0) 63 (71.6) 3 (3.4) 
 
Tilmicosin
b
 
     
78 (88.6) 5 (5.7) - 5 (5.7) 
 
Ceftiofur
b
 
 
88 (100) - - - - - 
   
Tulathromycin
b
 
    
49 (55.7) 33 (37.5) 6 (6.8) - - - 
Tylosin tartrate
c
     - - - - - 1 (1.1) 87 (98.9)   
a
Dotted and full lines indicate breakpoints for intermediately resistant and resistant, respectively.  Blanks indicate that isolates were not tested at the 
concentration specified.  Values presented at lowest concentrations tested include the number of isolates with MIC at that value but also those isolates 
with an MIC of 0 for that drug. 
b
Breakpoints determined from CLSI guidelines (CLSI, 2008) 
       
c
Breakpoint not available 
 *Resistance breakpoint defined by authors  
   
3
3
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2.2.4 PCR 
 Polymerase chain reaction screening for antimicrobial resistance genes was performed on M. 
haemolytica isolates exhibiting antimicrobial resistant phenotypes.  A list of the resistance genes 
evaluated, primer sets used (Chen et al., 2007; Kadlec et al., 2011; Klima et al., 2011; Ng et al., 2001) and 
the resistant phenotypes targeted is presented in Table 2.2.  Screening for virulence-related genes was 
conducted on all isolates used in the study. A list of the virulence genes evaluated and primer sets used 
(Lo et al., 2006) is presented in Table 2.3. 
 
Table 2.2 Primers used to screen for antimicrobial resistance genes in Mannheimia haemolytica isolated from 
feedlot cattle 
Phenotype 
targeted
a
 
Resistance gene PCR primer sequence 5'-3' 
Amplicon 
size 
Annealing 
temp (°C) 
Primer 
reference 
TET
R
 tet(H) ATACTGCTGATCACCGT 1076 60 11 
 
 
TCCCAATAAGCGACGCT 
   
AMP
R
, PEN
R
 blaROB-1 AATAACCCTTGCCCCAATTC 685 60 11 
 
 
TCGCTTATCAGGTGTGCTTG 
   
TIL
R
 erm(X) GAGATCGGRCCAGGAAGC 488 58 17 
 
 
GTGTGCACCATCGCCTGA 
   
 
erm(42) GGGTGAAAAGGGCGTTTATT 1,254 60 18 
 
 
ACGTTGCACTTGGTTTGACA 
   
 
msr(E)-mph(E) TACCGGAACAACGTGATTGA 3,277 60 18 
 
 
GAAGGGTTACGCCAGTACCA 
   
NEO
R
 aphA-1 TTATGCCTCTTCCGACCATC 489 54 16 
    GAGAAAACTCACCGAGGCAG       
a
 TET
R
, tetracycline resistant; AMP
R
, ampicillin resistant; PEN
R
, penicillin resistant; TIL
R
, tilmicosin resistant; NEO
R
, 
neomycin resistant 
 
 All PCR reaction mixtures (20 μL) contained (final concentrations): 1 × HotStarTaq PlusMaster 
Mix (Qiagen Canada, Toronto, Ontario), 0.2 μM primer and 1 × CoralLoad Concentrate (Qiagen Canada).  
Colony lysate was used for template DNA and generated by incubating single colonies of bacteria in 50 
μL of Tris EDTA buffer (pH 7.4) at 98°C for 5 min.  Lysate was centrifuged at 13 000 × g for 5 min, after 
which 2 μL of supernatant was added to the PCR as template DNA.  Polymerase chain reaction 
amplifications were performed using an Eppendorf Mastercycler (Eppendorf Canada, Mississauga, 
Ontario) with the following conditions: 95°C for 5 min; 30 cycles of 94°C for 30 s, respective annealing 
temperatures (refer to Tables 2.2 and 2.3) for 1 min, 72°C for 1 min and 72°C for 8 min.  For  erm(42) 
and msr(E)-mph(E) PCRs, the extension time was increased to 1.5 min to compensate for larger 
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products.  A touchdown assay, as previously described (Chen et al., 2007), was used for erm(X) gene 
screening. 
 
Table 2.3 Primers used to screen for  virulence genes in Mannheimia haemolytica isolated from feedlot 
cattle
a
  
Resistance 
gene 
Virulence-related genes PCR primer sequence 5'-3' 
Amplicon 
size 
Annealing 
temp (°C) 
gcp O-sialoglycoprotease CGCCCCTTTTGGTTTTCTAA 420 58 
  
GTAAATGCCCTTCCATATGG 
  
gs60 Outer-membrane lipoprotein GCACATTATATTCTATTGAG 429 55 
  
AGGCATACTCTAACTTTTGC 
  
tbpB 
Transferring-binding protein 
B 
CTACTTGCTGCTTGTTCCTC 137 60 
  
AGAACCGCTTACTGTACGTC 
  
lktC Leukotoxin GGAAACATTACTTGGCTATGG 440 58 
  
TGTTGCCAGCTCTTCTTGATA 
  
nmaA 
UDP-N-acetyl-D-glucosamine-
2-epimerase 
CTGTAGAAGCCGGAACAGTA 129 60 
  
CATCGCCATAAGGGTTGTGA 
  
adh Putative adhesion CTGCAAGTAAGGCAACATTG 150 58 
    GAATCCGCACCAATAGCAAT     
a
From reference 19. 
 
2.3 Results 
2.3.1 Serotype 
 All isolates, 49 collected from healthy animals located in 2 feedlots and 41 collected from BRD 
cases from 3 feedlots, typed as either serotype 1 (S1), 2 (S2), or 6 (S6) (Table 2.4).  Over 75% of isolates 
collected from healthy animals at either arrival or exit were identified as S2, whereas 90% of isolates 
from cattle with BRD were either S1 or S6.  
 
Table 2.4 Serotypes of Mannheimia haemolytica collected from the nasopharynx 
of healthy cattle or cattle treated for bovine respiratory disease (BRD)  
Cattle group No. of isolates 
Serotype (%) 
1 2 6 
Healthy  49 7 (14.3) 37 (75.5) 5 (10.2) 
BRD-treated 41 29 (70.7) 4 (9.7) 8 (19.5) 
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2.3.2 Pulsed-field gel electrophoresis 
Dendrogram analysis of the restriction patterns from all isolates revealed considerable diversity, 
with 80 unique pulsotypes (data not shown).  Two main clusters comprised of 51 and 39 isolates each 
were identified and exhibited a similarity of 39%.  Diversity within each main cluster was high, as 
indicated by a Simpson’s diversity index of 92.4% for the larger and 92.3% for the smaller cluster.  A 
minimum spanning tree generated from the PFGE similarity matrices reproduced the two main clusters 
described (Figure 2.1).  The first cluster (n= 51) was comprised largely of S1 and S6 isolates, while the 
second cluster (n = 39) was comprised solely of S2 isolates. 
  
  
 
Figure 2.1 Minimum spanning tree based on similarity matrix generated from pulsed-field profiles of Mannheimia haemolytica isolates collected 
from feedlot cattle. Bin size of 3.0% with distance indicated. Complexes were generated with a maximum distance of 2 (shown in shaded area 
around groups of isolates) and circle size is proportional to member count. Colors inside of circles indicate if the isolate came from an animal 
that was healthy (grey) or had BRD (white). Numbers inside of circles refer to serotype. Two main groups labeled A and B, dominate the tree. 
Group A is comprised of mostly S1 and S6 isolates and Group B is comprised completely of S2 isolates. 
3
7
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2.3.3 Antimicrobial Susceptibility 
 All M. haemolytica isolates grew in 256 μg/mL sulphadimethoxine, but failed to grow in 2/38 
μg/mL trimethoprim/sulfamethoxazole.  The MICs for the 16 antimicrobials tested are reported in Table 
2.1.  Overall, resistance to at least one antimicrobial was observed in 16 (18%) isolates.  Resistance to 
oxytetracycline was most common (18%), followed by neomycin (14.8%).  Five tetracycline–neomycin 
resistant isolates also exhibited resistance to ampicillin, penicillin, and tilmicosin.  There was a higher 
prevalence (P < 0.001) of antimicrobial resistance observed for isolates obtained from cattle with BRD 
(37%) as compared to those that were healthy  (2%). 
Of the 16 antimicrobial-resistant isolates detected, only one was recovered from a healthy 
animal and the remaining were isolated from cattle exhibiting BRD (Figure 2.2).  Most of these isolates 
exhibited multi-drug resistance, with 13 isolates being resistant to at least 2 antimicrobials.  All of the 
isolates exhibiting antimicrobial resistance phenotypes were S1.  There were 3 cases in which isolates 
with the same pulsotype, antimicrobial resistance phenotype, and resistance genes were obtained from 
different cattle.  This was observed in cases in which animals were located in different feedlots, located 
in the same feedlot but in different pens, and located in the same feedlot and pen. 
  
  
 
Figure 2.2 Dendrogram analysis of pulsed-field profiles from Mannheimia haemolytica isolates expressing antimicrobial-resistant phenotypes. 
The dendrogram was created using UPGMA clustering of Dice coefficient values. Similarity matrix was based on band-matching analysis, 
optimization and tolerance settings of 1.0% and 1.5%, respectively. 
a The only isolate collected from a healthy animal to express an antimicrobial resistance phenotype. Tet — tetracycline resistant; Amp — 
ampicillin resistant; Pen — penicillin resistant; Til — tilmicosin resistant; Neo — neomycin resistant; AMR — antimicrobial resistance. 
 
3
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2.3.4 Resistance genes 
 Polymerase chain reaction screening showed agreement between antimicrobial resistant 
phenotypes and the presence of an associated antimicrobial resistance gene. Oxytetracycline resistance 
corresponded to the presence of tet(H), neomycin resistance to the presence of aphA-1, and 
ampicillin/penicillin resistance to the presence of blaROB-1 (Figure 2.2).  Neither erm(X), erm(42) nor 
the msr(E)-mph(E) genes that confer resistance tilmicosin were identified. 
2.3.5 Virulence related genes 
 Polymerase chain reaction screening for the virulence-related genes leukotoxin C (lktC), a 
putative adhesin (ahs), an outer- membrane lipoprotein (gs60), an O-
sialoglycoprotease(gcp), transferring-binding protein B (tbpB), and UDP-N-acetyl-D-glucosamine-2-
epimerase(nmaA) revealed the presence all 6 genes in S1 and S6 isolates regardless of whether the 
isolates were obtained from healthy cattle or cattle with BRD.  The tbpB and nmaA gene were not 
detected in any of the S2 isolates, whereas lktC, ahs, gs60, and gcp, were present. 
2.4 Discussion 
2.4.1 Serotype 
 Of the 12 serotypes currently described, S1 and S6 are thought to account for most M. 
haemolytica-associated BRD worldwide (Rice et al., 2007), with S1 recovered most frequently from 
pneumonic lesions in cattle (Lo et al., 2006).  The findings here are consistent with this position, as 92% 
of the isolates collected from cattle with BRD were either S1 or S6, with the majority being S1. Serotype 
2 is commonly recognized as a commensal organism in cattle (Lawrence et al., 2010), but has been 
identified as a causative agent of respiratory disease in sheep (Davies et al., 2001).  Here, the recovery of 
S2 from healthy cattle was close to 8 times higher than that from cattle with BRD. 
Of the cattle exhibiting BRD, S1, S2, and S6 serotypes accounted for approximately 70%, 10%, 
and 20% of the isolates obtained.  This distribution agrees with other reports in which M. 
haemolytica has been isolated from cattle exhibiting BRD, in the western (60% S1, 7% S2, and 26% S6) 
(Al-Ghamdi et al., 2000) and mid-western USA (60% S1, 10% S2, and 27% S6) (Purdy et al., 1997).  It is 
unclear why, given the broad sampling range and period between investigations, a similarity in the 
distribution of serotypes should be observed between studies.  Although the prevalence of S2 in nasal 
samples has been shown to decrease after transportation of cattle from farms to feedlots (Frank and 
Smith, 1983), S2 has been shown to account for 74% of M. haemolytica colonizing the nasopharynx of 
feedlot cattle (Klima et al., 2011).  Therefore, there is a clear shift in serotype populations, depending on 
animal health. 
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Although evidence suggests serotype-related differences exist in M. haemolytica host specificity 
and virulence (Davies et al., 2001), this relationship is not definitive as in 4 instances S2 isolates were 
recovered from cattle with BRD.  However, these isolates were not closely related and it is interesting to 
note that the pulsotype for one of the S2 isolates grouped more closely to S1 and S6 isolates.  Although 
serotype conversion has been investigated in M. haemolytica with both genotypic and phenotypic 
variability described in S1 and S2 isolates upon successive subculture (Villard et al., 2008), direct 
evidence for serotype switching has not been documented in this species.  It is unlikely, based upon the 
dissimilarity in pulsotype observed between the serotypes examined, that serotype conversion is playing 
a role in these populations.  It is possible that S2 isolates collected from diseased animals are a subset of 
the ubiquitous populations and are adapted in a way that makes them capable of extensive proliferation 
in immune-compromised bovine hosts. 
2.4.2 Polymerase chain reaction of virulence related genes 
 In this study we used PCR to screen for the presence of 6 genes previously shown to be related 
to virulence in M. haemolytica.  The results from this analysis show a consistent relationship between 
isolate serotype and virulence gene profile.  With the described primer sets, tbpB, which encodes 
transferring-binding protein B that is implicated in iron acquisition, and nmaA, which encodes UDP-N-
acetyl-D-glucosamine-2-epimerase that is involved in capsule biosynthesis, were detected in all S1 and 
S6 isolates, while they were not detected in S2 isolates.  This suggests that these genes are either absent 
in S2 isolates or they have divergent sequences that were not amplifiable by the PCR assays.  
Additionally, use of PCR to target virulence genes specific to serotypes of M. haemolytica could 
circumvent the need for serum based typing methods.  Further work would be needed to determine if 
the genes utilized in this study are useful for such a purpose, but these preliminary data suggest that the 
presence of nmaA could be useful in differentiating between S2 and either S1 or S6 strains of M. 
haemolytica.  Further investigations into targets such as these could also provide potential candidates 
for serotype-specific vaccine development against M. haemolytica. 
2.4.3 Pulsed-field gel electrophoresis  
 Analysis of PFGE patterns revealed levels of genetic diversity similar to what has been previously 
reported for M. haemolytica collected from the nasopharynx of beef cattle (Klima et al., 2011).  Two 
main groups were observed to cluster by serotype and to a lesser degree by the health status of the host 
from which the isolates were obtained.  There were 3 instances in which highly related isolates (100% 
similarity) were recovered from different cattle.  Clones observed in cattle within different pens and 
feedlots likely reflect the nature of the beef industry in which animals are mixed at auction marts and 
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then separated into groups at feedlots.  Based on these data, it is difficult to determine the stage at 
which these isolates spread among cattle, be it on-farm, at auction, during transport, or once inside the 
feedlot.  We have previous evidence of clonal spread of M. haemolytica in the general feedlot 
population (Klima et al., 2011), but a striking observation in the present study was that all cases of 
clones were S1 isolates collected from cattle exhibiting BRD.  This suggests that strain virulence may be 
an important factor in predisposition to M. haemolytica-related BRD. 
2.4.4 Susceptibility testing 
Mannheimia haemolytica isolates exhibited a low level of antimicrobial resistance (18%), 
consistent with previous reports that have examined antimicrobial resistance in M. haemolytica isolated 
from beef cattle (Catry et al., 2005; Hendriksen et al., 2008; Klima et al., 2011).  The most common 
resistance phenotype observed was to oxytetracycline, not unexpected as tetracyclines are frequently 
used in western Canadian feedlots, typically as a feed additive for the prevention of liver abscesses or as 
a long-acting injectable for metaphylactic and therapeutic use. 
The use of macrolide drugs in both human and veterinary medicine made the detection of 
tilmicosin resistance here a source of interest.  A reduction in the efficacy of macrolide drugs holds 
consequence not only for human health but also for BRD therapy as both tulathromycin and tilmicosin 
are used for the treatment of respiratory infection in cattle (Klima et al., 2011).  Of the isolates 
examined, 5 were resistant to tilmicosin, while none were resistant to tulathromycin.  Tilmicosin 
resistance has been detected infrequently in M. haemolytica (Catry et al., 2005; Hendriksen et al., 2008; 
Klima et al., 2011; Watts et al., 1994; Welsh et al., 2004), but recent characterization of the macrolide 
resistance genes erm(42), msr(E) and mph(E) that confer resistance to tulathromycin in P. 
multocida and M. haemolytica (Desmolaize et al., 2011), suggests that there is potential for increased 
levels of macrolide resistance in M. haemolytica populations in the future. 
Although the overall antimicrobial resistance levels described here were low, higher levels of 
resistance were observed in isolates collected from BRD cattle than from healthy animals, with all 
resistant isolates being S1. This suggests that antimicrobial resistance provides an advantage to the 
dominant serotype implicated in BRD. However, reasoning for this is complicated by the fact that the 
second most prevalent serotype in cattle exhibiting BRD, S6, exhibited no resistance to the 
antimicrobials tested. If antimicrobial therapy is driving resistance development in disease-related 
populations then the presence of antimicrobial resistance in a portion of the S6 isolates collected from 
BRD cattle would have been anticipated. 
43 
 
There is substantial under-reporting of serotype information in most of the antimicrobial 
resistance surveys with M. haemolytica. Consequently only one record was obtained that reports 
quinolone resistance in S6 M. haemolytica, (Katsuda et al., 2009).  This occurred in a group of isolates of 
identical genetic profile, indicating that spontaneous mutation occurred in a single population resulting 
in clonal spread of the phenotype. It is possible that S6 isolates are less prone towards the uptake of 
exogenous DNA and/or transferable genetic elements. However, the genetic elements required for 
competence have been detected in S1 and S2 isolates (Gioia et al., 2006; Lawrence et al., 2010) and 
appear to be conserved across Pasteurellaceae (Kuhnert and Christensen, 2008). There is also the 
possibility that S6 infection varies in presentation resulting in fewer S6 cases being treated with 
antimicrobials. 
2.5 Conclusion 
In conclusion, clear differences were observed between populations of M. haemolytica collected 
from healthy versus cattle exhibiting the symptoms of BRD. The most notable were the higher 
proportion of isolates from BRD cattle that exhibited antimicrobial resistance profiles, and the shift in 
prevalence from S2 isolates in healthy cattle to S1 and S6 isolates in cattle treated for BRD.  Although 
difficult to explain, all cases of clonal relatedness were observed in isolates collected from cattle that 
had BRD. This may highlight the importance of strain virulence in bacterial-associated BRD and indicate 
the potential for spread and dissemination of multidrug-resistant M. haemolytica among beef cattle. 
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3.1 Introduction 
In newly received feeder calves, shipping fever or Bovine Respiratory Disease (BRD) is the 
leading cause of death and illness, contributing to millions of dollars in losses through treatment costs, 
reduced meat yield and mortalities  (Larson and Step, 2012; Snowder et al., 2007).  Stressors as a result 
of weaning, marketing and transport predispose calves to viral infection that in turn can precipitate 
bacterial pathogenesis in the lower respiratory track (Rice et al., 2007).  Multiple viral and bacterial 
agents are implicated in BRD, including bovine viral diarrhea virus (BVDV), bovine respiratory syncytial 
virus (BRSV), bovine herpesvirus 1 (BHV-1), parainfluenza 3 virus (PI3V), Mannheimia haemolytica, 
Mycoplasma bovis, Pasteurella multocida and Histophilus somni.  The term bovine respiratory disease 
can cover a range of pneumonic illness, from acute fatal respiratory disease to chronic or prolonged 
intractable respiratory disease (Booker et al., 2008).  Although not absolute, acute fibrinous pneumonia 
or acute fatal pneumonia is most commonly associated with M. haemolytica, while chronic 
caseonecrotic pneumonia is typically associated with M. bovis (Gagea et al., 2006; Woolums, 2010).    
To date, vaccination has shown inconsistent efficacy against M. haemolytica, P. multocida and 
H. somni infection in feedlot cattle (Larson and Step, 2012).  As a result, antimicrobials are often the 
primary management practice used to reduce the incidence of BRD in feedlot cattle.  In western Canada, 
20-50% of newly arrived feedlot placements receive injectable metaphylactic antimicrobials for BRD 
prevention (Checkley et al., 2010) while 75% of USA feedlots with capacities of over 8000 head use 
injectable antimicrobials at arrival (USDA, 2012) 
As the largest user of antimicrobials worldwide (Silbergeld et al., 2008), the agricultural sector is 
a potential driving force for evolution, persistence and spread of antimicrobial resistance traits (Call et 
al., 2008), both in targeted pathogens and commensals of livestock (Catry et al., 2003).  The use of 
antimicrobials for growth promotion and metaphylaxis raises concerns over the extent these practices 
might contribute to antimicrobial resistance (AMR) in zoonotic bacterial pathogens (McEwen and 
Fedorka-Cray, 2002) and reduce the efficacy of antimicrobials employed to control infectious disease in 
cattle. 
Bacteria may be intrinsically resistant or acquire resistance to antimicrobial agents either by de 
novo mutation in their genomes or through the acquisition of additional genes via horizontal gene 
transfer through conjugation, transformation or transduction.  Horizontal gene transfer through 
conjugation requires a multi-protein apparatus, typically synthesized by the donor strain that physically 
connects the donor and recipient (Wozniak and Waldor, 2010), enabling transfer of one or multiple 
genes.  Typically conjugation systems employ plasmids or plasmid-derived DNA but, recently 
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chromosome-borne mobile genetic elements referred to as integrative conjugative elements (ICEs) have 
been identified (Wozniak and Waldor, 2010).  These elements commonly harbour clusters of accessory 
genes, including multidrug resistance cassettes accumulated through recombination.  Once generated, 
multidrug resistant elements can establish and persist in bacterial populations as the result of the use of 
a single antimicrobial that co-selects for the entire element. 
The development of widespread resistance in BRD pathogens would be economically 
devastating to the cattle industry (Watts and Sweeney, 2010).  To ensure prudent antimicrobial use, 
surveillance of antimicrobial resistance in bacterial agents of BRD is required if therapeutic efficacy is to 
be maintained.  Likewise, it is important to monitor the development of cross resistance to 
antimicrobials from drug classes of importance to human medicine. 
The objective of this study was to examine BRD mortalities from feedlots in North America for 
the occurrence of viral and bacterial agents associated with disease and to characterize their 
antimicrobial resistance profiles.   
3.2 Materials and Methods  
3.2.1 Sample collection 
 Nasopharyngeal swab and lung tissue samples were collected at post-mortem necropsy from 68 
BRD mortalities presenting acute fibrinous pneumonia in feedlots within Alberta (n = 42), Texas (n = 6) 
and Nebraska (n = 20).  Lung tissue samples consisted of a 4 cm3 section excised from the perimeter of a 
pneumonic lesion, stored and transported in Cary-Blair media (BD Canada Inc., Mississauga, ON).  
Nasopharyngeal samples were collected using commercially available deep-guarded culture swabs with 
a Cary-Blair agar reservoir (BD Canada Inc., Mississauga, ON).  Samples were stored at 4 °C for a period 
no longer than ten days prior to processing for bacterial isolation. 
Bacterial isolation of M. haemolytica, P. multocida and H. somni 
For each lung tissue sample, approximately 2 cm3 was excised with a sterile scalpel and 
homogenized with 10 mL of sterile Brain Heart Infusion (BHI; BD Canada Inc., Mississauga, ON) in a 
stomacher (Stomacher 400 Circulator, Seward Laboratory Systems Inc., USA) for 30 s.  A 500 µL aliquot 
of the stomacher suspension was serially diluted 1:10, with 10-1 and 10-2 dilutions and cultured onto 
Tryptic Soy Agar (TSA; BD Canada Inc., Mississauga, ON) plates containing 5% blood overnight at 37°C.  
An aliquot of the lung tissue stomacher suspension was stored in 20% glycerol at -80°C and later 
processed for the isolation of H. somni.  For this, approximately 10 µL of the frozen stocks were used to 
inoculate 900 µL of BHI broth.  A 100 µL aliquot of the resulting suspension was plated onto TSA plates 
containing 5% blood and incubated for 48 h at 37°C under a 5% CO2 atmosphere.   
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Colonies displaying morphology indicative of M. haemolytica (i.e. white-grey, round, medium-
sized, non-mucoid, exhibiting β-haemolysis) were confirmed as previously described (Alexander et al., 
2008).  Identity of colonies displaying morphology of P. multocida (translucent, greyish in colour, and 
mucoid in consistency) and H. somni (yellowish hue, haemolytic), were confirmed by PCR using 
HotStarTaq Plus Master Mix (Qiagen Canada Inc., Toronto, ON) according to manufacturer’s 
specifications with primers and annealing conditions as described (Table 3.1).  Colonies exhibiting 
morphologies not indicative of M. haemolytica, P. multocida or H. somni were co-isolated and 
genus/species identified based on DNA sequencing (Eurofins MWG Operon, Huntsville, AL) and BLAST 
analysis of 16S rRNA genes.    
  
  
Table 3.1 PCR primers and annealing conditions used for bacterial species confirmation, virus detection, antimicrobial resistance gene screening and detection of 
integrative conjugative elements (ICEs) associated genes from ICEPmu1 
PCR target 
/phenotype 
Primer name (F/ R)
a
 PCR primer sequence 5'-3' 
Amplicon 
size 
Annealing 
temp (°C) 
Primer 
reference 
Bacteria species confirmation PCR 
Mannheimia sp. 
MHlkt-int_F / MHlkt-
int_R 
GTCCCTGTGTTTTCATTATAAG/CACTCGATAATTATTCTAAATTAG 385 58 45 
Histophilus somni HS453_F / HS860_R GAAGGCGATTAGTTTAAGAG/TTCGGGCACCAAGTRTTCA 400 55 46 
Pasteurella multocida PM23_F / PM23_R GGCTGGGAAGCCAAATCAAAG/CGAGGGACTACAATTACTGTAA 1432 52 47 
Mycoplasma bovis 
PMB996-F / PMB1066-R TCAAGGAACCCCACCAGAT/AGGCAAAGTCATTTCTAGGTGCAA 71 60 
17 
Mbovis probe FAM-TGGCAAACTTACCTATCGGTGACCCT-TAMRA - - 
16S rRNA 27F/1492R AGAGTTTGATCCTGGCTCAG/ GGTTACCTTGTTACGACTT   1450 58 48 
Virus detection 
BVDV (ssRNA positive-
strand) 
b
RT_BVDVF / RT_ BVDVR AGCGAAGGCCGAAAAGAGGC/CAACTCCATGTGCCATGTACAG 312 58 This work 
PI3V (ssRNA negative-
strand) 
b
RT_PI3VF / RT_ PI3VR CATAAGTGATCTAGATGATGATCC/TTCATCTAGAATCTGAACTACTCC 460 55 This work 
c
N_PI3VF / N_PI3VR 
TGTCTTCCACTAGATAGAGGGATAAAATT/GCAATGATAACAATGCCATG
GA 
111 60 49 
BRSV (ssRNA 
negative-strand) 
b
RT_BRSVF / RT_ BRSVR CAAACTAAATGACACTTTCAACAAG/CATTTCATTCCTTAGTACATTGTTG 566 54 This work 
c
N_BRSVF / N_BRSVR CGTAGTACAGGTGACAACATTG/ACCAAAGCAGCAACACATAGCAC 422 63 This work 
BHV-1 (dsDNA) 
BHV-1F / BHV-1R TCGAGCGGCAAGAGCACAAG/GGAAATCTTCGTGGCCCAGATG 662 62 This work 
c
N_BHV-1F / N_BHV-1R TGAGGCCTATGTATGGGCAGTT/GGACACAACAAACAATGCGG 422 60 This work 
Antimicrobial resistance phenotype 
tet(H), tetR / CTET
R
, 
OXYT
R
 
tet(H)_F / tet(H)_R ATACTGCTGATCACCGT/TCCCAATAAGCGACGCT 1076 60 18 
ICE tetR_F / ICE tetR_R CGGCTTGGGTTAATAATGGCG/ATAACGCGAAAAGCTTCCGC 425 58 This work 
blaROB-1, blaOXA-2 / 
AMP
R
, PEN
R
 
blaROB-1_F / blaROB-1_R AATAACCCTTGCCCCAATTC/TCGCTTATCAGGTGTGCTTG 685 60 18 
blaOXA-2 _F / blaOXA-2 _R GCAGACGAACGCCAAGCGGA/CCCGCACGATTGCCTCCCTC 625 64 This work 
erm(42), msr(E), 
mph(E)  / TIL
R
,
 
TUL
R
 
erm(42)_F / erm(42)_R GGGTGAAAAGGGCGTTTATT/ACGTTGCACTTGGTTTGACA 1,254 60 50 
msr(E)_F / mph(E)_R ACCAGCCACCTTGATCTCAATG/GTTCCATTCGATCCAGTTATAGCG 620 60 This work 
mph(E)_F / mph(E)_R TCTGTAGCGGGTTTCCAATTGC/AATGGTTGCTGCGTATTCCTCG 401 60 This work 
aadA25 / SPT
R
 aadA25_F / aadA25_R GCAGTGGATGGCGGCCTGAA/TCGGCGCGATTTTGCCGGTT 503 66 This work 
aphA-1 / NEO
R
 aphA-1_F / aphA-1_R TTATGCCTCTTCCGACCATC/GAGAAAACTCACCGAGGCAG 489 54 51 
5
1
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strA, strB / NEO
R
,GEN
R
 
strA_F / strA_R AAGGCAAGGCGTTCGCGGTC/CCGGCGGCTGATCTGTCTGG 506 64 This work 
strB_F / strB_R TCGCACCTGCTTGATCGCGG/GCTCGAATATGCCGGGGAGCG 586 64 This work 
aadB / GEN
R
 aadB_F / aadB_R TTACGCAGCAGGGCAGTCGC/ GCGGCACGCAAGACCTCAAC 551 66 This work 
floR / FFN
R
 ICE floR_F / ICE floR_R GACGGTTCGCGACGTTTATG/GAAGACGAAGAAGGTGCCCA 320 58 This work 
sul2 /  TMP-SMX
R
 sul2_F / sul2_R CCAATACCGCCAGCCCGTCG/TGCCTTGTCGCGTGGTGTGG 489 64 This work 
Integrative conjugative element (ICE) associated genes from ICEPmu1  
hypothetical protein 
Pmu_02680F/Pmu_0268
0R 
TTATGAACCCGGTGCGAGTG/TGTGAGAGCAAAGACTCTGGT 
226 58 
This work 
integrase 
Pmu_02700F/Pmu_0270
0R 
ACGGAATCATAGACCTGCCAC/TCTGTTGCAGTTGTATGTCGGA 
735 58 
This work 
multicopper oxidase  
Pmu_03360F/Pmu_0336
0R 
CAAGGCAGTGCTGGGACATA/GTTCCTTGCGTTTCACCCAC 
458 58 
This work 
transposase tnpA 
Pmu_03510F/Pmu_0351
0R 
TGCCGCTTTTCGTCTTTGTG/TACACGCCGAAGTTTCCGAA 204 56 This work 
single stranded DNA-
binding protein 
Pmu_03540F/Pmu_0354
0R 
GACTTCTCGACGTTCTCCGG/ATCGTTGCAATTTCCTGTCC 110 58 This work 
a
 F and R denote forward and reverse primers. P denotes probe 
b 
RT denotes one-step Reverse Transcription-PCR primers 
c 
N denotes second round Nested PCR primers 
 
  
5
2
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3.2.2 DNA and RNA extractions 
 Total DNA and RNA were extracted according to manufacturer’s specifications from lung tissue 
samples using the QIAamp DNA tissue kit and RNeasy Mini Kit (Qiagen Canada Inc., Toronto, ON), 
respectively.     Total nucleic acid (DNA extraction without RNase treatment) was extracted from 
nasopharyngeal swabs using the following procedures: nasopharyngeal swabs were centrifuged at 
13,000 x g for 5 min and the supernatant was aspirated.  The swab was removed from the applicator 
and left inside the tube containing the pellet, resuspended in 180 µL of enzymatic lysis buffer and 
incubated for 30 min at 37°C.  A 25 µL aliquot of proteinase K and 200 µL of Buffer AL (provided with kit) 
were added to the suspension and incubated at 56°C for 30 min.  A sterile steel ball was added to the 
tube and samples were processed for 1 min at 30 Hz using a Tissue Lyser (Qiagen Canada Inc., Toronto, 
ON).  A 200 µL volume of ethanol (96-100%) was added and the suspension centrifuged at 8000 × g for 5 
min to pellet debris.  The supernatant was passed through a DNeasy spin column and nucleic acids were 
eluted as described in the kit protocol.  All samples were stored at -80°C until used.  
3.2.3 Viral and bacterial pathogen detection 
All viral and bacterial agents were detected by PCR using master mixes according to 
manufacturer’s specification and primers and annealing temperatures listed in Table 3.1.  An overall 
profile of respiratory tract occurrence was generated with an animal identified as positive if the agent 
was detected in the nasopharynx, lung or both.  Lung DNA and nasopharyngeal nucleic acid extractions 
were used as templates for PCR detection of Mannheimia sp., P. multocida and H. somni, nested PCR 
detection of BHV-1 and real-time PCR detection employing TaqMan® Fast Universal PCR Master Mix (Life 
Technologies Inc., Burlington, ON) of M. bovis (Sachse et al., 2010).  Lung RNA and nasal nucleic acid 
extractions were used as templates for PCR detection of BVDV, BRSV, and PI3V, employing SuperScript III 
One-Step RT-PCR System (Life Technologies Inc., Burlington, ON) for reverse transcription followed by a 
nested PCR.  A HotStar HiFidelity Polymerase Kit (Qiagen Canada Inc., Toronto, ON) was used for nested 
PCR of BVDV reverse transcription products, with generated amplicons sequenced (Eurofins MWG 
Operon, Huntsville, AL) and analyzed using Geneious R6 version 6.0.5 (Biomatters Ltd., Auckland, New 
Zealand).  Alignments generated in BLAST were used for identification of BVDV subspecies 1 and 2.   
DNA extracted from the following strains was used for bacterial positive controls: Pasteurella 
multocida ss multocida strain 17976B (CCUG), M. haemolytica strain BAA-410 (ATCC), Histophilus somni 
strain 700025 (ATCC) and Mycoplasma bovis strain 25523 (ATCC).  Positive controls for viral agents were 
prepared by cloning specific PCR products into plasmids using the first round PCR primers listed in Table 
3.1.  Amplicons generated from nucleic acids extracted from viral strains (BVDV1, Singer strain; BVDV2, 
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Ames 125-C strain; BHV-1, Colorado-34 strain) or positive nasopharyngeal/lung sample (BRSV and PI3V) 
were cloned into a TA vector pCR™2.1 (Life Technologies Inc. Burlington, ON).  Cloned fragments were 
confirmed by sequencing. 
3.2.4 Statistical analysis 
Pearson correlation analysis (SAS System for Windows, release 9.1.3, SAS Institute, Cary, NC) 
was used to determine the correlation between PCR results from nasopharyngeal and lung tissue 
samples for all bacterial and viral agents examined in this study and the level of significance was set at P 
< 0.01.  
3.2.5 Serotyping 
 Mannheimia haemolytica isolates were serotyped using the rapid plate agglutination procedure 
with rabbit antisera raised against reference strains of M. haemolytica as previously described (Klima et 
al., 2011).   
3.2.6 Pulsed-field gel electrophoresis  
Molecular typing was performed on all isolates of M. haemolytica, P. multocida and H. somni by 
PFGE according to previous methods (Klima et al., 2011).  Macrorestriction digests were completed 
using SalI for M. haemolytica, ApaI for P. multocida and SacII for H. somni.  Electrophoresis conditions 
for all three species employed a program of 6 V/cm for 22 h at 12°C with switch times from 4-40 s.  
Pulsed-field profile and statistical analyses were performed using BioNumerics V5.1 software (Applied 
Maths, Inc., Austin, TX, USA). 
3.2.7 Broth microdilution assay  
Antimicrobial susceptibility testing was performed on M. haemolytica, P. multocida and H. 
somni isolates by broth microdilution using a commercially available panel (Bovine/Porcine with 
Tulathromycin MIC Format, Sensititre; Trek Diagnostic Systems, Cleveland, OH), as previously described 
for M. haemolytica (Klima et al., 2014) and according to manufacturer’s specifications for P. multocida 
and H. somni.  Minimum inhibitory concentration (MIC) was assigned by the unaided eye as outlined in 
the Clinical and Laboratory Standards Institute document M31-A3 (CLSI, 2008). Clinical and Laboratory 
Standard Institute breakpoints were not available for clindamycin, ampicillin, penicillin, gentamicin, 
neomycin, tiamulin, sulphadimethoxine, trimethoprim/sulfamethoxazole or tylosin tartrate.  
Consequently, susceptibility designations for these drugs were not assigned.  Exceptions were made in 
cases where ampicillin, penicillin, neomycin or gentamicin MIC distributions for the population were 
bimodal and isolates exhibited both a high MIC and harbored a corresponding antimicrobial resistance 
gene determinant.  In these instances, isolates were classified as resistant.  In addition, the resistance 
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breakpoint for spectinomycin (≥128 µg/mL) was greater than evaluated by the panel (max. 
concentration evaluated was 64 µg/mL).  As a result, isolates were classified as spectinomycin resistant 
if they exhibited both a high MIC and harbored a corresponding antimicrobial resistance gene 
determinant.   
3.2.8 Screening for resistance determinants and Integrative conjugation elements (ICE)  
 PCR was used to screen for resistance gene determinants and ICE associated genes from 
ICEPmu1 in isolates of M. haemolytica, P. multocida and H. somni.  All PCR reactions used heat lysed 
colony suspension as template and primers and annealing conditions described in Table 3.1.  
Representative PCR products were sequenced to confirm the accuracy of amplified fragments. 
3.2.9 Bacterial conjugation assay  
 Conjugal mating experiments were performed to examine the mobility of ICEs among isolates of 
M. haemolytica, P. multocida and H. somni.  Spontaneous rifampicin resistant (RifR) isolates for P. 
multocida strain 17976B and Escherichia coli strain K12 were generated by selecting and purifying 
colonies on BHI or Luria-Bertani (LB; BD Canada Inc., Mississauga, ON) agar plates, respectively, 
containing 25 µg/mL rifampicin.  The RifR P. multocida was used as a recipient for M. haemolytica and H. 
somni donor strains while RifR E. coli was used as recipient for P. multocida donor strains.  Overnight 
cultures of donor and recipient strains were grown at 37°C on TSA plates containing 5% blood and 
mating assays were performed as previously described (Michael et al., 2012b).  Representative colonies 
of resulting transconjugants were streak-purified twice before the transfers of resistance conferring 
elements was verified by susceptibility testing and PCR screening for resistance determinants and ICE 
associated genes from ICEPmu1.  To ensure that transconjugants were not spontaneously resistant 
donor cells, they were characterized by PCR using the species-specific primers listed in Table 3.1. 
3.3 Results    
3.3.1 Bacterial and viral pathogen detection 
For the detection of bacterial and viral pathogens implicated in BRD (Table 3.2; BVDV, BRSV, 
BHV-1, PI3V, Mannheimia sp., M. bovis, P. multocida and H. somni) nucleic acid extractions from lung 
tissue and nasopharyngeal swabs were screened by PCR and used to generate an overall profile of their 
occurrence within the respiratory tract.  Samples were identified as positive if the viral or bacterial agent 
was detected in the nasopharynx, lung or both.  Mannheimia sp. were present in 91% of cattle, followed 
by BVDV (69%) with the subspecies BVDV1 accounting for 77% of BVDV positives.  BVDV2 was observed 
in 26% of cattle, with all BVDV2 containing samples originating from Alberta.  One animal screened 
positive for both BVDV subspecies, with BVDV2 detected in the nasopharynx and BVDV1 detected in the 
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lung.  Mycoplasma bovis (63%) and H. somni (57%) were detected in more than half of the mortalities, 
followed by BRSV (19%), PI3V (13%) and P. multocida (13%).  BHV-1 was not detected in any of the 
samples.  Significant positive correlations were found between PCR results from nasopharyngeal swab 
and lung tissue samples in individual animals for Mannheimia sp. (r = 0.391, p = 0.0011), P. multocida (r 
= 0.531, p<0.0001), M. bovis (r = 0.395, p = 0.0010) and BVDV (r = 0.630, p<0.0001).   
  
  
Table 3.2 PCR and culture based detection of bovine respiratory disease agents from BRD mortalities originating in Alberta, Nebraska 
and Texas
a
 
  Sample Origin
b
     
Species 
Alberta            
(% Alberta) 
Nebraska         
(% Nebraska) 
Texas                    
(% Texas) 
Detected in both 
sample types (%) 
Total (% Total) 
PCR data 
Mannheimia haemolytica  38 (90) 19 (95) 5 (83) 48 (77) 62 (91) 
Pasteurella multocida 6 (14) 1 (5) 2 (33) 3 (33) 9 (13) 
Histophilus somni 25 (60) 8 (40) 6 (100) 14 (35) 39 (57) 
Mycoplasma bovis 23 (55) 15 (75) 5 (83) 22 (51) 43 (63) 
Parainfluenza 3 virus 6 (14) 2 (10) 1 (17) 1 (11) 9 (13) 
Bovine respiratory syncytial virus 10 (24) 2 (10) 1 (17) 2 (15) 13 (19) 
Bovine herpes virus 1 - - - - - 
Bovine viral diarrhea virus (BVDV) 29 (69) 17 (85) 1 (17) 33 (70.2) 47 (69) 
BVDV-1 17 (41) 17 (85) 1 (17) - 35 (51) 
BVDV-2 11 (27) -  -  - 11 (16) 
BVDV-1/BVDV-2 1 (2) -  -  - 1 (1) 
 Culture data 
Mannheimia haemolytica  31 (74) 20 (100) 4 (67) - 55 (81) 
serotype 1 22 (52) 18 (90) 4 (67) - 44 (65) 
serotype 2 1 (2) 1 (5) - - 2 (3) 
serotype 6 8 (20) 1 (5) - - 9 (13) 
Pasteurella multocida 6 (14) 1 (5) 1 (16) - 8 (12) 
Histophilus somni 5 (12) 2 (10) 3 (50) - 10 (15) 
a
 Total PCR detection data and data broken down by sample origin are overall respiratory tract profiles, positive if agent was present 
in either nasopharyngeal swab sample, lung tissue sample or both.  Detection in both sample types represent number of positive 
animals with PCR detected agent in both nasopharyngeal swab and lung tissue sample.  Culture data represent isolates recovered 
from lung tissue samples 
b 
Alberta n =  42, Nebraska n =  20, Texas n =  6 , Total n =  68 
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Co-existence of multiple pathogens was found in 97% of BRD cases with Mannheimia sp., BVDV 
and M. bovis co-occurrence most frequently identified (16.2%), followed by Mannheimia sp., BVDV, M. 
bovis and H. somni  co-occurrence (11.8%) and Mannheimia sp. and BVDV co-occurrence (10.3%) (Figure 
3.1).  Overall, the most prevalent pathogens identified together were Mannheimia sp. and BVDV, being 
present in 63% of the cattle studied.   
 
Figure 3.1 Bacterial and viral co-infection in the respiratory tract of feedlot cattle mortalities that 
succumbed to bovine respiratory disease.  aBRSV, bovine respiratory syncytial virus; BVDV, bovine viral 
diarrhea virus; HS, Histophilus somni; MB,  Mycoplasma bovis; MH, Mannheimia haemolytica; PM, 
Pasteurella multocida; PI3V, parainfluenza 3 virus.  Overall respiratory tract profiles are presented with 
animals classified as infected if pathogenic agents were detected by PCR in nasopharyngeal swab 
sample, lung tissue sample or both. 
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Bacterial species that were identified by their 16S rRNA sequences, but not part of the BRD 
complex included Bacillus sp., Psychrobacter sp., E. coli, Carnobacterium sp., Carnobacterium sp., 
Enterobacter sp., Trueperella pyogenes, Pantoea agglomerans, Comamonas sp., Aeromonas sp., 
Alcaligenes sp., Arthrobacter oxydans, Lactobacillus sakei, Pasteurella trehalosi, Proteus mirabilis, 
Staphylococcus vitulinus and Streptococcus uberis (data not shown). 
3.3.2 Isolate recovery and characterization 
 Single isolates of M. haemolytica (n = 55), P. multocida (n = 8) and H. somni (n = 10) were 
recovered from lung tissue samples (Table 3.2).  From the 55 M. haemolytica isolates collected across 
North America, 80% (n = 44) were serotype 1, 3.6% (n = 2) were serotype 2 and 16.3% (n = 9) were 
serotype 6.  PFGE analysis identified a clonal subpopulation of M. haemolytica (n = 8) in isolates 
originating in Nebraska (Figure 3.2; MH09, MH11, MH31, MH34, MH35, MH42, MH44, MH08).  
Antimicrobial resistant isolates of P. multocida were found in cattle from Texas, Nebraska and Alberta 
and shared > 70% genetic relatedness (Figure 3.3A).  Isolates of H. somni from Alberta and Texas 
exhibited near identical pulsotypes (Figure 3.3B).  
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Susceptibility testing showed 72% of M. haemolytica and 50% of P. multocida isolates were 
antimicrobial resistant.  Of these, 30% of M. haemolytica (Figure 3.2; n = 16) and 12.5% of P. multocida 
(Figure 3.3A; n = 1) were resistance to more than seven antimicrobial classes including aminoglycosides, 
penicillins, fluoroquinolones, lincosamides, macrolides, pleuromutilins and tetracyclines.  All multidrug 
resistant isolates originated from samples collected in Texas or Nebraska.  Antimicrobial resistant 
phenotypes were observed in multiple M. haemolytica populations with pulsotypes ranging in similarity 
from 65-100% (Figure 3.2), indicating that resistance was not spread strictly by clonal dissemination.  All 
antimicrobial resistance phenotypes observed corresponded with PCR-positive results for the ICEs 
associated genes from ICEPmu1 listed in Table 3.3 with the exception of two P. multocida isolates for 
which a determinant for ceftiofur resistance was not identified. 
  
  
Table 3.3  Donor strain gene profile, transfer outcome and resulting transconjugant genotype and phenotype 
Donor 
Strain Donor strain resistance gene profile 
Donor strain ICE associated 
genes from ICEPmu1 profile
a
 
Transconjugant matches 
donor yes
b,c
/ no
d
 
MH2 aphA-1, tetR, tet(H) , strA, strB, sul2 Cu-oxi, tnpA, ssb  no
a
 
MH8 blaOXA-2, floR, addB, aphA-1, tetR, tet(H), erm(42), msr(E), mph(E), aadA25, strA, strB, sul2 Hypo, Int, Cu-oxi, tnpA, ssb  no
a
 
MH9 blaOXA-2, floR, addB, aphA-1, tetR, tet(H), erm(42), msr(E), mph(E), aadA25, strA, strB, sul2 Hypo, Int, Cu-oxi, tnpA, ssb  yes 
MH10 blaOXA-2, aadB, tetR, tet(H), msr(E), mph(E), aadA25  Hypo, Int, Cu-oxi, tnpA, ssb  yes 
MH11 blaOXA-2, floR, addB, aphA-1, tetR, tet(H), erm(42), msr(E), mph(E), aadA25, strA, strB, sul2 Hypo, Int, Cu-oxi, tnpA, ssb  yes 
MH24 blaROB-1, blaOXA-2, aadB, tetR, tet(H), msr(E), mph(E), aadA25  
Cu-oxi, tnpA, ssb  yes
b
 
MH25 blaROB-1, blaOXA-2, aadB, tetR, tet(H), msr(E), mph(E), aadA25 Cu-oxi, tnpA, ssb  no
a
 
MH26 blaROB-1, blaOXA-2, aadB, tetR, tet(H), msr(E), mph(E), aadA25  Cu-oxi, tnpA, ssb  no
a
 
MH27 blaOXA-2, addB, tetR, tet(H), msr(E), mph(E), aadA25  Cu-oxi, tnpA, ssb  no
a
 
MH28 blaOXA-2, floR, addB, aphA-1, tetR, tet(H), erm(42), msr(E), mph(E), aadA25, strA, strB, sul2 Hypo, Int, Cu-oxi, tnpA, ssb  yes 
MH29 blaOXA-2, addB, tetR, tet(H), msr(E), mph(E), aadA25  Hypo, Int, Cu-oxi,  tnpA, ssb  yes 
MH30 blaOXA-2, addB, aphA-1, tetR, tet(H), erm(42), msr(E), mph(E), aadA25, strA, strB, sul2 Hypo, Int, Cu-oxi, tnpA, ssb  yes 
MH31 blaOXA-2, floR, addB, aphA-1, tetR, tet(H), erm(42), msr(E), mph(E), aadA25, strA,  strB, sul2 Hypo, Int, Cu-oxi, tnpA, ssb   yes 
MH32 blaOXA-2, addB, aphA-1, tetR, tet(H), erm(42), msr(E), mph(E), aadA25, strA,  strB, sul2 Hypo, Int, Cu-oxi, tnpA, ssb   yes 
MH33 blaOXA-2, addB, tetR, tet(H), msr(E), mph(E), aadA25  Hypo, Int, Cu-oxi, tnpA, ssb    yes 
MH34 blaOXA-2, floR, addB, aphA-1, tetR, tet(H), erm(42), msr(E), mph(E), aadA25, strA,  strB, Hypo, Int, Cu-oxi, tnpA, ssb   yes 
MH35 blaOXA-2, floR, addB, aphA-1, tetR, tet(H), erm(42), msr(E), mph(E), aadA25, strA,  strB, sul2 Hypo, Int, Cu-oxi, tnpA, ssb   yes 
MH42 blaOXA-2, floR, addB, aphA-1, tetR, tet(H), erm(42), msr(E), mph(E), aadA25, strA,  strB, sul2 Hypo, Int, Cu-oxi, tnpA, ssb   yes 
MH43 floR, aphA-1, tetR, tet(H), erm(42), strA, strB, sul2 Hypo, Int, Cu-oxi, tnpA, ssb     yes 
MH44 blaOXA-2, floR, addB, aphA-1, tetR, tet(H), erm(42), msr(E), mph(E), aadA25, strA,  strB, sul2 Hypo, Int, Cu-oxi, tnpA, ssb    yes 
MH51 blaROB-1, blaOXA-2, aadB, tetR, tet(H), msr(E), mph(E), aadA25,  Cu-oxi, tnpA, ssb  no
a
 
MH52 blaOXA-2, floR, addB, aphA-1, tetR, tet(H), erm(42), msr(E), mph(E), aadA25, strA,  strB, sul2 Hypo, Int, Cu-oxi, tnpA, ssb    yes 
MH53 blaOXA-2, floR, addB, aphA-1, tetR, tet(H), erm(42), msr(E), mph(E), aadA25, strA,  strB, sul2 Hypo, Int, Cu-oxi, tnpA, ssb   yes 
MH54 blaROB-1, blaOXA-2, floR, addB, aphA-1, tetR, tet(H), erm(42), msr(E), mph(E), aadA25, strA,  strB, sul2 
 Cu-oxi, tnpA, ssb   yes
b
 
MH57 aphA-1, tetR, tet(H), strA, strB, sul2  Cu-oxi, tnpA, ssb no
a
 
PM8A aphA-1, tetR, tet(H), erm(42), strA, strB, sul2 Hypo, Int,  Cu-oxi, tnpA, ssb  yes 
PM22A blaOXA-2, addB, aphA-1, tetR, tet(H), erm(42), msr(E), mph(E), addA25, strA, strB, sul2 Hypo, Int,  Cu-oxi, tnpA, ssb yes
c
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PM39A aphA-1, tetR, tet(H), erm(42), strA, strB, sul2 Hypo, Int,  Cu-oxi, tnpA, ssb  yes 
HS25A floR, aphA-1, tetR, tet(H), msr(E), mph(E), strA, strB, sul2 Hypo, Int, tnpA, ssb  no
a
 
HS33A blaOXA-2, floR, addB, aphA-1, tetR, tet(H), erm(42), msr(E), mph(E), aadA25, strA, strB, sul2 Hypo, Int, Cu-oxi, tnpA, ssb   yes 
HS45A floR, aphA-1, tetR, tet(H), strA, strB, sul2 Hypo, Int, Cu-oxi, tnpA, ssb  yes 
HS56A aphA-1, tetR, tet(H), strA, strB, sul2 Hypo, Int, Cu-oxi, tnpA, ssb     yes 
a
Hypo, hypothetical protein; Int, integrase; Cu_oxi, multicopper oxidase; tnpA, transposase tnpA; ssb, single stranded DNA-binding protein 
b
element did not transfer; 
c
blaROB-1 not detected; 
d
ceftiofur resistant phenotype not observed 
6
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Antimicrobial susceptibility testing of H. somni isolates produced inconsistent results and 
therefore, only genotypic analyses were reported (Figure 3.3B).  Polymerase chain reaction for 
resistance determinants revealed four isolates harboring multiple resistance genes (HS45, HS56, HS25, 
HS33; Figure 3.3B) and one isolate exhibiting a gene profile similar to the multidrug resistant isolates of 
M. haemolytica and P. multocida described above (HS33; Figure 3.3B). 
3.3.3 Conjugal transfer of ICE/mobile genetic elements 
Mating assays were used to assess the transfer of mobile genetic elements conferring multidrug 
resistance from isolates of M. haemolytica (n = 25) and H. somni (n = 4) to a RifR strain of P. multocida 
and from P. multocida (n = 3) to a RifR strain of E. coli (Table 3.3).  All but eight matings successfully 
generated transconjugant colonies.  Susceptibility testing and PCR were used to confirm phenotypes and 
genetic transfer of resistance determinants and ICE associated genes from ICEPmu1 to transconjugants.   
Danofloxacin resistance in donor stains was not observed to be transferred to recipients, possibly 
because this determinant was not located on the ICE or was not functional in transconjugants.  In 21 of 
24 successful transformations, all resistance phenotypes and associated resistance genes were 
transferred, excepting danofloxacin.  In instances where successfully transformed recipients differed 
from the profiles of the donors, two transconjugants acquired all genes and corresponding resistance 
phenotype with the exception of the blaROB-1 gene and associated ampicillin and penicillin resistance 
(MH24, MH5; Table 3.3).  One transconjugant acquired all resistance phenotypes with the exception of 
ceftiofur which was observed in the donor P. multocida strain (PM22; Table 3.3).  In the eight cases 
where matings were unsuccessful, one donor isolate (MH8; Table 3.3) had the full complement of ICE 
associated genes from ICEPmu1, six of the donor isolates (Table 3.3; MH2, MH25, MH26, MH27, MH51, 
MH57) did not contain the hypothetical protein or integrase genes and one (HS25; Table 3.3) did not 
contain the multicopper oxidase gene as screened for by PCR.  However, two isolates with a partial 
complement of ICE associated genes from ICEPmu1 (containing three of the five screened genes: 
multicopper oxidase, transposase tnpA, single stranded DNA-binding protein) were successfully 
transferred (MH54, MH24; Table 3.3). 
3.4 Discussion 
With the exception of a few cases (Booker et al., 2008; Fulton et al., 2009; Fulton et al., 2000), 
epidemiological data associated with acute BRD mortalities seldom include the complete range of 
agents that can play a role in the disease.  Further, the prevalence of agents is often highly variable 
within individual cases, likely due to the multiple factors involved in BRD pathogenesis.  Consistently, in 
all studies including ours, M. haemolytica has been the predominant pathogenic agent detected, and is 
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often identified in mixed-infections with M. bovis and BVDV (Booker et al., 2008; Fulton et al., 2009; 
Fulton et al., 2000).  The occurrence of BVDV in this study was slightly higher than expected.  
Administration of modified live vaccines is a potential source of false positive data if the duration 
between vaccination and testing is too short and the vaccine virus is still detectible by PCR.  Although 
the majority of the cattle in this study received a modified live vaccine, more than 90% were sampled at 
least seven days after the vaccine was administered upon entry to the feedlot.  Persistently infected (PI) 
cattle are also known to be a primary source of BVDV exposure, leading to seroconversion in over 80% 
of previously virus free calves post contact (Ridpath et al., 2000).  Although not screened for in the 
feedlots sampled, PI animals could have contributed to the increased occurrence of BVDV seen here.  It 
was also interesting to note that all cases of BVDV2 were found in Alberta when BVDV2 has been 
detected in 27.9% of US stocker calves with acute respiratory disease (Fulton et al., 2000). Others have 
also shown that BVDV2 accounts for a substantial portion of the North American BVDV population (Ellis, 
2009).  It is possible the failure to detect BVDV2 in USA BRD mortalities reflects a lower prevalence rate 
of BVDV2 compared to Canada.  It is also possible that data are a result of the restricted sample size, a 
limitation of the PCR to identify cattle infected with multiple strains of BVDV or the result of the use of 
BVDV2 based modified live vaccines in Alberta, but not in USA Feedlots. 
Compared to previous investigations (Fulton et al., 2009; Welsh et al., 2004), the occurrence of 
P. multocida was lower than anticipated. However, it is acknowledged that P. multocida plays a 
significant role in dairy calf pneumonia and in subacute/chronic bronchopneumonia (Dabo et al., 2007; 
Panciera and Confer, 2010) and less of a role in acute fibrinous pneumonia in feedlot calves.  Despite 
selection for fibrinous pneumonia cases, M. bovis and H. somni were isolated at higher rates than 
expected; comparable to those detected in chronic and bronchiolar pneumonia cases in Alberta (Booker 
et al., 2008).  Likewise, the prevalence of BSRV in the current study was more similar to that reported in 
subacute pneumonia (Booker et al., 2008).  In the past five years, chronic pneumonia has accounted for 
an increasing proportion of reported BRD cases (Woolums, 2010) and it is not uncommon to see both 
fibrinous and caseonecrotic pneumonia occurring simultaneously within the same individual (Gagea et 
al., 2006).  Additionally, co-isolation of multiple respiratory pathogens is commonly reported in BRD 
diagnostic investigations (Booker et al., 2008; Fulton et al., 2009; Fulton et al., 2000; Lamm et al., 2012).  
Thus, the elevated detection of some pathogens not typically associated with fibrinous pneumonia may 
not be surprising.   
The only viral pathogen tested for, but not detected in this study was BHV-1.  Previously, BHV-1 
has been reported in up to 10% of BRD cases (Booker et al., 2008; Fulton et al., 2009).  However, if 
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calves had been infected with BHV-1 prior to sampling, the virus may not have been detected as it 
persists latently in the sensory neurons of the trigeminal ganglia or tonsils (Ellis, 2009) and is 
undetectable in nasal mucus post infection (Pastoret and Thiry, 1985).  Our limited sample size may also 
have contributed to our low level of detection of this pathogen.     
Previously, ribotyping of P. multocida obtained from nasal and tracheal swabs of calves with 
BRD found that 70% of the isolates obtained from these two locations were genetically identical 
(DeRosa et al., 2000) and Timsit et al. (2013) recently found that 77% of M. haemolytica collected from 
the nasopharynx and trans-tracheal aspirations had identical PFGE profiles.  Here, we were interested to 
see if nasopharyngeal swabs could serve as a reliable and economical alternative to lung tissue to detect 
both viral and bacterial agents implicated in BRD using PCR.  Comparisons of PFGE profiles or DNA 
sequences from M. haemolytica and BVDV respectively, collected from both the nasopharynx and lungs 
of individual animals, revealed that in over 80% of cases the agents were identical (data not shown).  
Further, high concordance was observed between nasopharyngeal swabs and lung tissue for PCR 
detection of Mannheimia sp. and BVDV, indicating that nasopharyngeal swabs may provide a 
representative profile of the involvement of these agents in acute BRD mortalities. 
Between 2000 and 2009, overall decreases in the susceptibility of M. haemolytica to 
danofloxacin, tilmicosin, tulathromycin, enrofloxacin and florfenicol have been observed, with the latter 
two antimicrobials in particular associated with increased resistance in H. somni (Portis et al., 2012).  
Over time, the MICs of tetracycline, tilmicosin and tulathromycin have also been increasing for H. somni 
(Portis et al., 2012), whereas bovine sourced P. multocida has shown reduced susceptibility to 
florfenicol, spectinomycin, tetracycline, tilmicosin and trimethoprim/sulphamethoxazole (Welsh et al., 
2004).  Consistent with these trends, the present study revealed a high overall rate of antimicrobial 
resistance.  Seventy-two percent of M. haemolytica isolated in this study were antimicrobial resistant, 
about twice that detected for M. haemolytica isolated from the nasopharynx of cattle displaying BRD 
(35%) in a previous study from our group (Klima et al., 2014).  Furthermore, evidence for multidrug 
resistance against more than three antimicrobials was found in 45% of the isolates collected during this 
project; agreeing with reports that multidrug resistance in BRD pathogens is on the increase (Esaki et al., 
2004; Lubbers and Hanzlicek, 2013; Tang et al., 2009).  
Recently, an isolate of P. multocida originating from a beef calf in Nebraska was shown to 
harbour an ICE (ICEPmu1) that carried 11 resistance determinants (Michael et al., 2012a).  The similarity 
between the antimicrobial resistant phenotypic profile of ICEPmu1 and the isolates recovered in this 
study prompted the search and subsequent detection of ICE in M. haemolytica, P. multocida and H. 
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somni.  Integrated conjugative elements are a diverse group of mobile genetic elements found in both 
Gram-positive and Gram-negative bacteria, including Proteobacteria, Actinobacteria and Firmicutes.  
Although resident in the host chromosome, ICEs retain the machinery required for excision and conjugal 
transfer (Wozniak and Waldor, 2010).  These elements contribute to the horizontal transfer of accessory 
genes that can bestow traits of antibiotic and heavy metal resistance, virulence, biofilm formation, 
nitrogen fixation, and metabolic adaptation (Bi et al., 2012; Wozniak and Waldor, 2010).  The modular 
structure of ICEs with tandem arrays of closely related elements promotes generation of novel ICEs 
through module swapping and recombination (Wozniak and Waldor, 2010).  Certain ICE families employ 
processes such as toxin-antitoxin systems to prevent their loss, ensuring reintegration back into the 
donor cell after conjugation has occurred (Wozniak and Waldor, 2009).  Integrated conjugative elements 
have been detected in H. somni with accessory genes for heavy metal and toxin resistance (Michael et 
al., 2012b), but prior to this report they have not contained multidrug resistance cassettes.  In M. 
haemolytica, a partial ICE was identified by Michael et al. (2012b) in the draft genome sequence of 
PHL213, and a putative ICEMh1 was recently detected in M. haemolytica strain 42548; the latter 
harbouring five resistance genes, aphA-1, strA, strB, sul2 and tetR-tetH (Eidam et al., 2013), a less 
developed complement of resistance genes than that identified in the present study.  
ICEPmu1 from P. multocida has been shown to undergo conjugal transfer among strains of M. 
haemolytica and E. coli (Michael et al., 2012b).  In this study, we successfully transferred ICEs from M. 
haemolytica and H. somni into a recipient strain of P. multocida, but not directly into E.coli.  
Transformation efficiency was not examined here and it is possible that ICE transfer from M. 
haemolytica to E. coli or from H. somni to E. coli occurs, but at low frequency.  Integrated conjugative 
elements from P. multocida were readily transferred into a recipient strain of E. coli, raising the 
possibility that P. multocida may act as a potential vector for ICEs among bacterial species.  
Further investigations into interspecies transfer of the ICEs detected here, in particular transfer 
from BRD pathogens into enteric zoonotic or environmentally persistent species that thrive in fecal 
material and water bodies in feedlot environments, are important.  Transfer of ICEs into environmental 
isolates, such as those we co-isolated with BRD pathogens (Actinobacter sp., Bacillus sp., 
Carnobacterium sp. and Psychrobacter sp.), could result in the dissemination of these elements into the 
broader environment, establishing a reservoir for their persistence.  In addition, many veterinary and 
zoonotic pathogens are present in the feedlot environment including Salmonella sp., Enterococci sp., 
Campylobacter jejuni, E. coli, Yersinia enterocolitica and Clostridium difficile.  Potentially pathogenic 
species including E. coli, Proteus mirabilis, Moraxella bovoculi and Streptococcus uberis were identified 
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in this study, but not examined for antimicrobial resistance phenotypes.  Multidrug resistance 
development in these organisms as a result of a single ICE transfer event could potentially have 
undesirable consequences for human health.  
In this study it was interesting that multidrug resistant ICEs were detected in a high proportion 
of the USA samples (88%) but not from the samples screened from Alberta.  In the USA, the majority of 
feedlots contain more than 32,000 animals, with the five largest feeding operations controlling 
approximately 20% of feeding capacity. The average feedlot in Alberta or Saskatchewan contains 
approximately 8000 head with 64% of feedlots in Alberta having capacities of less than 20,000 head 
(Galyean et al., 2011).  It is possible that larger, higher density operations require more antimicrobial 
input to prevent disease.  Likewise, the USA calves sampled were on average 250 lbs lighter and on feed 
17 days less than those in Alberta, indicating that they were likely considered high risk for developing 
BRD and targeted for metaphylactic treatment upon arrival.   
It is important to note that BRD mortalities were targeted in this study and the cattle examined 
were likely exposed to more antimicrobial therapies than the general cattle population.  Further, sample 
size was a limitation and a larger surveillance project would be required to comment on the prevalence 
of ICE-harbouring bacteria in North American cattle populations.  Future investigations into 
antimicrobial resistance profiles of P. multocida, M. haemolytica and H. somni from swine and poultry 
operations and at other levels of the beef production system, including cow-calf and various points 
during the marketing chain would be advisable.  Aarestrup et al. (2008) estimated that swine and 
poultry account for about 34% and 33%, respectively, of the global livestock antimicrobial market, 
whereas cattle account for only 26% (Aarestrup et al., 2008).  The majority of ICEs in this study could be 
co-selected for through the use of florfenicol, enrofloxacin, tilmicosin, or tetracycline; all drugs used to 
prevent or treat BRD (Welsh et al., 2004), but they are also approved for use in swine and poultry.  
Examination of the prevalence of ICE-harbouring bacteria in the general feedlot population would be of 
benefit as rates of resistance have been shown to differ between healthy and sick populations of cattle 
(Klima et al., 2014) and the high levels of resistance observed in mortality cases here may not be 
represent those of the general population. 
To our knowledge, this is the first detection of ICEs in M. haemolytica and H. somni from USA 
feedlots and the very recent identification of ICEPmu1 (Michael et al., 2012a) indicates that these 
elements may have recently emerged within the feedlot environment.  In the current study, isolates of 
M. haemolytica were obtained that exhibited resistant phenotypes against all antimicrobials commonly 
employed to treat BRD, except ceftiofur.  However, resistance to ceftiofur was observed in this study in 
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an isolate of P. multocida and the potential incorporation of this determinant into existing M. 
haemolytica could result in pathogenic isolates resistant to the entire suite of therapies commonly used 
to treat and prevent respiratory disease in feedlot cattle.   
3.5 Conclusion 
The identification of ICEs in this study is new information that may affect our thought processes 
relative to how antimicrobials are used for BRD control and treatment.  One hypothesis is that the 
presence or absence of ICEs relates to antimicrobial use, however in the current study the Alberta 
feedlots followed the same antimicrobial use protocols for BRD control and treatment as those in 
Nebraska.  As such, continued research should be supported to investigate interspecies barriers for ICE 
transfer and to describe donor vs. recipient range to provide more information about how features of 
these elements contribute to proliferation and spread.  Further, comparative sequence analysis of these 
identified ICE is required to confirm gene arrangement, and may give insight into of the evolutionary 
development of these specific elements.  If ICEs were to become established in bacterial populations 
implicated in BRD, it could compromise the ability of prophylactic use of antimicrobials to control this 
important disease. 
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4 Chapter 4: Draft genome sequence of a Mannheimia haemolytica serotype 6 isolate collected from 
the nasopharynx of a beef calf with bovine respiratory disease 
 
 
 
 
Chapter 4 has been published in Genome announcements. 
Klima, C.L., Cook, S.R., Hahn, K.R., Amoako, K.K., Alexander, T.W., Hendrick, S., McAllister, T.A., 2013. 
Draft Genome Sequence of a Mannheimia haemolytica Serotype 6 Isolate Collected from the 
Nasopharynx of a Beef Calf with Bovine Respiratory Disease. Genome announcements 1. 
 
 
 
 
This manuscript was drafted by Cassidy Klima with suggestions and comments from the collaborating 
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4.1 Introduction and results 
Mannheimia haemolytica, a member of the family Pasteurellaceae, is a commensal in the upper 
respiratory track of birds and mammals and can contribute to acute fibrinous pleuropneumonia.  In 
feeder cattle, this is termed bovine respiratory disease (BRD) and costs the North American industry 
millions yearly through treatment, reduced meat yield and mortalities.   
Host specificity and virulence of M. haemolytica is linked to serovar, with serotypes 1 (S1) and 6 
(S6) being infectious to cattle (Rice et al., 2007).  Whole genomes of serotypes 1 (Gioia et al., 2006) and 
2 (S2) (Lawrence et al., 2010), have been sequenced, but not S6.  We describe a draft genome sequence 
of M. haemolytica H23, a S6 isolate obtained from the nasopharynx of a beef calf with BRD.   
The M. haemolytica H23 genome was sequenced by Cofactor Genomics (St Louis, MO) using 
both Roche 454 Jr. and Illumina Genome Analyzer IIx.  A total of 99,677 single-end 400bp 454 reads and 
47,372,771 paired-end 80bp Illumina reads were generated, with respective coverages of 14x and 
2847x.  Independent assemblies using Newbler 2.5p1 (454) and SOAPdenovo (Illumina) were merged 
with Minimus2.  A draft genome of 69 contigs with a total of 2,662,064 bp, a GC content of 40.8% and 
N50 of 101,714 bp was produced and verified using optical mapping.  
 Gene prediction and function using the Integrated Microbial Genomes (IMG; 
http://img.jgi.doe.gov/) platform (Markowitz et al., 2010) identified 2704 genes representing 89.2% of 
total bp.  Of these, 2628 were protein coding sequences, 2197 with assigned functions; 416 for 
transporters, 764 signal peptides and 551 transmembrane proteins.  Compared to S1 and S2 genomes, 
52 genes coding for primarily hypothetical or phage-related proteins were exclusive to M. haemolytica 
H23.  A CRISPR element and a type III secretory component identical to S2 (Lawrence et al., 2010) were 
also detected.  Gene prediction identified 3 5S rRNA, 1 16S rRNA and 1 23S rRNA gene.   
 This Whole Genome was deposited at DDBJ/EMBL/GenBank under the accession 
AOGP00000000. The version described in this document is the first version, AOGP01000000. 
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5 Chapter 5: Comparative genomic analysis of Mannheimia haemolytica from bovine sources 
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5.1 Introduction 
Mannheimia haemolytica is an important bacterial pathogen of ruminants and the principal 
agent of bovine respiratory disease (BRD) in feedlot cattle, a condition responsible for an annual loss of 
over 3 billion US$ to beef producers worldwide (Watts and Sweeney, 2010).  An opportunistic pathogen, 
M. haemolytica’s role in disease is strongly associated with serovar.  Of the 12 capsular serotypes 
identified to date, serotype 1 (S1) and serotype 6 (S6) are the most prevalent in BRD (Al-Ghamdi et al., 
2000; Rice et al., 2007).  Serotype 2 (S2) is found frequently as a commensal in the upper respiratory 
tract of healthy cattle (Klima et al., 2011), but can produce pneumonia in ovine hosts, frequently causing  
high mortality rates that have devastated wild and domestic sheep populations (Lawrence et al., 2010b).  
Multiple virulence factors have been characterized in M. haemolytica, the most significant being 
a secreted leukotoxin and a capsular lipopolysaccharide (Zecchinon et al., 2005).  However, little is 
understood about how genetic differences among the serovars contribute to pathogenesis.  Until 
recently, whole genome sequences were only available for one bovine strain of S1 and two strains of S2, 
one being from cattle, the other from a sheep (Gioia et al., 2006; Lawrence et al., 2010a).  Although S1 is 
the principal serovar associated with BRD in North America, the prevalence of S6 in this disease has 
been increasing (Katsuda et al., 2008).    
Treatment of BRD in cattle relies heavily on antibiotics, making M. haemolytica a primary target 
for these therapies in feedlots.  As a result, there is risk for selection of antimicrobial resistant M. 
haemolytica within this setting.  The recent isolation of pan-resistant M. haemolytica isolates from beef 
calves (Eidam et al., 2015; Lubbers and Hanzlicek, 2013) is of concern both for maintaining drug efficacy 
and the risks associated with resistance gene transfer between bacterial species in the agriculture 
sector.  Such a risk is particularly relevant to zoonotic pathogens that can impact human health.  
Consequently, there is a need to develop less drug dependant strategies to control BRD. 
Veterinary vaccines play a major role in the management of disease and in conferring protection 
against pathogens, however the development of effective vaccines against BRD has been challenging. 
Comparative analysis between pathogenic and commensal serovars of M. haemolytica allows for the 
examination of virulence mechanisms that have not been phenotypically defined and can aid in 
identifying targets for vaccine design.  To better understand the genetic factors contributing to virulence 
we sequenced and performed comparative genomic analysis on 11 strains of M. haemolytica 
representing serotypes 1, 2 and 6 from cattle that were healthy, morbid or deceased as a result of BRD.   
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5.2 Materials and methods 
5.2.1 Isolate selection 
 Eleven isolates of M. haemolytica representing serotypes 1, 2 or 6, from healthy, pneumonic or 
cattle that succumbed to BRD were subject to whole genome sequencing (Table 5.1). These were 
selected from an archive of 532 isolates collected between 2007 and 2012 that had been previously 
characterized with pulsed-filed gel electrophoresis and antimicrobial susceptibility testing (Klima et al., 
2011; Timsit et al., 2013, as described in Chapters 2 and 3).  Candidates for sequencing were selected 
based on criteria that maximized diversity in both genotypes and antimicrobial resistance profiles, but 
also considered  strains collected from a variety of geographical locations including Canada (Alberta), 
USA (Nebraska, Texas) and France (Nantes).  Isolates collected from lung tissue, nasopharyngeal swabs 
or tracheal aspirations were all represented (Table 5.1).  
  
  
 
Table 5.1 Features of 11 Mannheimia haemolytica strains sequenced 
Strain Serovar Sample type 
Animal 
status 
Sampling 
Location 
Genomes 
Size Mb 
No. 
Contigs CDS 
No. prophage 
(% of genome) 
No. CRISPR 
Spacers 
ICE size  kb 
(%GC) 
M. haemolytica L024A 1 lung deceased Texas 2.64 116 2768 8 (11.3) 14 70.6 (40.2) 
M. haemolytica L044A 1 lung deceased Nebraska 2.6 122 2714 5 (6.9) 15 81.1 (41.6) 
M. haemolytica 157-4-1 1 nasopharynx healthy Alberta 2.6 116 2715 7 (11.6) 14 48.6 (39.3) 
M. haemolytica 535A 1 nasopharynx morbid Alberta 2.58 158 2730 6 (10.5) 13 47.1 (39.3) 
M. haemolytica T2 2 lung morbid France 2.43 107 2448 2 (4.1) 8 n/a 
M. haemolytica L033A 2 lung deceased Nebraska 2.57 128 2639 4 (8.2) 7 66.3 (40.2) 
M. haemolytica 587A 2 nasopharynx healthy Alberta 2.5 111 2547 5 (8.3) 4 n/a 
M. haemolytica L038A 6 lung deceased Alberta 2.6 134 2724 6 (10.9) 16 50.4 (39.1) 
M. haemolytica T14 6 trachea morbid France 2.56 101 2647 5 (9.2) 17 49.9 (39.1) 
M. haemolytica H23 6 nasopharynx morbid Alberta 2.6 69 2628 4 (7.6) 14 48.6 (39.3) 
M. haemolytica 3927A 6 nasopharynx healthy Alberta 2.52 105 2602 5 (7.4) 16 46.6 (39.4) 
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5.2.2 DNA extraction and sequencing 
Phenol: chloroform extraction was used to isolate genomic DNA.  Briefly, M. haemolytica cells 
from a 5 mL culture grown overnight in trypticase soya broth were harvested by centrifugation at 6000 x 
g for 5 min. The pellet was suspended in 1 mL of sterile 0.85 % NaCl and centrifuged again for 1 min to 
wash away growth media.  The washed cell pellet was resuspended in 700 μL of T10E25 (10mM Tris-HCl 
pH7.5; 25mM EDTA).  To the suspension, 175 μL of 5 M NaCl, 35 μL of 10 mg/mL Proteinase K and 44 μL 
of 20% SDS was added and the mixture was incubated at 65°C for 1-2 h until cells were completely lysed.  
The lysed mixture was extracted once with phenol, once with phenol:chloroform:isoamylalcohol 
(25:24:1) and twice with chloroform.  Ammonium acetate (10 M) was added to the final aqueous 
fraction to achieve a final concentration of 0.5 M followed by the addition of 1 volume of isopropanol to 
precipitate the DNA. The DNA was gently spooled out, added to a new tube containing ice-chilled 70% 
ethanol and centrifuged at 10,000 x g for 10 min to obtain a DNA pellet.  The supernatant was decanted 
and the tube was left open to air-dry.  The pellet was suspended in 100 μL of nuclease free deionized 
water. 
Genomic library construction and sequencing of the serotype 6 strain M. haemolytica H23 (Table 
5.1) was performed by Cofactor Genomics (St Louis, MO).  A draft genome was generated from 
combined assemblies of Roche 454 Jr. single-reads and paired-end reads generated using Illumina 
Genome Analyzer IIx (as discussed in chapter 4). This strategy was undertaken to generate a robust 
assembly and maximize sequence coverage in order to produce as high quality a draft genome as 
possible as this was the first S6 M. haemolytica strain sequenced.  Library construction and sequencing 
of the remaining 10 M. haemolytica isolates was performed using Roche-454 GS FLX Titanium chemistry 
by Genome Québec (McGill University, QC) with draft genomes assembled using Newbler software.  
With the exception of M. haemolytica H23, which was annotated through the NCBI Prokaryotic Genome 
Annotation Pipeline (PGAAP) (Angiuoli et al., 2008), gene prediction and functional annotation of  all 
other genomes were performed using the Integrated Microbial Genomes (IMG) platform (Markowitz et 
al., 2009).  
5.2.3 Comparative analysis 
 Sequences of the 11 draft genomes were aligned using Mugsy (Angiuoli and Salzberg, 2011). The 
core, accessory and pan-genomes were calculated using the pan-genomes analysis pipeline (PGAP) 
(Zhao et al., 2012).  Cluster analysis cut-off values were set at 85% sequence identity over 90% of the 
sequence length.  To examine the pan-genome of M. haemolytica with an expanded dataset, the 
analysis was also performed including an additional 10 M. haemolytica strains from public databases 
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(Table A1 in Appendix A).   Single nucleotide polymorphism (SNP) discovery and validation was 
performed using in-house scripts on filtered 454AllDiffs.txt files, using the serovar 1 M. haemolytica 
USDA-ARS-USMARC 183 strain as the reference.  A SNP atlas was produced using Circos (Krzywinski et 
al., 2009) depicting the single point differences compared to the reference genome M. haemolytica 
USDA-ARS-USMARC 183 (Figure B1 in Appendix B).  For bacteriophage analysis, contigs were ordered 
based on alignment against M. haemolytica strain M42548 using progressive Mauve (Darling et al., 
2010), with the resulting concatenated contigs analyzed for the presence of prophage using PHAST 
(Zhou et al., 2011).  Prophages were aligned using MAFFT (Katoh and Standley, 2013) and phylogenetic 
analysis generated using neighbor tree reconstruction in Phylip v. 3.68 (Sanchez et al., 2011).  Genes not 
annotated by PHAST were examined using PSI BLAST (Altschul et al., 1997) and IMG (Markowitz et al., 
2013).  Proposed arrangements for integrative conjugative elements (ICEs) were constructed by pairwise 
alignments against ICEPmu1 and ICEMh1 (GeneBank accession numbers:  CP003022, CP005383, 
respectively).  In-house scripts were used to BLAST unassembled reads against previously assembled 
ICEs where possible to verify gaps.  CRISPR-Cas regions were compiled using the CRISPRdb (Grissa et al., 
2007).  Alignments of individual prophage, CRISPR-Cas, ICEs and virulence genes were performed using 
Geneious version 6.1.6.  Where provided, reference locus IDs originated from M. haemolytica H23 
(AOGP01000042).  This genome was used as a reference as it has already been published and submitted 
to NCBI.  For cases when a locus ID was not available from M. haemolytica H23, reference locus IDs were 
supplied from the first fully closed genome of M .haemolytica, strain M42548 (CP005383).     
5.3 Results and discussion 
5.3.1 Sequencing statistics 
 Sequencing of the 11 M. haemolytica strains resulted in draft genomes ranging from 2.43Mb to 
2.60Mb, with assemblies containing 69-158 contigs (Table 5.1).  Compared to S2 strains, S1 and S6 
genomes contained on average, 100kb more genomic content, which was mainly attributable to added 
or enlarged integrated mobile genetic elements such as integrative conjugative elements and prophage.  
Percent identity among the genomes ranges from 79.0% to 97.8% (Figure 5.1).  Sequence diversity was 
highest amongst the three S2 genomes, ranging from 87.0% to 96.2% identity. 
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Figure 5.1 Dendrogram of 11 Mannheimia haemolytica genomes.  Tree generated by hierarchical 
clustering based on coding sequences within genomes. 
 
5.3.2 Core, dispensable and pan-genome analysis  
Pan-genome analysis serves two main functions, the first being to define clusters of orthologue 
groups within a dataset.  The purpose of this is to identify the pan-genome which is defined as the global 
compliment of genes that code for all of the proteins a species can produce (Tettelin et al., 2005).  From 
this analysis, the core genome defined as the set of genes common to all strains, can also be 
determined, along with the dispensable genome that contains the genes present in two or more strains. 
The accessory genome can also be described which contains those genes present in the dispensable 
genome along with all strain specific genes unique to each isolate.  Analysis of the different genome 
subsets can provide important insights into the evolution of a species and identify potentially important 
novel genes (Callister et al., 2008). The core genome is expected to be comprised largely of coding 
sequences (CDSs) that are essential for cell function and survival, most of which are derived from a 
common ancestor (Callister et al., 2008).  The dispensable genome contains the bulk of the diversity in a 
species (Medini et al., 2005) and is more likely to contain genes obtained through horizontal gene 
transfer.      
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The second function of pan-genomic analysis is to determine the pan-genome status.  First 
described by Tettelin et al. (2005) an open pan-genome is one where the addition of new strains to the 
dataset will continue to result in the accumulation of new genes.  Conversely a closed pan-genome 
occurs when the addition of new strains eventually results in the number of strain specific genes 
converging at zero, this being the point where the dataset encompasses the number of genome 
sequences required to sufficiently characterize the species (Medini et al., 2005).  Open pan-genomes are 
frequently observed in species that inhabit diverse ecological niches, have complex lifestyles and are 
prone to horizontal gene transfer (De Maayer et al., 2014; Tettelin et al., 2005), while closed pan-
genomes exist in species from isolated, narrow niches or where recent divergence has led to limited 
genetic diversity within the gene pool (Tettelin et al., 2005).  A key example of a closed pan-genome 
occurs with Bacillus anthracis where the sequencing of four strains was found to completely 
characterize the species (Medini et al., 2005). Defining the status of the pan-genome can be used to 
determine the inclusiveness of a genomic dataset.  Estimating the genomic diversity within a population 
of isolates in this fashion can allow for prediction of the number of whole genome sequences required 
to fully characterize a clade of organisms (Tettelin et al., 2005; Vernikos et al., 2015).   
Analysis of the core genome of the 11 M. haemolytica strains identified 1,594 genes, accounting 
for approximately 60% of each genome (Figure 5.2; Figure 5.3).  The accessory genome contained 
almost 3x the number CDSs (4587) of the core genome and although the dispensable genome contained 
some genes associated with survival and maintenance, over three quarters were hypothetical genes of 
unknown function.  Approximately 300 unique genes (ranging from 257 to 367) were present in each of 
the 11 strains; (Figure 5.2).  These were mostly of a hypothetical nature or unidentified CDSs within 
prophage regions.  Characterization of these unknown genes would provide additional insight into the 
function and biology of M. haemolytica. 
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Figure 5.2 Size of the core genome, dispensable genome and number of strain unique CDS in 11 
Mannheimia haemolytica genomes.  Petals contain number of unique CDS per strain.  Pink petals 
represent S2 strain, blue S1 strains and green S6 strains.  Analysis based on 85% sequence identity 
across 90% length. 
 
Figure 5.3 Percentage of genes from the core and dispensable genomes categorized based on Clusters of 
Orthologous Groups.   
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To obtain a more comprehensive perspective of the core- and pan-genomes of M. haemolytica, 
10 publically available M. haemolytica genomes were included in the analysis along with the 11 isolates 
sequenced in the current work.  This analysis determined the core genome of 21 M. haemolytica strains 
to contain 1,333 genes with the pan-genome remaining open, continuing to increase by approximately 
286 new genes with the incorporation of each new strain (Figure 5.4 and Figure 5.5).  Extrapolation of 
the curve fitted to the new gene plot for the 21 M. haemolytica strains estimated that even after the 
addition of 1000 genomes to the dataset, 123 unique genes per genome would still be added to the pan-
genome.  The pan-genome analysis when applied based on serovar showed that both S1 (n=8) and S6 
(n=7) pan-genomes remained open (Figure 5.6A and Figure 5.6B), increasing with the addition of each 
new strain by 305 and 295 genes, respectively. However, the analysis shows the S2 pan-genome (n=6) to 
be closed with no new genes being added after the inclusion of six genomes (Figure 5.6C).  
 
 
Figure 5.4 Pan and core genome of 21 Mannheimia haemolytica isolates.  For the pan-genome the 
number of specific genes is plotted as a function of the number of strains sequentially added.  For the 
core genome the number of shared genes is plotted as a function of the number of strains sequentially 
added.   
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Figure 5.5 New gene discovery plot for pan-genome analysis of 21 Mannheimia haemolytica genomes 
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Figure 5.6 Pan and core genomes of Mannheimia haemolytica isolates based on serovar. For the pan-
genome, in grey, the number of specific genes is plotted as a function of the number of strains 
sequentially added.  For the core genome, in black, the number of shared genes is plotted as a function 
of the number of strains sequentially added. Panel A: serotype 1 strains, n= 8. Panel B: serotype 6 
strains, n=7. Panel C: serotype 2 strains, n=6.  
 
It was expected that the M. haemolytica pan-genome would be open given this bacterium 
inhabits a complex niche, can exhibit both commensal and pathogenic phenotypes, and contains  many 
serovars with varying degrees of mobile genetic elements (MGE) (Gioia et al., 2006; Lawrence et al., 
2010a).  It was surprising that the S2 pan-genome was closed, especially when one considers that the 
89 
bulk of genomic diversity seen at the whole genome level occurs across S2 strains.  It is clear the higher 
abundance of MGE within S1 and S6 strains contributes significantly to the diversity of unique CDSs in 
these serovars.  The evolutionary basis for the overall lack of diversity and abundance of MGE in S2 
compared with the pathogenic serovars remains unknown.  It would be of interest to investigate if a 
closed pan-genome also occurs in S2 strains obtained from ovine sources.  It is possible that a host 
species specific accessory gene pool occurs within the different ruminants and that potentially 
pathogenic MGE are more abundant in S2 strains associated with ovines.  
5.3.3 SNP analysis  
  A total of 22,506 SNPs were identified and of these 20,833 were from annotated genes, with 
the remainder arising from intergenic regions (Table 5.2).  The percentage of SNPs in each genome 
ranged from 0.0031 to 0.5722%, 31× and 16× higher in S2 than in S6 and S1 genomes, respectively.  A 
total of 5,230 nonsynonymous SNPs (nsSNPs) were discovered in 1543 coding sequences, 2990 resulting 
in non-conservative amino acid substitutions (e.g. exchange of polar amino acid for a nonpolar amino 
acid) at 1208 loci.  Over 80% of the nsSNPs occur within the S2 genomes with M. haemolytica T2 
exhibiting the highest degree of divergence (Figure B1 in Appendix B).  This is not unexpected as S2 
strains have been shown to be highly diverse (Klima et al., 2011).  Over 60% of nsSNPs occured within 
genes assigned to one of 6 COG categories including: unknown function (378), general function 
prediction only (147), carbohydrate transport and metabolism (101), amino acid transport and 
metabolism (97), replication, recombination and repair (97) and cell wall/membrane/envelope 
biogenesis (96) categories.  The latter category is not surprising given greater diversity has been 
observed in outer membrane proteins among serotype 2 strains than either serotype 1 or serotype 6 
strains (Davies and Donachie, 1996).  Bacteriophage associated elements comprised a large proportion 
of the genes of unknown function. 
  
  
Table 5.2 Single nucleotide polymorphism analysis of 11 Mannheimia haemolytica genomes using M. haemolytica USDA-ARS-USMARC 183 as 
reference   
  M. haemolytica genome 
  L044A L024A 157-4-1 535A T14 3927A L038A H23 L033A 587A T2 
Number of SNPs 1804 1452 173 81 339 487 443 529 14724 13284 12195 
No. of sSNPs in coding regions 1312 1076 68 29 150 181 152 156 10545 9401 8709 
No. of nsSNPs in coding region 296 252 87 44 160 275 260 332 3100 2939 2729 
CDS with nsSNPs 99 96 52 40 60 76 72 74 1183 1163 1034 
CDS with nsSNPS unique to strain 60 46 19 17 42 23 28 38 311 292 634 
9
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A total of 72 nsSNPs that would result in premature stop codons were identified.  These 
occurred most frequently in single genomes and over 50% were associated with genes of hypothetical 
function or phage regions (38).  An outer membrane siderophore receptor (F388_05956) which is 
functional in S2 strains was predicted to be non-functional in three of the S1 strains.  An additional six 
genes associated with iron acquisition (F388_09151, MHH_c20980, F388_03340, MHH_c28330, 
F388_10280, F388_03345) contain premature terminators making them non-functional in at least one of 
the S2 genomes.  Given the importance of iron acquisition for pathogenesis and host adaptation in M. 
haemolytica (Roehrig et al., 2007) it is possible the mutations in these genes within the S2 genomes 
could play a role in reduced virulence of this serotype.  The functional counterparts of these proteins in 
S1 and S6 strains would be interesting candidate antigens for a vaccine as they may be important for 
pathogenesis. 
5.3.4 Virulence factors 
Mannheimia haemolytica has multiple virulence factors that have been extensively studied and 
reviewed previously (Highlander, 2001).  These include multiple fimbriae, adhesions, outer membrane 
proteins (Confer, 2009), neuraminidases (Griffin, 2010), transferrin-binding proteins and capsular 
polysaccharides (Rice et al., 2007). One of the most important elements of M. haemolytica pathogenesis 
is a secreted leukotoxin of the RTX repeat family that has cytolytic activity against bovine leukocytes 
(Highlander et al., 2000).  Leukotoxin is produced by a locus containing four genes: lktC, lktA, lktB, and 
lktD (Davies et al., 2002; Rice et al., 2007).  The lktA gene encodes for the inactive protoxin (pro-Lkt), the 
lktC gene encodes for a transacylase that post-translationally activates pro-LktA and the lktB and lktD 
genes code for a proteins that transport the active LktA from the cell (Davies et al., 2002; Rice et al., 
2007; Thumbikat et al., 2005).  
Seventy-two different genes with known roles in virulence were compared, the vast majority 
exhibiting >95% sequence identity among all sequences in the 11 M. haemolytica genomes (Table A2 in 
Appendix A).  Genes with sequence identities <95% included TbpA and TbpB, which are part of a 
transferrin-iron uptake system, both the leukotoxin genes lktA and lktC, a surface antigen serotype-
specific antigen 1 (Ssa1), the heme sequestering hemophore HuxA, the S-ribosylhomocysteinase LuxS 
which is involved in quorum sensing, the outer membrane protein PlpE, and WecC which is associated 
with LPS synthesis.  Sequence variation between serovars for TbpA and TbpB (Lee and Davies, 2011), 
LktA and LktC (Davies and Baillie, 2003; Davies et al., 2002; Davies et al., 2001) and PlpE (Confer et al., 
2006) have been documented previously.  In all of these cases, sequence diversity within virulence 
genes occurs largely within the S2 strains, with genes in S1 and S6 strains nearly identical.  
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5.3.5 Mobile genetic elements 
Horizontal gene transfer through transduction, transformation and conjugation is the primary 
means for prokaryotic organisms to obtain new genetic material (Wozniak and Waldor, 2010).  Mobile 
genetic elements including plasmids, phages, genomic islands or genomic modules can transfer DNA 
that may alter the pathogenicity of an organism through the provision of toxins and antimicrobial 
resistance genes (Wozniak and Waldor, 2010).  They may also provide factors that regulate virulence 
gene expression, influence adhesion or enhance immune evasion (Wagner and Waldor, 2002).  As a 
result horizontal gene transfer plays an important role in the evolution, maintenance and transmission 
of virulence genes and the development and spread of antimicrobial resistance (Keen, 2012).   Two 
types of MGE, ICE and prophage, were identified in the M. haemolytica genomes here, each contained 
genes with the ability to contribute to the virulence of the strains examined.  
5.3.6 Bacteriophage  
Prophage can be a significant source of genetic diversity in bacterial genomes and act as vectors 
for virulence factors including extracellular toxins, proteins involved in adhesion, modulation of host 
activity, resistance to serum and altered antigenicity, as well as mitogenic factors (Busby et al., 2013; 
Fortier and Sekulovic, 2013).  Phage content in the genomes ranges from 4.1-11%, with a total of 57 
intact prophages identified across the 11 sequenced strains, all clustering into 14 profiles based on 
nucleotide similarity (Figure 5.7; Table 5.3). Overall, S2 genomes contained fewer intact prophages (2-5) 
than S1 (5-8) or S6 (4-6) genomes.  Clusters P1, P2, P3, P4, P7, P8, P13 and P14 resembled phage from 
the Siphoviridae family and clusters P6, P9, P10, P11, and P12 resembled phage from the Myoviridae 
family.  Prophages vB_Mha-L024AP10 and vB_Mha-157-4-1P6 clustered independently contained fewer 
base pairs and although they contained multiple phage components they did not align against the 
reference strain M. haemolytica strain M42548, and thus may not represent true prophages.   
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Figure 5.7 Phylogenetic analysis of 57 prophage found in 11 whole genome sequences of Mannheimia 
haemolytica.  Phage cluster number identified at each node.  
  
  
Table 5.3 Metadata for prophage found in Mannheimia haemolytica  
      
Prophage length in kb (No. CDS): 
Cluster 
Max 
length 
(kb) 
Percent 
similarity  Spacera  
Toxin-
antitoxin 
Prophage 
family 587A  L033A T2 L038A H23 T14 3927A 154-7-1 L044A L024A 535A 
P1 42.7 95.3 - RelB/E Siphoviridae - - - 38.5 (36) 41 (39) 38.9 (38) 39 (38) 30.9 (36) 31.5 (36) 39.9 (39) 34.7 (35) 
P2 56.1 92.2 31 - Siphoviridae - - - 51.1 (64) - - - 42.9 (62) 42.1 (61) 38.7 (59) 53.9 (64) 
P3 43.3 84 8, 28, 29, 
30, 31 
HigA/B Siphoviridae 52.1 (81) 104.1 (148) - - - - - - - - - 
P4 97.9 60.7 11, 12, 15 - Siphoviridae 38.8 (45)  44.6 (52) 76.1 (82) 77.5 (83) 76.9 (82) 27.6 (29) 76.1 (81) 65.2 (82) 76.2 (82) 75.1 (84) 
P5 54 - - HigA/B Siphoviridae - - 53.9 (62) - - - - - - - - 
P6 20.5 - - HipA/ B Myoviridae - - - - - - - 20.4 (26) - - - 
P7 54 67.1 3, 6, 17, 
25 
HicB/C Siphoviridae 30.3 (51) 35.4 (48) - - - - 37.2 (52) 48.8 (52) 25.5 (43) 27.6 (48) 31 (46) 
P8 39.1 59.7 3, 6, 16, 
25 
HigA Siphoviridae - - - 32.5 (51) 37.4 (51) 34.4 (46) 
 
- - 22.3 (24) - 
P9 47.1 94.5 - - Myoviridae - - - 46.3 (60) 41.8 (51) 41.9 (57) 42 (57) 46 (60) 46.2 (61) 45.2 (61) 40.9 (56) 
P10 14.1 - - HipB Myoviridae - - - - - - - - - 14 (21) - 
P11 47.5 85.1 26, 27 HipB Myoviridae - - - 38.3 (51) - 43.4 (57) 40.1 (54) 34.8 (48) - 35 (49) 35 (49) 
P12 43.3 84 - - Myoviridae 41.9 (58) 41.1 (56) - - - - - - - - - 
P13 29.3 - - HicB/C Siphoviridae - 29.3 (39) - - - - - - - - - 
P14 44.7 - - HigA Siphoviridae 44.7 (47) - - - - - - - - - - 
a
CRISPR spacer found with >90% sequence identity to phage sequence 
 
  
9
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Complete (P1, P3, P5, P6, P7, P13) or partial (P8, P10, P11, P14) toxin-antitoxin systems occurred 
in 10 of the 14 phage clusters identified.  Toxin anti-toxin systems are small genetic modules that consist 
of an operon coding for a stable toxin that inhibits cell growth and an unstable antitoxin that protects 
against the toxin’s effects (Van Melderen and De Bast, 2009; Wang and Wood, 2011).  Toxin-antitoxin 
systems are commonly carried on MGE including phages and plasmids to ensure maintenance of the 
element once it is integrated into the host (Yamaguchi et al., 2011).  When co-expressed these 
components form a stable complex inhibiting the toxin’s activity.  Free antitoxin is highly unstable and 
degrades quickly requiring its continued synthesis to inhibit the toxin’s function (Yamaguchi et al., 2011).  
Toxin-antitoxin systems are widespread in bacteria and are thought to promote cellular adaption 
through the regulation of cell growth.  These elements can also regulate gene expression, control 
bacterial populations and contribute to programmed cell death and abortive infection (Yamaguchi et al., 
2011),.  a strategy used by bacteria to deter the spread of phages throughout the bacterial population.  
During phage infection, protein expression in the host can be slowed or arrested.  If the infected host 
bacterium codes for a toxin-antitoxin system the liable antitoxin it produces will degrade, leaving the 
toxin to kill the cell, ultimately preventing the phage from replicating and spreading.  The toxin-antitoxin 
systems identified here are mainly associated with Siphoviridae-like prophages, although two 
Myoviridae-like prophages (P10 and P11) contained a copy of the HipB antitoxin without its 
corresponding HipA toxin (Table 5.3).  It is possible these are remnants of previously functioning toxin-
antitoxin systems or are maintained by the phages as a means to avoid abortive infection by the host.  
This is a possibility given the HipA toxin gene was present in other regions of the chromosome of those 
M. haemolytica strains that contained both P10 and P11 phages. 
Multiple virulence associated genes were present in the prophages identified, including a 
periplasmic chaperone LolA (P5), involved in outer membrane localization of lipoproteins, and Plp4 (P4), 
a lipoprotein with homology to OmpA.  A peptidoglycan glycosyltransferase, MtgA (P5) with homology 
to penicillin binding protein was also present.  A mutation in this gene in Brucella abortus was previously 
shown to attenuate virulence (Derouaux et al., 2008).  SanA (P2) was also detected, which functions in 
murein synthesis, but also has been implicated in vancomycin resistance (Rida et al., 1996).  A gene 
coding for a cytoplasmic protein UspA (P4, P14) was also present.  Although the direct mechanisms by 
which this protein functions is unclear, it has been shown to promote cell survival during exposure to 
environmental stress (Siegele, 2005). 
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5.3.7 CRISPR-Cas 
 Nearly half of all bacterial genomes sequenced encoded for an adaptive immune system called 
CRISPR-Cas (clustered regularly interspaced short palindromic repeats-CRSIPR associated proteins) 
(Makarova et al., 2011; Szczepankowska, 2012). This system protects against invading genetic elements 
like phages and plasmids (Makarova et al., 2011). Three major types and ten subtypes of CRISPR-Cas 
systems have been identified (Makarova et al., 2011) all containing a CRISPR array typically localized 
near 4 to 20 CRISPR associated (Cas) genes.  The CRISPR array consists of a leader sequence followed by 
numerous conserved direct repeat (DR) sequences, interspersed with variable spacer sequences 
(Szczepankowska, 2012). Spacers are typically derived from viruses or plasmids (Sampson et al., 2013; 
Samson et al., 2013; Szczepankowska, 2012) and are used by a suite of Cas proteins to target reinfection 
by these same viruses or plasmids through a process called interference (Makarova et al., 2011).  Cas 
proteins support the integration of spacers into the CRISPR array, the processing of the transcribed 
CRISPR array into mature crRNA that contain a spacer and a partial DR, and the targeting and cleavage of 
reinvading nucleic acids complimentary to the spacer sequences (Makarova et al., 2011).  The selection 
of proto-spacers (spacer precursors) from the invading nucleic acid is dependent on the presence of a 
proto-spacer-associated motif (PAM), which is a short nucleic acid sequence located either downstream 
or upstream of the proto-spacer.  Proto-spacer-adjacent motifs are not incorporated into the spacer 
itself, enabling the CRISPR-Cas system to distinguish between target proto-spacer and the host CRISPR 
array (Szczepankowska, 2012).  In addition to its role in defence CRISPR-Cas has also been implicated in 
gene expression and regulation of cellular processes including biofilm formation, lysogenization, spore 
formation, replicon maintenance and segregation, and DNA repair-recombination (Szczepankowska, 
2012).   
All of the M. haemolytica genomes contain a single type I-C/Dvulg CRISPR-Cas system (Figure 
5.8A) (Makarova et al., 2011).  These are highly conserved within serovar (>98% nucleotide identity) 
with the greatest sequence variation occurring between S2 and S1/S6 genomes, although overall 
pairwise identity across all strains was still >95% (Table S2).  The leader and trailer sequences in all 
CRISPR arrays were highly conserved with >98% pairwise identify among strains (Figure 5.8B), a result 
that was expected as these regions are typically conserved within a species (Karginov and Hannon, 
2010).  Six different DR sequences of 32 nucleotides were identified in the CRISPR arrays, with variations 
in positions 1, 11, 22, 24 and/or 32 (Figure 5.8D).  The CRISPR arrays are organized into two blocks in 
both the S1 and S6 genomes, each block consisting of a unique DR sequence followed by 4-8 identical 
DR sequences (Figure 5. 8C).  In S2 strains, one block of DRs occurs and is identical to those in the first 
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block of S1/S6 arrays.  Direct repeat sequences are target sites for Cas proteins (Stern et al., 2010) and 
sequence variation in these regions could affect the regulation of crRNA maturation.   
  
  
  
Figure 5.8 Schematic of CRISPR-Cas systems identified in whole genome sequence analysis of 11 Mannheimia haemolytica genomes. Panel A: 
Cas loci present in serotype 1,6 and 2 genomes. Panel B: consensus sequence for leader and trailer regions of CRISPR arrays.  Underlined regions 
are complimentary to psi-tag. Panel C: CRISPR array spacer and direct repeat organization.  Diamonds represent direct repeat sequences while 
numbered tiles represent spacer sequences. Panel D: Sequences of the 6 unique direct repeats detected in CRISPR arrays.  Panel E: 3D structure 
of direct repeats found in CRISPR arrays.  Psi-tag indicated by grey shaded regions. Panel F: sequence alignment of protospacers with suspected 
PAM highlighted in grey (TTC).  
9
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A conserved terminal eight nucleotide motif ((T/A)ATTGAAA) or psi-tag, implicated in Cas 
protein binding (Hale et al., 2009) and self-discrimination (Marraffini and Sontheimer, 2010), was 
identified in the DR sequences and in the leader (in reverse orientation) and the trailer of all CRISPR 
arrays (Figure 5.8E).  The significance of this feature is unclear, but it could play a role in regulation of 
CRISPR activity.  All DRs exhibit homology (90-100% nucleotide identify) to those occurring in arrays in 
other Pasteurellaceae members including Bibersteinia trehalosi USDA-ARS-USMARC-190, Mannheimia 
varigena USDA-ARS-USMARC-1312 and Aggregatibacter actinomycetemcomitans D7S-1 and have a 
secondary structure consistent with those from the CRISPR-Cas I-C/Dvulg subtype (Kunin et al., 2007) 
(Figure 5.8E). 
Thirty-two unique spacer sequences (35-37 nt) were identified in the CRISPR arrays, with S2 
genomes containing fewer spacers (4-8) than S1 (13-15) and S6 (14-17) (Figure 5.8C).  A duplicate spacer 
was identified in the array of M. haemolytica 535A, an occurrence that has been previously identified 
(Jansen et al., 2002).  The majority of the spacers are of phage origin, most corresponding to prophages 
present in the chromosome of the strains sequenced here (Table 5.4).  It is possible that these CRISPR 
spacers are regulating lysogeny of the phages in these genomes; a phenomenon previously observed in 
E. coli (Edgar and Qimron, 2010).  
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Table 5.4 Spacer sequences identified in CRISPR arrays from 11 M. haemolytica genomes 
Spacer 
No. of 
genomes with 
CRISPR spacer 
No. of genomes 
with sequence 
outside of spacer Spacer targeta Gene target 
1 8 0 n/a CRISPR  2 6 0 n/a CRISPR  
3 6 6 prophage hypothetical 4 8 0 n/a CRISPR 
5 8 4 prophage hypothetical 6 8 8 prophage putative tail 
7 8 0 n/a CRISPR 8 7 2 prophage regulatory protein Rha 
9 6 0 n/a CRISPR  10 3 0 n/a CRISPR  
11 8 8 prophage hypothetical 
12 8 5 prophage hypothetical 13 7 8 bacterial  UDP-N-acetylglucosamine 2-epimerase 14 8 5 bacterial glycosyl transferases group 1 
15 6 7 prophage tail sheath protein FI 16 3 4 prophage Mu protein F  
17 7 7 prophage hypothetical 18 2 8 prophage hypothetical 
19 2 0 n/a CRISPR 20 2 0 n/a CRISPR 
21 2 0 n/a CRISPR 22 1 0 n/a CRISPR 
23 1 0 n/a CRISPR 24 1 0 n/a CRISPR 
25 1 7 prophage DNA helicase 26 1 6 prophage hypothetical 
27 1 8 prophage head morphogenesis protein 28 1 10 prophage hypothetical 
29 1 10 prophage hypothetical 30 1 1 prophage pyruvate kinase 
31 1 15 prophage hypothetical 32 1 0 n/a CRISPR a
n/a, spacer sequence not identified in prophage located in host chromosome 
 
Bacteriophages have developed multiple strategies to avoid CRISPR regulation, including 
mutations within either the proto-spacer or PAM or through phage encoded anti-CRISPR systems (Peng 
et al., 2003; Sorek et al., 2008).  As a result, it is not surprising to see multiple prophages integrated into 
the S1 and S6 genomes even though these strains contain large CRISPR arrays.  Homology searches of 
the prophage regions here failed to identify any previously described phage encoded anti- CRISPR 
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systems (Peng et al., 2003; Sorek et al., 2008).  Consistent with other type I-C CRSIPR-Cas (Kupczok and 
Bollback, 2014), examination of the upstream sequences of the proto-spacers revealed a 3nt PAM of 
GAA conserved in all but one target proto-spacer sequence (Figure 5.8F).    
Approximately 18% of all CRISPR bearing organisms contained self-targeting spacers (Stern et 
al., 2010). However, these spacers lack conservation, meaning they don’t typically occur in more than 
one strain or isolate, and they are often associated with CRISPR systems that have partially or fully 
degraded activity (Stern et al., 2010).  An exception to this occurs in the intracellular pathogen 
Francisella novicida, where a self-targeting CRISPR-Cas system facilitates immune evasion during 
infection (Sampson et al., 2013).  In this species the CRISPR system suppresses expression of an immune 
stimulatory lipoprotein (BLP) that would otherwise trigger the activation of Toll-like Receptor 2-
dependant proinflammatory response in the host during infection.  Absence of this regulation 
completely attenuates the bacteria during infection making CRISPR-Cas critical for F. novicida 
pathogenesis (Sampson et al., 2013).  
Two spacers present in S1 and/or S6 but not in S2 CRISPR arrays were complimentary to 
sequences encoded  on the host chromosome; one for a glycosyl transferases group 1 domain 
(F388_04799), and a second for  a UDP-N-acetylglucosamine 2-epimerase (F388_04774).  Glycosyl 
transferases transfer activated sugars to a variety of substrates and UDP-N-acetylglucosamine 2-
epimerase is a rate limiting enzyme in the sialic acid biosynthetic pathway.  Sialic acids are nine-carbon-
sugars prevalent on the surface of vertebrate cells that serve a variety of biological, biophysical and 
immunological functions (Lewis and Lewis, 2012).  As a result many pathogens, including Neisseria 
meningitidis, Campylobacter jejuni, Group B Streptococcus, Pseudomonas aeruginosa and Haemophilus 
influenza (Angata and Varki, 2000), incorporate sialic acid on their cell surface as a form of molecular 
mimicry to avoid immune detection in the host or to aid in adhesion (Lewis and Lewis, 2012; Severi et 
al., 2007).  Given the CRISPR systems here appear intact it is possible that like F. novicida, M. 
haemolytica employs CRISPR-Cas to regulate gene expression of proteins that control the display of 
sugar moieties and sialic acid on the bacterial cell surface.  This would possibly contribute to immune 
subversion or enhanced colonization during infection as spacers against these genes were not identified 
in commensal S2 strains.   
5.3.8 Integrative conjugative elements 
Putative ICEs were identified in 9 of the 11 genomes sequenced, ranging in in size from 46.6 to 
81.1 kb (Figure 5.9A).  These elements are self-transmissible MGE that encode all of the necessary 
machinery for replication and conjugative transfer (Jackson et al., 2011; Wozniak and Waldor, 2010).  
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Integrative conjugative elements are integrated into the host genome, but under certain conditions can 
excise, circularize and replicate.  Transfer of ICEs in Gram-negative bacteria typically occurs through 
conjugation machinery coded for by a type 4 secretion system (T4SS), a system similar to that coded for 
on conjugative plasmids, consisting of a membrane spanning secretion channel and extracellular pilus 
(Wozniak and Waldor, 2010).  After an element has excised from the chromosome, a relaxosome 
formed by several proteins assembles at the origin of transfer.  A relaxase nicks the double stranded 
circular element and then while maintaining a complex with the single stranded DNA is recognized by a 
coupling protein and recruited to the T4SS translocation channel.  After the DNA is translocated, the 
relaxase detaches and the element is circularized.  Complimentary DNA is synthesized and the double 
stranded element is integrated into the chromosome by an integrase (Juhas, 2015).  A copy of the 
original ICE remains in the donor and undergoes complimentary strand synthesis and reintegrates back 
into the host genome (Wozniak and Waldor, 2010).  Indeed, all the ICEs identified here were integrated 
into the same copy of the tRNALeu gene and contained a type IV secretion system (T4SS), a coupling 
protein, an integrase and a relaxase (Figure 5.9; Table A2 in Appendix A), (Guglielmini et al., 2014).   
  
  
 
 Figure 5.9 Schematic of putative integrative conjugative elements identified in whole genome sequences of Mannheimia haemolytica.  Genes are represented 
as arrows.  Grey background indicated regions >94.5% sequence identity. Panel A: proposed ICE genes arrangement. Panel B: resistance gene regions with 
alignments against cassettes found in other bacterial species.  
1
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All T4SSs identified belonged to the MPFG family, originally described in ICEHin1056 from 
Haemophilus influenzae (Guglielmini et al., 2014), but prevalent in Pasteurellaceae (Gallibacterium 
anatis, Pasteurella multocida and Histophilus somni) and various Gammaproteobacteria (Vibrio cholera, 
E. coli, Pseudomonas aeruginosa, Klebsiella pneumonia and Salmonella enterica).  Three distinct 
sequence profiles for the T4SS region were identified with an overall nucleotide similarity of 85.8%, 
indicating that the ICEs did not all originate from the same source.  However, 6 of the 9 ICEs had a 
nucleotide similarity of 95.5% across the entire array.  This, coupled with their prevalence across 
genetically diverse isolates indicates that ICEs may have an ancient lineage within this species.  None of 
these ’common’ ICE profiles contained accessory gene cassettes so it is unlikely that they are being 
selected for by antimicrobials.  However, contig alignment against the previously identified ICEMh1 
indicates that they may contain a HipA/B toxin/anti-toxin system.  Closure of these genomes would be 
required to conclusively determine if this system is contained within these elements, but the presence 
of toxin-antitoxin systems could explain why ICEs are being maintained in the M. haemolytica 
population in such high abundance.  This observation would indicate that these elements would not 
have to necessarily contain genes coding for antimicrobial resistance (AMR) in order for selective 
pressure to ensure their retention within the genome. 
Entry exclusion prevents conjugative transfer of duplicate elements with closely related transfer 
apparatuses into bacterial cells (Thomas and Nielsen, 2005) and is system characteristic of conjugative 
plasmids (Garcillán-Barcia and de la Cruz, 2008).  Two mechanisms for entry exclusion in F plasmids have 
been identified, one that alters the cell’s outer surface, making it less receptive to pilus attachment and 
the second which is mediated by proteins that sit in the inner membrane and prevent DNA entry 
(Marrero and Waldor, 2007a, b; Thomas and Nielsen, 2005).  An exclusion system has been well 
characterized in the SXT/R391 family of ICEs and is mediated by small inner membrane proteins 
expressed by both the donor (TraG) and recipient cells (Eex) (Marrero and Waldor, 2007a).  We 
annotated a TraG homolog in the T4SSs here (F388_01689) a gene that exhibited >80% nucleotide 
similarity to that in ICEs from other Pasteurellaceae species (Mannheimia varigena USDA-ARS-USMARC-
1388:CP006953, Bibersteinia trehalosi USDA-ARS-USMARC-190:CP006956, Pasteurella multocida 
36590:CP003022, Actinobacillus pleuropneumoniae; NZ_ADX001000031, Actinobacillus suis ATCC 
33415:Ga0057047_gi672591300.1, Haemophilus parasuis D74:Ga0040714_123, Haemophilus somnus 
2336:NC_010519).  A potential analog to Eex was also identified in our work (F388_01694) and in the 
genomes of the species listed above.  This coding sequence displays characteristics that are similar to 
Eex in SXT/R391; being cytoplasmic, located in the opposite orientation but adjacent to the TraG gene 
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and displaying significant AA similarity in the N terminal region, but a high degree of diversity in the C-
terminal region (Marrero and Waldor, 2007b). 
Only three of the ICEs, ICEMhL024A, ICEMhL044A and ICEMhL033A, contained cassettes with 
accessory genes but those that did possessed genes coding for AMR.  These cassettes were highly similar 
to those previously identified in Pasteurella multocida (PRJNA86887) and Bibersteinia trehalosi 190 
(GCA_000521765.1) with portions of these cassette or individual genes also being identified in strains of 
E. coli, Klebsiella pnuemoniae, Salmonella, Actinobacter baumannii, Serratia marcescens and Neisseria 
meningitides (Figure 5.9B).  In addition to multiple AMR genes including; aphA1, strB, strA, sul2, floR, 
erm42, tetH, aadB, aaA25, msrE, and mhpE, a blaROB-1 was also identified in ICEMhL033A with a single 
nucleotide substitution from C to T at position 370. This substitution generated a premature stop codon, 
rendering this gene non-functional in making these strains susceptible to these antimicrobials (as 
presented in Chapter 3).  
Although only one of the three S2 strains examined here contained ICE, it harboured an 
extensive AMR profile.  As S2 strains are prevalent commensals among healthy cattle the spread of AMR 
ICEs among these populations may be more significant to the environmental resistome than AMR ICE in 
S1 and S6 strains that may be removed from the population through effective drug therapies or if the 
host animal succumbs to disease.  All of the AMR containing ICEs originated from strains of M. 
haemolytica isolated from cattle in the USA.  Phylogenetic analysis of a larger population incorporating 
different Pasteurellaceae species from different animal production systems would be of benefit to 
determine the origin of these elements.  Source tracking of isolates is a common practice to gain insight 
into AMR development and spread, but with the mobility of those elements between species it may 
become just as important in the future to track ICEs between and within production systems rather than 
focusing on AMR at the species or strain level.   
The potential for entry exclusion in ICEs from M. haemolytica may affect AMR dissemination.  If 
the absence of ICEs resistance cassettes is widespread among M. haemolytica populations, entry 
exclusion could render these strains resistant to the uptake of ICEs from other members within the 
population that may contain AMR genes.  This would limit ICE spread primarily to clonal dissemination in 
M. haemolytica populations or to those cases where the entry exclusion system was ineffective.  If non-
AMR ICEs are as prevalent in the Pasteurellaceae family as they appear based on this dataset, entry 
exclusion by these elements could explain why there is relatively a low overall occurrence of AMR  in 
members the Pasteurellaceae family (Klima et al., 2011; Watts and Sweeney, 2010).    
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A D-lactate dehydrogenase was identified in ICEMhL024A that is also present in the 
chromosome of various Pasteurellaceae species (Bibersteinia trehalosi: USDA-ARS-USMARC-190, USDA-
ARS-USMARC-192, USDA-ARS-USMARC-188; Haemophilus parasuis: 84-17975, KL0318; Haemophilus 
somni 129PT; Actinobacillus pleuropneumoniae: JL03, AP76, SH0165) including the ICEs in multiple 
genomes of M. haemolytica  (Mannheimia haemolytica: M4258, USDA-ARS-USMARC-185, USDA-ARS-
USMARC-185, D153).  Lactate is a by-product of bacterial fermentation.  The L-form of this carboxylic 
acid is readily metabolized in the liver and tissues of mammals, but high levels of  D lactate can 
accumulate in the blood of cattle during acidosis, a condition common in feedlot calves feed high grain 
finishing diets (Nagaraja et al., 1981).  It is possible that D-lactate dehydrogenase is being used by M. 
haemolytica to metabolize the D isomer of lactate as an energy source.   
A multicopper oxidase was also identified in resistance region three of all three ICEs exhibiting 
AMR (Figure 5.9B).  Multiple roles have been proposed for multicopper oxidases that include iron 
transport and copper resistance (Kellner et al., 2008).  Copper is a trace element added to cattle feed 
(Larney et al., 2014), the vast majority of which, as with all other heavy metals, is excreted in faeces and 
urine (Petersen et al., 2007).  It is possible the multicopper oxidase here is playing a role in copper 
resistance as a result of environmental exposure.  It is also conceivable that the gene is functioning in 
iron sequestration, a function linked to the pathogenesis of M. haemolytica (Sathiamoorthy et al., 2011). 
5.4 Conclusion 
 Multiple factors contribute to virulence in M. haemolytica.  Comparative analysis of whole 
genome sequences of pathogenic and non-pathogenic serovars has highlighted sequence diversity and 
functional differences in key virulence factors in particular iron acquisition and outer membrane 
proteins.  Overall, S2 genomes contained fewer intact prophages.  These elements likely contribute to 
virulence profiles in S1 and S6 strains as some of these phages were shown to harbour virulence-
associated genes.  It is also possible that CRISPR-Cas is playing a role in the surface expression of sialic 
acid residues on the surface of S1 and S6 strains contributing to immune evasion during infection.  
Integrative conjugative elements were found in all but two strains, both of which were serotype2, and 
are likely playing a role in enhancing host survival in strains that harboured multidrug resistant 
cassettes.  It is possible that these elements are regulating their own dissemination through populations 
through entry exclusion.  This holds implication for spread of AMR within M. haemolytica as well as 
possibly other bacterial populations as a result of the transfer of these mobile genetic elements within 
bacterial populations.   
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6 Chapter 6: In silico identification and high throughput screening of antigenic proteins as candidates 
for a Mannheimia haemolytica vaccine 
 
 
 
 
Chapter 6 is not intended for publication. 
 
 
 
 
This manuscript was drafted by Cassidy Klima with suggestions and comments by Dr. Tim McAllister, Dr. 
Rahat Zaheer, and Shaun Cook.  Experimental design, data collection and analysis were undertaken by 
Cassidy Klima and Dr. Rahat Zaheer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
114 
6.1 Introduction 
Vaccination is one of the most efficient and cost-effective management strategies to control and 
eliminate disease (Rappuoli and Aderem, 2011).  With the significant advancements in “omics” 
technologies over the past two decades, the approaches used for vaccine design have also evolved.  
Traditional methods used to generate first and second generation vaccines have focused on the whole 
organism based on the principals of “isolate, inactive and inject” proposed by Pasteur in the 19th 
century (Doolan et al., 2014).  The availability of whole genome sequencing has shifted the focus 
towards in silico antigen prediction for the development of third generation vaccines.  This reverse 
vaccinology (RV) approach starts from the genome rather than the whole organism and identifies the 
entire catalog of proteins that an organism has the potential to express at any point in time.  This 
strategy has the added benefit of being applicable to cultivatable and non-cultivatable species (Rappuoli, 
2001). 
In silico prediction of vaccine candidates relies on software that can screen whole genome 
sequences and identify coding DNA.  The subcellular localization of these sequences is determined by 
bioinformatics tools that identify signatures like signal peptides, transmembrane helices or cell-wall 
anchor motifs associated with surface exposed or secreted proteins (Bertholet et al., 2014).  These 
proteins are most likely to be accessible to the immune system and thus make good vaccine targets.  
Comparative genomics and pan-genome analysis can be coupled with this strategy to ensure the 
antigens selected provide maximum coverage for a universal vaccine against a diverse species or to 
avoid cross reactivity against non-target species like commensal organisms (Moriel et al., 2008). 
 The strategy to start from the genome rather than the organism was first proposed by Rappuoli 
(2000).  Since the conception of RV, progress in genomic, proteome, and transcriptome analysis have 
had a massive impact on the speed that novel antigens are being identified (Rappuoli and Aderem, 
2011).  However, challenges still exist with evaluating the antigenicity of a large number of vaccine 
candidates.  Traditional antigen production strategies require the cloning and expression of several 
hundred proteins (Pizza et al., 2000) and their purification prior to evaluation in immunogenicity assays.  
These methods are often laborious and challenging due to the many complications associated with 
expression of outer membrane proteins including issues of low solubility, the formation of inclusion 
bodies, protein instabilities and toxicity to the expression host (Rosenblum and Cooperman, 2014).  
 This study employed a RV approach to identify conserved antigens in pathogenic strains of M. 
haemolytica for the purpose of developing of a bovine vaccine against this organism.  A comparative 
genomics approach was taken to identify candidates in the pan-genome that provide broad protection 
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against serotypes 1, 2 and 6 of this pathogen.  To screen antigen candidates in a high throughput 
manner, this study utilized the unique application of a cell-free translation system coupled with ELISA to 
screen proteins for their immunoreactivity against sera generated n cattle experimentally infected with 
M. haemolytica.  This methodology drastically reduced the time required to screen hundreds of antigen 
candidates for immunoreactivity, over the span of weeks as compared to the months that would be 
required to clone and express individual candidate proteins within a host expression system.   
6.2 Material and methods 
6.2.1 Antigen candidate selection 
Pan-genome analysis was used to identify groups of coding genes present in the whole genome 
sequence of 23 M. haemolytica isolates (Table 6.1).  The analysis, performed using a pan-genome 
analysis pipeline (PGAP) (Zhao et al., 2012), produced a gene cluster file that grouped all orthologues 
present in the dataset based on cut-off values set at 95% sequence identity over 90% of the sequence 
length.  From this file, orthologous clusters were selected based on the gene occurrence in at least 50% 
of genomes.  A single representative gene from each cluster was selected, prioritizing the M. 
haemolytica L044A genome. The M. haemolytica L044A genome was given priority due to its large size 
among the sequenced genomes, anticipating its use as a template for amplifying the majority of target 
genes for downstream expression and immunoreactivity studies.  If the representative gene was absent 
in M. haemolytica L044A, it was selected from the genomes of strains from serotypes 1 or 6 including M. 
haemolytica L024A, L038A or H23.  The resulting group of genes was screened using SignalP (Petersen et 
al., 2011) to identify N-terminal signal peptides, indicative of gene products that are secreted from the 
cell.  The TMHMM server v 2.0 was also used to identify proteins containing transmembrane helices that 
are typically associated with the cell membrane (http://www.cbs.dtu.dk/services/TMHMM-2.0/). The 
program PSORTb 3.0 (Nancy et al., 2010) was used to predict the localization of each gene product 
within the cell. Those candidates identified as having N-terminal signal peptides, with fewer than 4 
transmembrane helices, with known or predicted localization to either the periplasm, cell membrane, 
extracellular secretion, identified as lipoproteins, or predicted hypothetical proteins with  these 
desirable features were further examined  in an immunoreactivity assay using a coupled-cell free 
transcription/translation system for protein expression.  
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Table 6.1 Strains of Mannheimia haemolytica used in pan-genome 
analysis 
  Strain Accession Number Serovar Isolate origin 
M. haemolytica L024A n/a 1 Texas 
M. haemolytica L044A n/a 1 Nebraska 
M. haemolytica 157-4-1 n/a 1 Alberta 
M. haemolytica 535A n/a 1 Alberta 
M. haemolytica T2 n/a 2 France 
M. haemolytica L033A n/a 2 Nebraska 
M. haemolytica 587A n/a 2 Alberta 
M. haemolytica L038A n/a 6 Alberta 
M. haemolytica T14 n/a 6 France 
M. haemolytica H23 n/a 6 Alberta 
M. haemolytica 3927A n/a 6 Alberta 
M. haemolytica USDA-ARS-USMARC 2286 NC_021883.1 n/a Nebraska 
M. haemolytica D174 NC_021739.1 6 Iowa 
M. haemolytica D171 NC_021738.1  2 Iowa 
M. haemolytica D153 NC_021743.1 1 Iowa 
M. haemolytica MhSwine2000 ATTA00000000.1 1 Iowa 
M. haemolytica MhBrain2012 ATSZ00000000.1 1 Georgia 
M. haemolytica D38 AUNL00000000.1  6 Iowa 
M. haemolytica D35 AUNK00000000.1 2 Iowa 
M. haemolytica D193 ATSY00000000.1  1 Iowa 
M. haemolytica M42548 NC_021082.1 1 Pennsylvania 
M. haemolytica USDA-ARS-USMARC-183 NC_020833.1 1 Kansas 
M. haemolytica USDA-ARS-USMARC-185 NC_020834.1 6 Kansas 
M. haemolytica PHL213 NZ_AASA00000000.1 1 n/a 
M. haemolytica Bovine A2 NZ_ACZY00000000.1 2 n/a 
M. haemolytica Ovine A2 NZ_ACZX00000000.1 2 n/a 
 
6.2.2 Protein expression 
The EasyXpress Protein Synthesis kit (RiNA GmbH, Germany) was used to express genes 
encoding for protein candidates in vitro according to manufactures specifications. Template for the PCR 
reactions use to generate selected genes originated from overnight cultures of M. haemolytica L044A, 
M. haemolytica L024A, M. haemolytica L038A or M. haemolytica H23 grown of tryptic soy agar (TSA) 
blood at 37°C.  The DNA was isolated using phenol: chloroform extraction method, as described in 
chapter 5.   
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According to the EasyExpress Liner Template kit instructions, a two-stage PCR process was used 
to generate a transcriptionally active PCR product.  This product contained the coding sequence of the 
targeted antigen along with the regulatory elements required for optimal transcription and translation 
in a cell-free expression system and an N-terminal Strep-tag, and a C-terminal 6xHis tag.  The first PCR 
used primers generated specifically for each coding sequence with an additional 5’ adaptor consisting of 
30 nt for the forward primer and 20 nt for the reverse.  These 5’ adaptors were targets for the second 
round of PCR that was used to add the regulatory elements and end terminal tags to the final PCR 
product.  For the first round of PCR a two-step program was used.  After an activation step of 95°C for 30 
s, 5 cycles of 94°C for 1 min, 55° for 1 min and 72°C for 2 min were performed followed by 35 cycles of 
94°C for 1 min, 62°C for 1 min and 72°C for 2 min, followed by a final 10 min extension at 72°C.  A list of 
the gene targets, their characteristics and primers used is presented in Table A3 in Appendix A.  The 
second round of PCR used amplicon products from the first PCR as template according to 
manufacturer’s specifications.  A two-step program was also used for this second round of PCR.  After an 
activation step of 95°C for 30 s, 5 cycles of 94°C for 1 min, 50° for 1 min and 72°C for 2 min were 
performed followed by 35 cycles of 94°C for 1 min, 53°C for 1 min and 72°C for 2 min, followed by a final 
10 min extension at 72°C.  The HotStar HiFidelity Polymerase Kit (Qiagen Canada Inc., Toronto, ON) was 
used for both rounds of PCR reactions.   
The EasyXpress Protein Synthesis kit was used according to manufacturer’s specifications to 
express the tagged proteins used for immunoreactive screening.  A 40 µL reaction volume was set up for 
each targeted protein expression using 5.6 μL of the final product from the final PCR reaction as 
expression template.  The expression reactions were incubated in a thermo-mixer at 33°C for 90 min at 
300 rpm.    
6.2.3 Generation of sera against M. haemolytica for antigen screening 
To generate the sera for screening antigenic candidates, three groups of three calves each were 
challenged twice, on day 1 and 28, with intranasal challenge of either serotype 1, 2 or 6 strains of M. 
haemolytica.  The sequences used were the ones sequenced during the present study and used to infer 
pan genome.  The serotype 1 group inoculum consisted of a mixture of M. haemolytica L024A, M. 
haemolytica L044A, M. haemolytica 535A and M. haemolytica 157-4-1.  The serotype 2 group inoculum 
consisted of a mixture of M. haemolytica 587A, M. haemolytica L033A, and M. haemolytica T2.  And the 
serotype 6 group inoculum consisted of a mixture of M. haemolytica L038A, M. haemolytica H23, M. 
haemolytica T14, and M. haemolytica 3927A.   
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To prepare bacteria for intranasal challenge, 350 mL aliquots of brain heart infusion (BHI) broth 
were each inoculated at 1:100 dilution of overnight cultures M. haemolytica strains.  The cultures were 
grown at 37°C to an optical density at 600 nm between 0.6 – 0.8.  Cultures of like serotypes were pooled 
using equal volumes and the colony forming units (cfu) of resulting suspensions were adjusted to 7.9 – 
6.4 x 109 cfu/mL.  A 25 mL aliquot of each pooled cell suspension was used for intratracheal 
administration to the animals.  The second challenge was prepared the same as the first except the 
administered dosages were lower ranging between 2.7 – 3.7 x 109 cfu/mL.  Blood samples were 
collected on day 42 and processed for sera isolation as previously described (Harland et al., 1992).  
Serum samples were stored at -80°C.  For immunoreactivity screening, equivalent volumes of sera from 
each of the animals inoculated with each specific serotype strains of M. haemolytica were pooled.  
Throughout the study animals were handled in accordance with the guidelines set by the Canadian 
Council on animal care (http://www.ccac.ca/). 
6.2.4 Enzyme-linked immunosorbent assay to determine immunoreactivity of sera 
Proteins were screened with ELISA, in parallel for their relative quantity and immunoreactivity 
with polyclonal antisera raised in calves experimentally infected with M. haemolytica.  For the ELISAs  
360 µL of solubilisation buffer (50 mM sodium phosphate [pH 8.0], 300 mM NaCl, 10 mM imidazole and 
1.2% Triton X-100) was added to 40 µL of the translated protein product and mixed.  One hundred 
microliters of solubilized protein mixture was added into each of four wells in Ni+2 coated plates (Pierce, 
Cat # 15142 or 15442) and incubated for 1 h at room temperature with shaking at 400 rpm in a plate 
thermomixer (Eppendorf Canada Inc., Mississauga, ON).  The mixture containing the unbound proteins 
was removed and the wells were washed 3 times for 5 min each, with 200 µL of wash buffer (50 mM 
sodium phosphate [pH 8.0], 300 mM NaCl, 30 mM imidazole).  Strep-tactin-HRP conjugate (150 µL; 
product # 161-0382; Bio-Rad Laboratories, Inc. Hercules, CA, USA) was added to one set of wells (Strep-
ELISA plate) and diluted 1:10,000 using antibody dilution buffer (phosphate buffered saline (PBS) 
containing 0.05% Tween-20 and 2% bovine serum albumin). The Strep-ELISA plates were incubated for 1 
h at room temperature with shaking at 400 rpm.  The polyclonal antibodies raised in calves against 
serotypes 1, 2 or 6 of M. haemolytica were each added at 1:500 dilution in antibody dilution buffer to 
the Ni+2 bound proteins in one of the remaining three plates (anti-S1 sera-ELISA plate; anti-S2-ELISA sera 
plate; anti-S6-ELISA sera plate) and incubated for 1 h at room temperature with shaking at 400 rpm. 
Plates were washed 3 times for 5 min each using 200 µL of ELISA wash buffer (PBS containing 0.05% 
Tween-20).  The Strep-ELISA plates were processed for detection using SIGMAFASTTM OPD tablets 
(P9187, Sigma-Aldrich, Oakville, ON, Canada) according to manufacturer’s instructions. To the anti-S1 , 
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anti-S2 and anti-S6 sera-ELISA plates, goat anti-bovine IgG-HRP antibody was diluted 1:30,000 in dilution 
buffer (200 µL) and incubated at room temperature for 1 h with shaking at 400 rpm.  The resultant 
mixture was washed 3 times, for 5 min each with 200 µL of ELISA wash buffer.  The anti-S1, anti-S2 and 
anti-S6 sera-ELISA plates were processed for detection as described above.  All assays were performed 
in duplicate. The data from all plates was normalized by subtracting the corresponding blank samples.  
Relative immunoreactivity was calculated as the ratio of OD between test and control well standardized 
against the highly expressing control protein PlpE. 
6.3 Results 
Pan-genome analysis identified 11,538 orthologous clusters of genes across the 23 analyzed M. 
haemolytica genomes.  A total of 2,341genes were present in at least half of the genomes and used for 
further analysis.  From the list of 2341 genes, a total of 240 candidates were identified by SignalP and 
PSORT containing N-terminal signal peptides with diverse sub-cellular localizations (78 periplasmic, 52 
outer membrane, 15 extracellular, 13 cytoplasmic membrane and 82 unknown).  For ease of use in the 
expression system, some (n=43) genes were truncated into equivalently sized products (size range ≤ 
1kb) resulting in a total of 291 candidates for screening for immunoreactivity with bovine sera.  A total 
of 246 of the 291 proteins expressed and were captured so as to be measurable using the Strep-ELISA 
plates.  In total, 186 candidate proteins were immunoreactive to at least one type of sera tested; 58 
periplasmic, 45 outer membrane, 12 extracellular, 10 cytoplasmic membranes and 61 unknowns. Of 
these screened candidates, 105 were immunoreactive to all sera screened; 32 periplasmic proteins, 26 
outer membrane proteins, 6 extracellular proteins, 7 cytoplasmic membrane proteins and 34 unknown 
proteins.  The top ten antigens ranked based on immunoreactivity are shown in Figure 6.1 and include 
the serine protease Ssa-1 (MhL044A_02282), competence protein ComE (MhL044A_02398), a solute 
binding protein (MhL044A_00030), an outer membrane protein (MhL044A_02240), a molybdenum ABC 
transporter (MhL044A_02132), an ABC (ATP-binding cassette)-type dipeptide transport system 
(MhL044A_00839), a filamentous hemagglutinin (MhL044A_00334_402H), a conserved hypothetical 
protein (MhL044A_01577), a chaperone for outer membrane protein SurA (MhL044A_00827) and a 
porin protein (MhL024A_01035_563B). The overall rankings of the proteins based on ELISA, broken 
down by the serum used and by the overall average of relative immunoreactivity are presented in Table 
A3 in Appendix A. 
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Figure 6.1 Top ranked antigen candidates based on serological screening.  Relative immunoreactivity 
was calculated as the ratio of OD between test and control well standardized against the control protein 
PlpE. 
 
6.4 Discussion 
 Of the top ten ranking candidates identified, the first five are discussed in further detail.  The 
highest ranking candidate in the immunoreactivity assay was the serotype-1 specific antigen, Ssa1.  This 
protein has been implicated in colonization of the nasopharynx (Highlander, 2001) and likely has 
protease activity (Sathiamoorthy et al., 2011).  Although shown to elicit a strong antibody response in 
both rabbits and cattle (Lo, 2001) it has also been shown to be down-regulated 27-fold during infection 
in vivo (Sathiamoorthy et al., 2011).  Ssa1  has previously been examined as a vaccine candidate against 
M. haemolytica (Ayalew et al., 2011) and has recently been found to rank within the top 10 of 55 
vaccine candidates identified through two-dimensional polyacrylamide gel-based immunoproteomic 
analyses of M. haemolytica outer membrane vesicles (Ayalew et al., 2010).  Although previously only 
shown to express in vitro in S1 strains of M .haemolytica (Highlander, 2001) the data here suggests that 
the antigen can also elicit an antibody response in vivo from S6 strains and to a lesser extent S2 strains. 
The second highest ranking candidate was identified as the competence protein ComE.  
Competence is the mechanism by which bacteria acquire exogenous DNA through transformation (Chen 
and Dubnau, 2004) and is a feature common to both Gram-positive and Gram-negative bacteria 
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(Redfield et al., 2006).  Homologs of ComE have been found in all members of the Pasteurellaceae family 
functioning in fibronectin adhesion, DNA adhesion and in natural transformation (Mullen et al., 2008).  
Although ComE was predicted by PSORT to be localized to the cytoplasmic membrane, the homolog 
ComEA in P. multocida was shown by transmission electron microscopy to be localized to the bacterial 
surface (Hatfaludi et al., 2010).  Incidentally, P. multocida ComEA (PMCN03_2052) expresses 43.5% 
pairwise identity with ComE from M. haemolytica and also localizes to the cytoplasmic membrane. 
The third highest ranked protein was predicted to be a solute binding protein with PSI-BLAST 
identifying it as the periplasmic component of a maltose ABC (ATP-binding cassette) transporter. The 
ABC transporters have a diverse range of functions in bacteria including nutrient uptake and drug 
resistance, but are also associated with virulence through metal ion acquisition and the facilitation of 
bacterial attachment (Garmory and Titball, 2004).  Protein components of ABC transport systems have 
been previously shown to be immunogenic  against bacteria using mouse models (Garmory and Titball, 
2004) with vaccines targeting ABC systems in Mycobacterium tuberculosis (Briles et al., 2000) and 
Streptococcus pneumonia (Tanghe et al., 1999) being developed in this manner.  Interestingly, the fifth 
highest ranking candidate protein was also the periplasmic component of an ABC transporter, but one 
specified for molybdenum transport.  The components of ABC transporters that are expected to be the 
most immunogenic are the outer membrane proteins as they are anticipated to interface with the host 
immune system.  However, given that two of the top five antigen candidates here were identified as 
periplasmic components, it may be important to include proteins localized to this cellular compartment 
in vaccine design when applying RV.  It is possible that because these proteins are not readily accessible 
to the immune system, they are not targets for opsonization and although clearly able to be displayed 
by antigen presenting cell resulting in an antibody response, they may not in fact be protective during 
challenge trials 
The fourth highest ranked candidate in this assay was identified as an unknown outer 
membrane protein.  No further information could be determined about its function although it is also 
found in Mannheimia varigena and Bibersteinia trehalosi, which are also members of the 
Pasteurellaceae family.  This finding is particularly interesting, as it highlights the advantages of using RV 
to identify candidates that may potentially offer protection against multiple species of respiratory 
pathogens.   
Multiple antigens that have been previously identified as candidates for the development of 
vaccines against M. haemolytica, but did not rank within the top 10 candidates were identified..  These 
include leukotoxin (Ayalew et al., 2009; Lee et al., 2001), the GS60 antigen that belongs to the LppC 
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family of outer membrane lipoproteins (Lee et al., 2008), the lipoprotein PlpE (Ayalew et al., 2009), the 
outer membrane proteins OmpA (Ayalew et al., 2011), and the transferrin-binding proteins TbpA and 
TbpB (Potter et al., 1999).  The LktA protein (MhL044A_00993) did not express or bind with sufficient 
affinity to for its use in this ELISA assay so it was not evaluated further.  The overall average 
immunoreactivity for PlpE (MhL044A_02777) was low, ranking at 95tht and the OmpA protein 
(MhL044A_01473) ranked 108th.  In theory, cell free systems contain all of the necessary components for 
transcription, translation and protein folding including ribosomes, aminoacyl-tRNA synthetases, 
translation initiation and elongation factors, ribosome release factors, nucleotide recycling enzymes, 
metabolic enzymes, chaperones, and foldases (Carlson et al., 2012).  However, cell free systems are 
limited in the post-translational modification of proteins and do not always result in proteins that 
undergo proper folding (Carlson et al., 2012).  As a result, it is possible that some proteins here did not 
fold into the correct confirmation, resulting in lower immunoreactivity values due to lack of functional 
epitopes.   
The transferrin-binding protein TbpA was included in this analyses but it was truncated into two 
products (MhL044A_01700_465A, MhL044A_01700_465B) ranking 84th and 105th, respectively.  It is 
possible that the full length protein may have produced a higher immunoreactivity score if truncation 
disrupted its natural epitope.  A similar truncation was performed on the TbpB gene.  The N-terminal 
portion of the protein (MhL044A_01701_292A) ranked 186th while the C-terminal portion 
(MhL044A_01701_293B) ranked 25th. 
A limitation of the approach used here is that candidate selection was designed to target 
proteins with high sequence similarity within a large portion of the bacterial population.  Those genes 
that express sequence variation less than 95% identity over 90% length would not have clustered 
together and as a result would not have had been represented in over 50% of the dataset and included 
for further bioinformatic analysis.  It is likely that this was the case with the GS60 antigen which was not 
selected in the initial screening. 
The immunoreactivity of proteins to serum provides a quantitative measure for humoral 
responses indicating the magnitude of antibody generation in response to challenge.  The ability for an 
antigen to elicit antibody production does not necessarily correlate with the degree of protection from 
infection.  It is possible that candidates not readily displayed on the cell surface and thus unavailable to 
the immune system for opsonization may still be taken up and displayed by antigen-presenting cells 
resulting in antibody generation.  Further investigation into the quality of antibody response, by 
examining affinity, avidity, diversity and capacity to neutralize, needs to be undertaken for the 
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candidates here before they can be reasonably evaluated for use in vaccine formulation.  An 
investigation into the cellular immune responses of each candidate is also required as this arm of the 
immune system is intimately linked with humoral immunity, the activities of T helper cells required to 
promote a robust and enduring antibody response to infection. 
6.5 Conclusion 
In conclusion, a RV approach was used to identify potential vaccine candidates in M. 
haemolytica and a high throughput method employed to evaluate their immunoreactivity.  The method 
as presented was not optimized to maximize the success of translated products beyond the kit 
requirements.  Even so, over 80% of the protein candidates were expressed and bound effectively to the 
Ni+2 plates.  However, this system could potentially be adjusted further to improve the expression, 
stability and binding affinity of difficult candidates by using protein structure prediction to identify and 
truncate hydrophobic regions that could lead to protein instability or inaccessibility of the C-terminal 
Hisx6 tag for binding.  The assay identified multiple vaccine candidates of which Ssa1 was ranked the 
highest; this is a serine protease that others have identified as being highly immunogenic. An additional 
four high ranking proteins, the competence protein ComE, the solute binding protein, and a 
molybdenum ABC transporter which have not been  previously examined in serological assays were  also 
shown to hold promise for vaccine design against this species of respiratory pathogen.  The 
development of efficacious vaccines against agents of respiratory disease in cattle will help reduce the 
negative economic impact BRD has on the North American industry.  The framework generated from 
this research can be used for vaccine development against other pathogens of this complex respiratory 
infection in cattle. 
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7 General discussion, conclusions and future directions 
7.1 General discussion 
Although bovine respiratory disease research originated in the 1800’s (Taylor et al., 2010) this 
condition is still one of the foremost health problems faced by beef producers in North America.  A 
complicating factor towards resolving this disease is its complex etiology.  A component of this project 
examined the viral and bacterial agents contributing to BRD mortalities in North America.  Studies with 
similar intent have occurred in the past 10 years (Booker et al., 2008; Fulton, 2009; Gagea et al., 2006) 
but these did not incorporate BRD cases encompassing as broad a geographic range and did not 
characterize bacterial isolates as extensively as this study. I found Mannheimia haemolytica to be the 
most frequently recovered bacterial pathogen from BRD cases.  However, all other agents with the 
exception of bovine herpesvirus 1 were also detected in BRD mortalities including P. multocida, H. 
somni, M. bovis, bovine viral diarrhoea virus, bovine parainfluenza 3 virus, and bovine respiratory 
syncytial virus.  The lack of bovine herpesvirus 1 was not unexpected as this virus can be difficult to 
detect post-infection (Pastoret and Thiry, 1985). 
A key finding of this study was the prevalence of integrative conjugative elements (ICEs) 
detected in isolates of M. haemolytica, P. multocida and H. somni.  Some of these ICEs containing gene 
cassettes conferred resistance to all antimicrobials used in BRD therapy, with the exception of ceftiofur.  
Although a similar multidrug resistant ICE profile was identified previously in P. multocida (Michael et 
al., 2012), the work here was the first to report these elements in M. haemolytica and H. somni from 
beef calves.   
Multidrug resistance conferring ICEs (i.e. resistance to greater than six antibiotic classes) were 
only identified in isolates collected from American feedlots, occurring in over 80% of M. haemolytica 
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collected from Nebraska and Texas.  The average feedlot in the USA contains approximately four times 
the number of cattle compared to those in Canada (Galyean et al., 2011).  And with the five largest 
feeding operations controlling 20% of feeding capacity in the USA (Galyean et al., 2011), the intensive 
aggregation of animals in confined spaces is likely translating into more frequent drugs use to prevent 
disease.  The congregation of large numbers of cattle within feedlots can also be predicted to facilitate 
the ease by which pathogenic strains of bacteria can spread within herds.  There is also the possibility 
that Pasteurellaceae species carrying AMR are originating from other agricultural sectors in this region, 
like swine or poultry, where P. multocida and M. haemolytica also cause disease and are targets for 
antimicrobial therapies (Angen et al., 1999; Ewers et al., 2006; Kehrenberg et al., 2001).  Further 
investigation into the dispersal of ICEs within North America will likely shed some light on their origin 
and give insight into management practices that could be promoting their development and spread.  
The detection of multidrug resistant M. haemolytica, P. multocida and H. somni together from 
BRD mortalities is significant.  Currently up to 50% of animals receive antibiotics either prophylactically 
or therapeutically to prevent or treat this disease (Checkley et al., 2010; Hilton, 2014).  Thus, the failure 
of therapies used in feedlots to control BRD will likely result in a substantial increase in death loss.  
Given the current dependency of antibiotics, without working therapeutics it is unlikely that the beef 
industry would be able to maintain its current structure, as losses to disease would undercut 
profitability.   
Alternatives to antibiotic use for BRD management exist and include preconditioning programs 
that promote animal immune health by reducing stress and pathogen exposure through weaning, 
vaccination, dehorning, deworming and treatment for external parasites prior to the animal moving to 
the feedlot (Schumacher et al., 2012).  Animal husbandry practices are also used and include increasing 
the forage level in the diet, reducing the number of animals in pens, minimizing the mixing of cattle from 
multiple sources and ensuring adequate ventilation (Edwards, 2010).  The use of ancillary anti-
inflammatory drugs has also been promoted as a means to decrease the severity of clinical symptoms 
and inflammation induced lung damage, reduce fever and increase appetite, but there is little or no 
clinical evidence to support the reliability or effectiveness of these treatments (Francoz et al., 2012). 
Concern exists over the potential transfer of multidrug resistant ICEs into zoonotic pathogens.  
This project examined the mobility of ICEs between Pasteurellaceae species and E. coli showing that 
these elements could conjugate in vitro between species.  Further investigation will be required to 
determine the likelihood of such a transfer event in the feedlot setting, but the work here shows the 
possibility exists and that it would be prudent to continue surveillance of these important mobile 
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genetic elements in the agricultural sector.  Furthermore, surveillance of ICE containing bacterial 
pathogens in feedlots will likely play an increasingly important role in providing veterinarians the 
information they need to develop drug administration regimes to effectively combat multidrug resistant 
infections. 
Prior to initiation of this study whole genome sequence data was only available for three strains 
of M. haemolytica: a serovar 1 strain isolated from a beef calf, one serovar 2 isolated from a cattle and 
one serovar 2 isolated from sheep (Gioia et al., 2006; Lawrence et al., 2010).  Subsequent sequencing 
projects were submitted to NCBI in the interim, those M. haemolytica genomes available at the time 
Chapters 5 and 6 were performed were included in the analysis as specified in those studies.  From this 
project, draft genomes of 11 M. haemolytica were generated representing serovars S1, S2 and S6.  This 
included the first documented whole genome sequence of a serotype 6 strain of M. haemolytica.  As 
anticipated, sequence diversity was the highest in S2 strains, with S1 and S6 exhibiting similar genomic 
characteristics in terms of the presence of bacteriophage and spacer arrays within CRISPR-Cas.  
Comparative analysis highlighted two spacers within S1 and S6 CRISPR arrays with the potential to 
contribute to M. haemolytica virulence through the regulation of expression of sialic acid.  These spacers 
were lacking in S2 strains supporting our understanding of S1 and S6 playing a more central role in 
bovine disease.  Although rare, evidence of CRISPR-Cas mediated regulation of virulence factors has 
been previously described (Sampson and Weiss, 2013).  It would be interesting to determine if a similar 
mechanism was working in CRISPR-Cas from other respiratory pathogens including P. multocida and H. 
somni.  A comparative analysis of CRISPR arrays from bacterial species infecting the respiratory tract of 
cattle, focusing on self-targeting spacers could highlight factors that allow these microbes to avoid host 
immune responses and persist in this niche.   
Pan-genome analysis was performed with the 11 M. haemolytica genomes generated here with 
an additional 15 M. haemolytica genomes present in public databases.  All of the coding sequences in 
the dataset were identified and further screened using bioinformatics tools for signatures that identify 
their gene products as being cell surface associated.  To my knowledge, this is the first application of 
reverse vaccinology (RV) to compare pathogenic and non-pathogenic strains of M. haemolytica to 
identify potential vaccine candidates.  
Although RV provides a means to rapidly identify vaccine candidates, evaluation of those 
proteins for their suitability in vaccine formulation still presents a challenge.  This project utilized the 
unique application of a cell-free translation system coupled with ELISA to screen proteins for their 
immunoreactivity.  By using this high throughput strategy, within a manner of weeks 291 protein 
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candidates were screened using serum generated in calves challenged with S1, S2 or S6 strains of M. 
haemolytica.  This is a massive reduction in time from the months expected to be required for the 
traditional approach of cloning, expressing and purifying each protein.   
Of the top five candidates identified here, two were periplasmic components of the ABC 
transport system.  It is unclear with serology testing if the antibodies generated against these proteins 
result in protection.  As periplasmic components, it is unlikely that they are targets for antibody 
opsonization.  However, antibodies generated against the lipoproteins of similar ABC systems have been 
shown to provide protection, the theory being that the antibodies diffuse through the cell wall and 
interfere with the biological function of the transport system (Garmory and Titball, 2004).  The challenge 
trial used to generate the sera for serology screening required the heavy dosing of animals with 
bacterial inoculant.  It is possible that degraded cell components as part of this mixture were taken up, 
displayed by antigen presenting cells and elicited a host antibody response in a manner not reflective of 
natural M. haemolytica infection.  This is a limitation of experimental infection and although not for 
certain, it is possible that sera obtained from naturally infected animals could be less immunoreactive to 
these periplasmic components.  
It is important to note that RV analysis is limited to proteins and cannot be used to identify non-
protein coding antigens like lipopolysaccharides or lipids.  Also, correlates for protection are rare making 
screening for protective immunity the rate limiting step for this application (Bertholet et al., 2014).  
Other limitations to this work include the scope of the dataset used.  Although we targeted samples 
from a wide geographic range, pan-genome analysis revealed that we could add hundreds more 
genomes to the analysis and not fully cover the diversity within M. haemolytica populations.  In 
addition, all bioinformatic screening is based on cut-off values which are user defined.  We applied cut-
offs with the intent to target antigens that would be protective across at least half of the strains 
analyzed.  Alternative screening parameters couldl result in the identification of different antigen 
targets.   
This project identified multiple candidates for use in vaccine design against M. haemolytica, but 
did not fully evaluate their suitability for use in vaccine formulation.  Serological assays only examine the 
likelihood for antigens to bind to antibodies, and do not necessariy reflect  protective efficacy.  As a 
result animal models are still required to measure in vitro efficacy of the antigens identified using in 
silico tools (Bambini and Rappuoli, 2009).  Ideally a comprehensive immune stimulus profile comprised 
of information about immunoreactivity, cellular immune response and in vivo protein expression should 
be used to determine the suitability of each vaccine candidate prior to use in animal challenge trials.  
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7.2 Future work 
Future work should examine cell-mediated immune responses.  Epitope prediction programs 
can be employed to generate a short list of antigen candidates from the original pan-genome analysis 
described in Chapter 6.  Advancements in software have allowed for reasonable prediction of class I 
MHC peptide binding but class II MHC peptide binding prediction programs are less reliable and still 
need further improvements (Sette and Rappuoli, 2010).  However, as functional and structural genomics 
progress and bioinformatic resources grow, epitope prediction will also likely improve making vaccine 
design more targeted and streamlined.   
In addition to cell-mediated immune assays in vivo protein expression data is required to 
determine if proteins are produced in sufficient abundance to act as targets for the host immune 
system.  Although RV can be used to identify genes it cannot determine if the genes are expressed 
during infection.  This information can only be obtained through proteomic or transcriptomic analysis, 
the latter possible with RNAseq studies of lung lavage samples collected from animals experimentally 
infected with M. haemolytica (Reddy et al., 2012).  
Once good antigen candidates are identified, fusion proteins or chimeras can be engineered to 
facilitate patents and reduce the cost of protein expression that can be a detriment to vaccine 
production (Lakshmi et al., 2013).  Vaccine delivery is also a component of this work that can be 
explored further.  The use of vesicles as delivery systems is an area of current focus (Watson et al., 2012) 
as well as the use of DNA based vaccines (Yang et al., 2015).   
Another logical progression from this project is to apply the approach used to other pathogens 
of BRD.  Comparative analysis of M. haemolytica, H. somni and P. multocida with representative 
commensals can be used to highlight targets that may be protective against all three organisms.  
Difficulties in this strategy may be to identify targets that are not cross reactive to other non-target 
species.  It is important to note that although RV can deliver antigen candidates in a relatively short 
period of time, the identification of a suitable antigen is one step in vaccine design and full vaccine 
development requires formulation, proof of principal, clinical trials, patenting, licencing and approval, 
and marketing.   
Lastly, multiple avenues exist here to further characterize the ICEs discovered.  Sequence 
analysis of the P. multocida and H. somni isolates could be performed to resolve these elements as they 
were only examined using phenotypic analysis and PCR.  Further characterisation of ICE components 
focusing on the type 4 secretion systems will also provide more insight into the mechanisms of transfer 
and maintenance of these MGE.  Larger scale surveillance of ICEs in North America should be 
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undertaken in an attempt to identify the source and relatedness of these elements within animal 
production systems.  This could include metagenomic screening of animal and environmental samples 
and possibly those from humans.  The threat of movement of ICEs into zoonotic pathogens should also 
be considered and evaluated.  Conjugation studies between ICE and pathogens related to human health 
should be pursued. 
Bovine respiratory disease is a complex, multifactorial condition.  As a result any solution to 
manage it will likely also be complex and multifaceted.  It is tempting to look at antimicrobials as the 
silver bullet for disease in feedlot settings, and to some degree the applications of these therapies are 
very effective and necessary.  However, sustainability of this approach to controlling infection is always 
a challenge.  At this stage the application of antibiotics is driven by ground level policy, based on the 
priorities of the individual producers.  A more global view of the relationships between antibiotic 
applications and the consequences for resistance development is necessary to help develop a 
framework for decision making around prudent usage of these medicines in agriculture.   
 With the advancements in omics technologies vaccine development has undergone some 
significant changes and the potential exists to address some of the diseases left unchallenged by 
conventional methodologies.  Vaccines are a better strategy for prevention of disease than 
antimicrobials as they are more efficient, cost effective and sustainable.  However, even with the use of 
vaccines and antimicrobials it is not likely that BRD will be completely eradicated from production 
systems.  The majority of BRD agents are commensals found in healthy animals.  There is the possibility 
that effective vaccination that removes the threat of one BRD agent will see it replaced by another.  To 
some extent this may be occurring already as there has been a shift in respiratory profiles from acute M. 
haemolytica associated disease to more chronic H. somni and M. bovis associated infection (Booker et 
al., 2008; Gagea et al., 2006).  The solution to BRD likely lies in a new paradigm for beef production.  
However, current focus on disease prevention through encouraging preconditioning programs at the 
cow-calf level and through the development and use of effective vaccines are likely going to become key 
initiatives for BRD management in the future. 
7.3 Concluding remarks 
By developing a successful vaccine providing broad protection against pathogenic M. 
haemolytica, the Alberta and Canadian beef sector will be one step closer to effectively controlling BRD. 
It is well recognized that M. haemolytica is a major component of BRD. However, this project has 
generated a foundation to identify vaccine candidates against other etiological agents associated with 
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BRD using RV. Ultimately, if feedlots were able to manage BRD using vaccination it would dramatically 
impact the feedlot stage of the beef industry value chain and reduce the use of antimicrobials.   
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Appendix A 
 
Table A1 Mannheimia haemolytica from public databases used in pan-genome analysis  
Isolate   Accession No. Serotype 
M. haemolytica D153 NC_021743.1 1 
M. haemolytica MhBrain2012 ATSZ00000000.1 1 
M. haemolytica D193 ATSY00000000.1  1 
M. haemolytica PHL213 NZ_AASA00000000.1 1 
M. haemolytica D171 NC_021738.1  2 
M. haemolytica D35 AUNK00000000.1 2 
M. haemolytica Bovine A2 NZ_ACZY00000000.1 2 
M. haemolytica D174 NC_021739.1 6 
M. haemolytica D38 AUNL00000000.1  6 
M. haemolytica USDA-ARS-USMARC-185 NC_020834.1 6 
 
Table A2 Percent identities of Cas genes, virulence factors, and ICE associated genes from 11 Mannheimia haemolytica isolates  
     
% pairwise identity (% identical sites) 
  
Reference 
IDa 
AA 
length 
% pairwise 
identity (% 
identical 
sites) 
sequence 
length all S1/S6 S1 S6 S2 
CRISPR-Cas 
Cas1 n/a 337 98.8 (97.0) 1014 
97.8 
(94.9) 
100 
(99.9) 
100 
(100) 
100(99.9
) 
99.9 
(99.9) 
Cas2 n/a 97 100 (100) 294 
100 
(100) 
100 
(100) 
100 
(100) 
100 
(100) 
100 
(100) 
Cas2b n/a 90 100 (100) 273 
     
Cas2 vs Cas2b n/a 99 77.9 (24.2) 299 
85.3 
(49.5) 
    
Cas3 n/a 762 99.5 (98.2) 2289 
99.2 
(97.1) 
100 
(100) 
100 
(100) 
100 
(100) 
98.3 
(97.4) 
Cas4 n/a 224 95.6 (89.7) 675 
95.0 
(88.6) 
99.9 
(99.7) 
99.9 
(99.9) 
99.9 
(99.9) 
100 
(100) 
Cas5 n/a 225 99.8 (99.1) 678 
99.5 
(97.6) 
100 
(100) 
100 
(100) 
100 
(100) 
98.4 
(97.6) 
Cas7 n/a 287 99.6 (99.0) 864 
99.4 
(97.9) 
100 
(100) 
100 
(100) 
100 
(100) 
99.2 
(98.8) 
Cas8 n/a 594 99.7 (98.5) 1785 
98.6 
(95.7) 
99.8 
(99.3) 
100 
(100) 
99.6 
(99.3) 
98.9 
(98.4) 
LPS Pathway 
         3-deoxy-D-manno-
octulosonic-acid 
transferase WaaA MHA_0068 427 99.9 (99.8) 1281 
100 
(99.9) 
100 
(100) 
100 
(100) 
100 
(100) 
100 
(100) 
possible 
glycosyltransferase 
WcaA-like MHA_0100 267 99.3 (99.8) 801 
99.9 
(99.6) 
100 
(100) 
100 
(100) 
100 
(100) 
99.8 
(99.8) 
possible 
glycosyltransferase 
WcaA-like MHA_0101 323 99.7 (99.1) 966 
99.8 
(99.3) 
100 
(100) 
100 
(100) 
100 
(100) 
99.6 
(99.4) 
Pasteurellaceae 
conserved hypothetical 
protein MHA_0102 395 99.9 (99.5) 1188 
100.0 
(99.8) 
100 
(100) 
100 
(100) 
100 
(100) 
99.9 
(99.8) 
possible 
glycosyltransferase MHA_0103 261 99.9 (99.6) 786 
99.9 
(99.6) 
100 
(100) 
100 
(100) 
100 
(100) 
99.7 
(99.6) 
possible O-antigen MHA_0105 401 99.5 (98.3) 1207 99.9 100 100 100 99.9 
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export protein (99.6) (99.9) (99.9) (100) (99.8) 
UDP-N-
acetylglucosamine 2-
epimerase WecB MHA_0106 394 99.7 (99.0) 1185 
99.9 
(99.5) 
100 
(100) 
100 
(100) 
100 
(100) 
99.7 
(99.6) 
heptosyltransferase II 
(inner core) WaaF MHA_0191 345 99.7 (99.9) 1038 
100 
(99.9) 
100 
(100) 
100 
(100) 
100 
(100) 
100 
(100) 
phosphomannomutase 
ManB MHA_0517 550 99.7 (99.1) 1653 
99.5 
(97.9) 
100 
(100) 
100 
(100) 
100 
(100) 
98.8 
(98.2) 
UDP-N-
acetylglucosamine 2-
epimerase WecB  MHA_0521 371 99.1 (98.4) 1116 
98.2 
(96.7)8 
98.2 
(96.7)8 
100 
(100)4 
98.3 
(96.7)4 nd 
ECA biosynthesis protein 
WecC MHA_0522 423 97.4 (95.5)8 
1207 
(1272) 
96.4 
(93.8)8 
96.4 
(93.8)8 
100 
(100)4 
98.3 
(96.5)4 nd 
UDP-N-acetyl muramyl 
pentapeptide 
phosphotransferase 
WecA MHA_0726 354 100 (100) 1065 
100 
(100) 
100 
(100) 
100 
(100) 
100 
(100) 
100 
(100) 
lipopolysaccharide chain 
length determinant 
protein WzzB MHA_0727 271 99.9 (99.6) 813 
100 
(99.9) 
100 
(99.9) 
99.9 
(99.9) 
100 
(100) 
100 
(100) 
UDP-N-acetyl-D-
mannosaminuronic acid 
dehydrogenase WecC MHA_0728 414 99.9 (99.8) 1245 
99.9 
(99.7) 
100 
(99.8) 
100 
(100) 
100 
(99.9) 
99.8 
(99.8) 
probable fucosamine 
acetyl transferase MHA_0729 214 99.9 (99.5) 645 
99.2 
(95.7) 
100 
(100) 
100 
(100) 
100 
(100) 
97.1 
(95.7) 
ECA biosynthesis protein 
WecE MHA_0730 473 100 (100) 1422 
99.9 
(99.7) 
100 
(100) 
100 
(100) 
100 
(100) 
99.9 
(99.8) 
lipopolysaccharide N-
acetylglucosaminyltransf
erase MHA_0825 398 100 (100) 1197 
100 
(99.9) 
100 
(100) 
100 
(100) 
100 
(100) 
100 
(100) 
ADP-glyceromanno-
heptose 6-epimerase 
HldD MHA_1050 308 100 (100) 927 
100 
(99.9) 
100 
(100) 
100 
(100) 
100 
(100) 
99.9 
(99.9) 
UDP-glucose 4-
epimerase GalE MHA_1349 338 99.8 (99.4) 1017 
99.9 
(99.8) 
100 
(100) 
100 
(100) 
100 
(100) 
99.9 
(99.8) 
lipid A acyltransferase MHA_1392 316 100 (100) 951 
99.9 
(99.8) 
100 
(100) 
100 
(100) 
100 
(100) 
99.9 
(99.9) 
glycosyltransferase LpsA MHA_1558 263 99.8 (99.6) 792 
99.9 
(99.7)9 
99.9 
(99.7)6 
100 
(100)2 
99.9 
(99.7)4 
100 
(100)3 
lipid A acyltransferase MHA_1562 313 99.9 (99.7) 942 
99.9 
(99.8) 
100 
(100) 
100 
(100) 
100 
(100) 
100 
(100) 
heptosyltransferase II 
(inner core) WaaF MHA_1600 343 99.8 (99.1) 1032 
99.9 
(99.5) 
100 
(99.9) 
100 
(100) 
99.9 
(99.9) 
99.8 
(99.7) 
O-antigen ligase WaaL MHA_1845 418 100 (100)8 1257 
100 
(100)8 
100 
(100)8 
100 
(100)4 
100 
(100)4 nd 
dTDP-glucose 4,6-
dehydratase RmlB MHA_1846 335 100 (100)8 1008 
100 
(100)8 
100 
(100)8 
100 
(100)4 
100 
(100)4 nd 
conserved hypothetical 
protein MHA_1847 193 100 (100)8 582 
100 
(100)8 
100 
(100)8 
100 
(100)4 
100 
(100)4 nd 
possible LPS sugar 
transferase MHA_1848 423 100 (100)8 1272 
100 
(100)8 
100 
(100)8 
100 
(100)4 
100 
(100)4 nd 
LPS chain length 
determining protein Wzz MHA_1853 375 100 (100)6 1128 
100 
(100)6 
100 
(100)6 
100 
(100)2 
100 
(100)4 - 
phosphomannomutase 
ManB MHA_2240 444 99.9 (99.5) 1335 
99.9 
(99.6) 
100 
(99.9) 
100 
(99.9) 
100 
(100) 
99.8 
(99.7) 
 D,D-heptose 1-
phosphate 
adenosyltransferase/7-
phosphate kinase HldE MHA_2564 475 99.7 (99.4) 1428 
99.9 
(99.7) 
100 
(100) 
100 
(100) 
100 
(100) 
100 
(99.9) 
heptosyltransferase II 
(inner core) WaaF MHA_2704 345 99.4 (98.3) 1038 
99.8 
(99.3) 
100 
(100) 
100 
(100) 
100 
(100) 
99.6 
(99.3) 
heptosyltransferase II 
(inner core) WaaC MHA_2705 319 99.9 (99.7) 960 
99.9 
(99.7) 
100 
(99.9) 
99.9 
(99.9) 
100 
(100) 
99.9 
(99.8) 
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3-deoxy-8-
phosphooctulonate 
synthase MHA_1912 284 99.7 (98.9) 855 
98.6 
(95.8) 
100 
(100) 
100 
(100) 
100 
(100) 
97.2 
(95.8) 
3-deoxy-D-manno-
octulosonate 8-
phosphate phosphatase MHA_2646 179 99.8 (99.4) 540 
99.9 
(99.8) 
100 
(100) 
100 
(100) 
100 
(100) 
99.9 
(99.8) 
3-deoxy-D-manno-
octulosonate 
cytidylyltransferase MHA_0212 251 100 (100) 756 
100 
(100) 
100 
(100) 
100 
(100) 
100 
(100) 
100 
(100) 
3-deoxy-D-manno-
octulosonic-acid 
transferase  MHA_0068 426 99.9 (99.8) 1281 
100 
(99.9) 
100 
(100) 
100 
(100) 
100 
(100) 
100 
(100) 
acyl-[acyl-carrier-
protein]--UDP-N-
acetylglucosamine O-
acyltransferase  MHA_0687 264 100 (100) 795 
100 
(99.9) 
100 
(100) 
100 
(100) 
100 
(100) 
99.9 
(99.9) 
ADP-L-glycero-D-manno-
heptose-6-epimerase MHA_1050 308 100 (100) 927 
100 
(99.9) 
100 
(100) 
100 
(100) 
100 
(100) 
99.9 
(99.9) 
D,D-heptose 1,7-
bisphosphate 
phosphatase MHA_0543 182 99.3 (98.4) 549 
99.4 
(98.4) 
100 
(100) 
100 
(100) 
100 
(100) 
99.5 
(99.3) 
lipid-A-disaccharide 
kinase MHA_1351 333 99.8 (99.4) 1002 
99.7 
(99.0) 
100 
(100) 
100 
(100) 
100 
(100) 
99.4 
(99.1) 
lipid-A-disaccharide 
synthase MHA_0736 392 99.8 (99.5) 1179 
99.9 
(99.8) 
100 
(100) 
100 
(100) 
100 
(100) 
99.9 
(99.9) 
Lipopolysaccharide 
kinase - 3-deoxy-D-
manno-octulosonic acid 
kinase (Kdo/WaaP) MHA_0049 235 99.1 (97.9) 708 
98.9 
(97.5) 
100 
(100) 
100 
(100) 
100 
(100) 
100 
(100) 
phosphoheptose 
isomerase 583 MHA_1457 193 100 (100)10 582 
99.9 
(99.7)10 
100 
(99.8)8 
99.9 
(99.8)4 
100 
(100)4 
100 
(100)2 
phosphoheptose 
isomerase 585 MHA_2736 194 99.8 (99.5) 585 
99.9 
(99.7) 
100 
(100) 
100 
(100) 
100 
(100) 
100 
(100) 
rfaE - D-alpha,beta-D-
heptose 7-phosphate 1-
kinase MHA_2564 475 99.7 (99.4) 1428 
99.9 
(99.7) 
100 
(100) 
100 
(100) 
100 
(100) 
100 
(99.9) 
UDP-2,3-
diacylglucosamine 
hydrolase MHA_1959 233 100 (100) 702 
100 
(100) 
100 
(100) 
100 
(100) 
100 
(100) 
100 
(100) 
UDP-3-O-[3-
hydroxymyristoyl] 
glucosamine N-
acyltransferase MHA_0689 341 100 (100) 1026 
99.6 
(98.6) 
100 
(100) 
100 
(100) 
100 
(100) 
99.1 
(98.6) 
UDP-3-O-[3-
hydroxymyristoyl] N-
acetylglucosamine 
deacetylase MHA_2062 306 99.9 (99.7) 921 
99.9 
(99.7) 
100 
(99.9) 
100 
(100) 
99.9 
(99.9) 
100 
(100) 
Virulence factors 
         neuraminidase 
(sialidase) MHA_1532 791 99.8 (98.7) 2377 
100 
(100) 
100 
(100) 
100 
(100) 
100 
(100) 
100 
(100) 
gcp gene - O-
sialoglycoprotein 
endopeptidase MHA_1559 343 100 (100) 1032 
100 
(100) 
100 
(100) 
100 
(100) 
100 
(100) 
100 
(100) 
filamentous 
hemagglutinin (FhaB) MHA_0866 3214 99.6 (99.2) 9465-9645 
99.5 
(99.0)7 
100 
(100)5 
100 
(100)4 - 
100 
(100)2 
hemolysin 
activation/secretion 
protein FhaC MHA_0867 598 98.8 (96.3) 1797 
98.7 
(96.3) 
99.8 
(99.4) 
100 
(99.9) 
99.7 
(99.4) 
99.2 
(98.8) 
Ssa1 MHA_2492 942 93.3 (81.7) 2253-2829 
94.0 
(83.1) 
99.9 
(99.4) 
100 
(100) 
99.7 
(99.4) 
96.0 
(94.6) 
PlpE MHA_1514 360 84.6 (60.6) 1068-1071 
88.7 
(71.1)9 
100 
(100)7 
100 
(100) 
100 
(100)3 
100 
(100)2 
autotransporter 
adhesins MHA_2701 2023 100 (99.9) 5658-6072 
100 
(99.9)8 
100 
(99.9) 
100 
(100) 
100 
(100) nd 
autotransporter MHA_1367 1383 100 (99.9) 4152 100 100 100 100 nd 
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adhesins (99.9)8 (99.9) (100) (100) 
autotransporters MHA_0563 1398 100 (99.9) 4197 
100 
(99.9)10 
100 
(100)7 
100 
(100) 
100 
(100)3 
100 
(100) 
autotransporters MHA_2800 1503 99.9 (99.4) 4512 
99.9 
(99.8)9 
100 
(100) 
100 
(100) 
100 
(100) - 
HmbR1 - hemoglobin 
receptor MHA_1639 614 99.9 (99.8) 1767-1845 
99.9 
(99.8) 
100 
(99.9) 
100 
(100) 
100 
(100) 
100 
(100) 
HmbR2 - hemoglobin 
receptor MHA_2261 719 99.9 (99.4) 2160 
100 
(99.9) 
100 
(99.9) 
100 
(99.9) 
100 
(100) 
100 
(100) 
 HxuA - hemophore MHA_1004 940 98.1 (94.3) 2817-2823 
97.9 
(94.0) 
100 
(100) 
100 
(100) 
100 
(100) 
98.2 
(97.3) 
TbpA - transferrin-
binding protein MHA_0196 937 95.8 (83.8) 2787-2811 
95.1 
(78.5) 
100 
(99.9) 
100 
(99.9) 
100 
(100) 
86.5 
(79.8) 
TbpB - transferrin-
binding protein MHA_0197 605 82.9 (52.4) 1752-1767 
85.0 
(57.1) 
99.7 
(99.1) 
99.8 
(99.5) 
99.8 
(99.5) 
75.8 
(63.9) 
FhuE like - ferric 
hydroximate 
siderophore receptor MHA_2388 710 99.6 (99.2) 1704-2133 
99.7 
(99.3)10 
100 
(100) 
100 
(100) 
100 
(100) 
100 
(100)2 
ferric hydroximate 
siderophore receptor MHA_1541 704 99.1 (96.7) 1917-2076 
99.8 
(99.3) 
99.9 
(99.7) 
100 
(99.9) 
100 
(100) 
99.7 
(99.6) 
Fur - ferric uptake 
regulator MHA_2790 146 99.9 (99.3) 441 
100 
(99.8) 
100 
(100) 
100 
(100) 
100 
(100) 
99.8 
(99.8) 
GS60 - outer membrane 
lipoprotein MHA_2734 573 100 (100) 1772 
99.9 
(99.8) 
100 
(99.9) 
100 
(99.9) 
100 
(100) 
100 
(100) 
OmpA MHA_1054 378 97.7 (93.9) 1119-1137 
98.4 
(95.9)10 
100 
(100)7 
100 
(100) 
100 
(100) 
98.0 
(97.0) 
LuxS MHA_2788 169 99.2 (97.6) 510 
98.1 
(94.1) 
100 
(100) 
100 
(100) 
100 
(100) 
96.1 
(94.1) 
LktC MHA_0253 184 93.3 (79.3) 456-555 
97.8 
(92.4) 
99.9 
(99.8) 
99.9 
(99.8) 
100 
(100) 
98.5 
(97.8) 
LktA MHA_0254 954 94.9 (86.3) 2862 
93.7 
(82.9) 
100 
(100) 
100 
(100) 
100 
(100) 
95.3 
(93.0) 
LktB MHA_0255 708 99.8 (99.2) 2127 
98.5 
(95.7) 
100 
(100) 
100 
(100) 
100 
(100) 
98.7 
(98.0) 
LktD MHA_0256 478 99.9 (99.8) 1437 
100(99.9
) 
100 
(99.9) 
100 
(100) 
100 
(99.9) 
100 
(100) 
ICE associated genes 
         
TraC n/a 945 98.4 (96.7) 2838 
95.1 
(89.7) 
96.0 
(89.7) 
93.5 
(89.7) 
100 
(100) - 
TraD n/a 734 98.6 (97.3) 2202 
95.5 
(91.0) 
96.1 
(91.0) 
94.0 
(91.0) 
100 
(100) - 
TraG n/a 490-506 82.6 (38.7) 1473-1519 
93.4 
(84.2) 
95.4 
(84.2) 
91.4 
(84.1) 
99.9 
(99.9) - 
TraU n/a 313 97.4 (93.3) 942 
96.0 
(89.6) 
100 
(100) 
94.8 
(89.6) 
100 
(100) - 
TrbI n/a 484 94.6 (89.3) 1455 
92.9 
(85.8) 
93.9 
(85.8) 
90.6 
(85.8) 
100 
(100) - 
tyrosine recombinase n/a 254 99.1 (96.1) 765 
98.1 
(92.9) 
98.4 
(93.5) 
96.7 
(93.5) 
100 
(100) - 
tyrosine recombinase 
900bp n/a 299 100 (100) 900 
100 
(100) - - - - 
Relaxase/ TraI n/a 516-661 96.0 (89.9) 1551-1986 
96.1 
(89.5) 
97.4 
(89.5) 
95.0 
(89.6) 
100 
(100) - 
multicopper oxidase n/a 515 100 (100) 1548 - - - - - 
DNA topoisomerase  n/a 683 96.1 (92.2) 2052 
92.4 
(84.7) 
93.5 
(84.7) 
89.8 
(84.7) 
100 
(100) - 
ParB n/a 548-549 95.8 (91.6) 1647-1650 
94.0 
(88.1) 
94.9 
(88.1) 
92.0 
(88.1) 
100 
(100) - 
pilL n/a 209-210 94.3 (88.6) 630-633 
94.5 
(89.0) 
95.3 
(89.0) 
92.6 
(89.0) 
100 
(100) - 
areference locus ID given from M. haemolytica sv. 1 PHL213; accession NZ_AASA00000000.1. n/a, not provided 
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Table A3 The gene targets, primers used for expression, and ranking based on immunoreactivity screening using sera raised in cattle 
experimentally infected with strains of either serotype 1, serotype 2 or serotype 6 of Mannheimia haemolytica 
Gene target locus IDa 
Forward Primer/ 
reverse primer  (5'-3')b 
Protein 
length 
(aa) 
PSORT 
Location 
Rank for 
immuno-
reactivity 
against 
anti-S1 
serac 
Rank for 
immuno-
reactivity 
against 
anti-S2 
serac  
Rank for 
immuno-
reactivity 
against 
anti-S6 
serac  
Rank for 
overall 
average 
immuno-
reactivity 
MhH23_00891 
CAAAATACTGCTCAAA
ACAGTG/ 
ATTATTCCTCAATGACC
TCGG 210 Unknown 122 103 - 139 
MhH23_00892 
ACTACATCAATAGAAA
GTAGCAC/ 
ATAAACGAGAGATTGC
CATTCAC 245 Unknown 129 121 - 152 
MhH23_00894 
TTAACGGTAATCGCTG
ATTTCG/ 
GGTTTCAGTAATCAGG
GC 168 Unknown 23 6 - 16 
MhH23_00901 
GCATCCAAAATCCCAG
ACTTC/ 
TCCGACTGCAAGTTTG
ACTAAC 129 Cytoplasmic - - - - 
MhL024A_00046 
GCAACAGAACCTACAA
AAAC/ 
GAATCTTTGCTGTAATT
CTACG 194 Periplasmic - - - - 
MhL024A_00488 
CAAAGCATCAAGACGG
AGATG/ 
TTTGTATTTTTTGTGAT
ATTCACG 123 Unknown - - - - 
MhL024A_00497_357A 
GACGGTTATTTAAGTA
ACGA/ 
AACAAATGTATAAAGA
GCTTC 357 Unknown 52 54 73 69 
MhL024A_00497_358B 
CGTGCAATGGGGTTAT
TTAC/ 
TTGATAGTGATAATTT
GCGTGT 358 Unknown 82 77 104 106 
MhL024A_01035_562A 
GAATTGCCAACCCAAC
AG/ 
AGGATTTTCAAATGAA
ATATAAGTGA 562 Cytoplasmic 96 99 111 123 
MhL024A_01035_563B 
GTCTGGACTTGGGGAT
TAAAA/ 
TCGTTCAAACTCAAAG
CGT 563 Cytoplasmic 8 9 8 10 
MhL024A_01315 
AATGATCCTTTCTTTGG
AG/ 
TAATTTGATGTTAATTT
CATAAGGG 137 Unknown 124 123 181 178 
MhL024A_01509_334A 
TCAATCACTGATAAACT
GGAA/ 
GACAGGTACACTACTT
GAGC 334 Unknown 91 93 124 125 
MhL024A_01509_334B 
ACTCGTGGCTTGATTG
AAA/ 
ATTTTTACCAAGAATAT
AATCAGCT 334 Unknown 24 34 30 31 
MhL024A_01510 
AACGTAATATTTTCCTG
TACCAGC/ 
AGTATTCATCAAATGA
ACATCAAAC 142 Unknown 121 135 172 177 
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MhL024A_01515 
GATAGTTGAAGTTTTT
AGACAC/ 
TTGTTTTTGGCGACTAC
TATAA 221 Unknown - - - - 
MhL024A_01796 
AAGCATAAATTCAAAC
TAAACC/ 
CTCTGTTTTATATTTTTC
AATGTAAG 356 Periplasmic - - - - 
MhL024A_01813 
ATGACAGAAAAAGCTG
AACAAG/ 
CTTGGTTGCAGAAATG
GATTTTG 115 Unknown 120 127 142 162 
MhL024A_02718 
ATGATGAGAAAATTAG
CAAAACAG/ 
AATTGGAGCAGAGGTA
GGT 220 Extracellular 102 108 138 141 
MhL044A_00003 
CAACCGACCTTAACCG
TTTAC/ 
CCAGCTCTTTGACCAAT
CGG 317 Periplasmic - - - - 
MhL044A_00027 
GGTAAGTCTATTCATAT
TAACTCGG/ 
TACATTTTTTAAGAAAA
TTTGGCG 298 Periplasmic 79 130 117 132 
MhL044A_00028 
TTCCACGGATATGCAC
GTTC/ 
AGCTTCAAATTGAACA
CCG 429 Outer 45 67 166 109 
MhL044A_00030 
AAAATGACGGAAGGT
AAACTC/ 
TTGTTGTTTTTGAATGC
GTGA 396 Periplasmic - - 4 3 
MhL044A_00033_342A 
ATGAAAAATGCGTTAC
CTTATCT/ 
TGTTAAGTAAAATCCG
CCAAAG 342 Periplasmic - - 135 169 
MhL044A_00033_343B 
CGCACATTAGGCGAAA
AATGGA/ 
TTTATCTTCATTCAACA
CACGCTTA 343 Periplasmic - - - - 
MhL044A_00041 
GATACCGATCAGCCGA
TTA/ 
CTTGTTATCTTGAAGTT
CATTTGGAA 168 Unknown - - 173 202 
MhL044A_00066 
GGTGAACAAAGTGATG
CAAGAG/ 
TTTTTGAGGTGTGCAA
CC 131 Unknown 95 119 178 165 
MhL044A_00067_359A 
ATAAAGCAAACTGTAT
TAGCA/ 
ATAGCCTAATTCCGTTG
A 359 Outer 64 74 86 91 
MhL044A_00067_360B 
GATATGCAAACCTATA
CAGCAG/ 
AAACTCCACTGATGCC
ATTAC 360 Outer - - 122 148 
MhL044A_00068 
GCAGAAAAAATTGTTT
CAACTGCG/ 
TTTTAAACAAGGTTGA
ATAGTGGTG 284 Periplasmic - - - - 
MhL044A_00074 
TGCTCGGTTTCAACGC
AATC/ 
TTGAGTGACCCAAAGA
TAATCTGCC 278 Unknown 83 88 27 76 
MhL044A_00097 
TCAACAAAAATTGAAC
AAACC/ 200 Unknown 111 110 128 142 
141 
AGAATTTCTATTTTTTA
GGATATCTA 
MhL044A_00117 
TGCAGCTCGAACACCC
CCGT/ 
ATTGGCGTGATGATGG
GCAAAAT 98 Unknown - - - - 
MhL044A_00156 
GCCGACCTACCTAATA
TTACAA/ 
GAAATCTTCAAAATATT
GTTGAATAG 349 Periplasmic 60 69 83 86 
MhL044A_00167 
CTTTCTACTCCTGCCCC
AGC/ 
GCCTCTCCAAGTGCGA
ACTG 184 Unknown - 36 - 38 
MhL044A_00168 
GAAACAGCCACAGTTG
CTCAG/ 
TTTTCCCCAATTCACAG
AATGTT 510 Unknown - - - - 
MhL044A_00169_335A 
GACATTAAAGAAAGTG
CGATTGTG/ 
GGTAATAATTTTAGTTT
TTCCACCT 335 Cytoplasmic - - 159 194 
MhL044A_00169_335B 
GTGCGTGATAAAGTTC
GTATTGAG/ 
TGACCAATCAAGCATC
ATCTGT 335 Cytoplasmic - - - - 
MhL044A_00180 
GTGACTTCTGCGGCGG
TT/ 
CACTTTGGTTACTCCAC
CTACATT 196 Periplasmic 93 62 155 127 
MhL044A_00199 
GATGTTCAGCTTTCTCC
ACT/ 
CTCGCCATTTTTTAATA
ATAAATAGG 386 Unknown - - 106 129 
MhL044A_00201_314A 
ATGACTCAGCTTGATTC
CG/ 
TTCACGGTCAAAGTTT
ACATCT 314 Outer - - 119 143 
MhL044A_00201_314B 
GGAGAAGTGACACAA
GCGGT/ 
TTTGTGCATTAATTGTA
TCCCCTGCC 314 Outer - 122 - 149 
MhL044A_00214 
CAACCTAATATTTTTAC
ACCAGA/ 
CTCTTTTTCTCCTTGTG
TCAT 293 Periplasmic 69 79 90 96 
MhL044A_00217 
GAAACAGTTACTCATC
TTGATAC/ 
TTTACTTACTTTGAGAT
CCATAC 132 Outer 114 101 163 155 
MhL044A_00218_283A 
GTGTTATACGACCGAG
TAG/ 
GTATTTTTCAGACATAC
TTCCC 283 Outer 71 84 76 93 
MhL044A_00218_284B 
TTAAAAGAGTTCGGGG
TGTATG/ 
TGTATAGAATGGCTCA
CCGTA 284 Outer 50 45 101 74 
MhL044A_00220 
AATTGGACAAAAATTA
ATGATGTG/ 
AACACAATATTTGGTG
AGCATTA 271 Unknown 72 80 94 100 
MhL044A_00233_406A 
TCTATTGTACGTGGTG
ATGTC/ 
TACATAATGTGGGTGG
TGA 406 Extracellular - 24 70 52 
142 
MhL044A_00233_406B 
TTAGAAAAAGAAAATA
ATGCAG/ 
AAAAACCATTAAAATT
AAGAAAG  406 Extracellular 68 18 65 57 
MhL044A_00292 
TGCTCTAATGCAAACA
CACAAT/ 
TGAGGTTAATGCTTTAT
CTACATC 175 Unknown 43 81 59 70 
MhL044A_00297 
GAAACTAGCCCTTATG
TA/ 
TAAAGTGATAGGCTGT
TTTG 211 Unknown - - - - 
MhL044A_00301 
GAAGCAACATTACCCA
CAG/ 
TTGCAAAATCACATAG
AAATTTG 464 Periplasmic 118 128 194 184 
MhL044A_00308 
ATCTCAAAAGCAGGAC
GA/ 
TTCTGTGGCTTTCATTT
CAGG 218 Periplasmic 133 - 141 173 
MhL044A_00309 
GAAGAGGCGAAAACT
GAATCAT/ 
TTCTGCTTTTGGTGCTG
CTAC 500 Periplasmic 135 - 179 193 
MhL044A_00323 
TCTGAAGTCGAATTTA
ACCGC/ 
AGGTTTATCCAATTTCT
CAAG 184 Outer - - 182 205 
MhL044A_00327 
GAGCCGTTTAAAGTAG
TTACC/ 
TTTGCTTCGTTCGAACC
CTTC 298 Periplasmic 12 - 32 26 
MhL044A_00334_401A 
ATGAATAAGCATTGTT
TTCGC/ 
TTTCTGAATATTGCCAC
CC 401 Outer 38 37 49 45 
MhL044A_00334_401E 
CGGTTAGGCATTACCT
TATC/ 
TTCACTGCCCAATGTAT
TGC 401 Outer - - 167 198 
MhL044A_00334_402B 
ATCCAGCAAAGTGGCG
AAACGG/ 
TACAAACTGCGATGCA
ATAATCCCCT 402 Outer - - - - 
MhL044A_00334_402C 
AATGAAAAAGGCGGT
ATTTATATC/ 
TGTTAAATTAAACCAC
GTCCATA 402 Outer 25 21 26 29 
MhL044A_00334_402D 
ATGACGCCTGAAATTA
TTCAAG/ 
ATTGAATTTCTGCGCA
AAGGTG 402 Outer - - 148 185 
MhL044A_00334_402F 
GGCAATAAAGCGAGC
GTGA/ 
CACCCCACTTGTCCCTC
C 402 Outer - 68 33 58 
MhL044A_00334_402G 
CTGGGCAATAAAAACG
AAAGC/ 
GGCATTAAAAGAACCT
ACAG 402 Outer - - 137 172 
MhL044A_00334_402H 
GATGTGGTGACAGCAT
TA/ 
CATATCGGATTTGATTC
GTTGA 402 Outer 9 5 3 7 
MhL044A_00335_299A 
CTTGTACAACAAGCAC
GCATTG/ 299 Outer - - - - 
143 
GGTAAAAGAGGTATA
GAACAGGTC 
MhL044A_00335_299B 
CATTCGATGAAACAAA
AAGGTGAT/ 
GGCAAACACGTCATAA
CTAAA  299 Outer - 116 105 137 
MhL044A_00341 
GAGACAGGTAAAACAT
ATCGTTT/ 
TTTGAAAATGATCTGG
TTTTTTGG 547 Periplasmic 30 138 100 107 
MhL044A_00349 
CAAACCATCACAGGAG
CCGG/ 
GTAGAGCGAATTTCCT
TGTCC 346 Periplasmic - - - - 
MhL044A_00367_360A 
GGGAAAGAACCATCAA
AAAG/ 
GTTATCAAAAAATCGA
GTGATAAA 360 Periplasmic 51 71 66 73 
MhL044A_00367_360B 
TTTGATAACCCAGAAC
CAACAT/ 
TTTTCTTGTTAATTCCTC
TTGATAG 360 Periplasmic - - 56 66 
MhL044A_00375 
ATGCTGAAAAAAATCG
GAC/ 
AGTAATAGTTACATCA
AAGTTAAG 347 Periplasmic 42 56 41 50 
MhL044A_00376 
AGTTCAGATACAACCT
CTAAGTCTC/ 
TAAACGACGAGCCTGC
CA 173 Unknown - - - - 
MhL044A_00396 
GGAGAAACAACGGCC
AGT/ 
TGGCGTTGTGGTCATG
TTA 103 Unknown - 8 37 28 
MhL044A_00415 
GGCGGCAAAGTTACTG
ATAATATT/ 
ATATACATTTGCAGTAC
GAGGTG 98 Unknown - - 183 206 
MhL044A_00453 
GCAGACACTTACATTA
CTGAAAATC/ 
AGCCCAACCGCTGTTG
TTACGTC 203 Unknown 127 109 170 170 
MhL044A_00463 
AAAGATGTTACTATTCC
AACTG/ 
TTTCTCAAATGCTGTTT
TAATG 299 Unknown - - - - 
MhL044A_00478 
AATGATGTTGTTAATAT
CTCCAAAATT/ 
ATTTTCCTTGGTGACTT
TCAGCA 324 Unknown - 16 17 20 
MhL044A_00482 
AATTTGCTCACTATTAG
CGAG/ 
AGTGGTTTCTAGCTTG
ATATTAC 190 Unknown 41 22 43 37 
MhL044A_00490 
AATATAACCATTGAGC
TTAAACAG/ 
AAAATAATTCGACCGC
TTACAAA 478 Cytoplasmic 54 42 68 64 
MhL044A_00491_345A 
GAAACAACCTCTCAAG
CAGAACTA/ 
TTTGACATCCCAATGG
CGAGC 345 Outer - - - - 
MhL044A_00491_346B 
CAAGAAATCAACTTAG
ATAACC/ 
ACTTAAATTGCGATCTT
TTCC 346 Outer 77 95 88 103 
144 
MhL044A_00500_395A 
TCTGATTTTTGGAAAA
GCGACCTTA/ 
ATAGGCTAAAGAGGA
ATAACCAGC 395 Periplasmic - - - - 
MhL044A_00500_396B 
AAAGAAGGGAATTTAT
TTGTTG/ 
ATTTAGACCGAAATTA
CTTTCA 396 Unknown 17 20 20 24 
MhL044A_00536 
AAACGTGGCGGTGGG
AG/ 
TGGAATTAAGTTACAT
TGTAATGGCGTG 189 Unknown 132 129 192 189 
MhL044A_00545 
GCTCCGGTAAATACGT
TGATTA/ 
CTCCGATAAACTCACCC
CATA 531 Periplasmic - - 120 145 
MhL044A_00566 
ACCTCACTGCGTTTTGG
TTAT/ 
TAACGCATCCACTTTTT
TCAATAA 328 Periplasmic - - 125 151 
MhL044A_00567 
GAAACCTCATTCCGCTT
TG/ 
CAATGCATCAATGGCT
TTAACT 327 Periplasmic - - - - 
MhL044A_00570 
CCGTTCGTACAAGAAG
CAAA/ 
CACGCCCCAAATCGCT
TTGTA 369 Unknown - - 81 98 
MhL044A_00578 
GATAAATTAGTGATTG
CCCACCG/ 
AAATTCCACGCCCGTA
TCAG 357 Unknown - - - - 
MhL044A_00591 
ATGTCAAAGAAGAAAA
AACA/ 
ATGCTCTCTAATACTTG
CTA 367 Outer 67 60 78 81 
MhL044A_00592 
ATGAAACAAAAAAAAT
TAAATACTAC/ 
AATTGTATTAGCTGTAC
CTG 394 Outer 73 82 93 101 
MhL044A_00643_396A 
GCACCTTTCGTAGTAA
AAGA/ 
ATCAACACTTTCATAGA
AACC 396 Outer 11 11 7 11 
MhL044A_00643_397B 
ATGTCAATGCCAAATG
TAGAA/ 
GAATGAACTACCAATG
TTGAA 397 Outer 59 75 72 83 
MhL044A_00644 
GATACTATTGGTTTCGT
AGATC/ 
TTTTTTCGCTTCTTCTG
GTTTAG 263 Outer 65 44 67 68 
MhL044A_00653 
GCCGCTGAAAAAATAG
TC/ 
TTTTACAATTTCAAATT
CTAAACCT 158 Unknown 57 83 92 94 
MhL044A_00663 
GAATCGTTCAGAACAT
TAACC/ 
TAAGCCCGCCATTTTG
ATAAT 162 Outer - - - - 
MhL044A_00670 
GTACATTTTAGACCGCT
TGGCA/ 
GCCGTTTGGTGTAACA
GTTGTG 159 Extracellular - - 185 207 
MhL044A_00720 
AAAGATGAGCTTGTGG
TATTTAG/ 312 Periplasmic - - 54 62 
145 
TTCGCTGATTTCTGCAA
AAC 
MhL044A_00752 
CGTTTAACCGTTTATTG
TAGTG/ 
TTTCGCTAATTTTACTT
CATTTACCC 344 Periplasmic - 134 52 110 
MhL044A_00780_305A 
CAAAGGCTGTCTGACG
TAGAT/ 
GCCTATCCCAATTTCCA
CTTCAT 305 Outer - - - - 
MhL044A_00780_306B 
CTTAACTGGAAGAAAC
CTTGG/ 
ATCGGAACCTAAACCA
ATATAAA 306 Outer 62 25 28 40 
MhL044A_00782 
CAGATTCAGCAAAAAA
TCCAAC/ 
AATCGGCGTGCCTTTA 387 Outer 63 - 85 89 
MhL044A_00790 
GCAAATGAAGTGAATG
TTTATTCTTA/ 
TTTTTTCTCAGAGAAAT
CGTCAAA 342 Periplasmic 130 - 144 174 
MhL044A_00809 
GCGTGTAATGAAGAAA
AAGCG/ 
TTTTGCTGCTTTTAACT
CTTGGT  364 Periplasmic - - - - 
MhL044A_00814 
ACGCATAAAAACAGCG
ATGAGC/ 
GCCGTCCCAAGCTTTA
ATTGC 273 Outer 101 29 16 54 
MhL044A_00822 
TACTTATTGTTGTTTTG
GGTTA/ 
ATTGTTCATAATTTGCT
TAGCCG 327 Periplasmic 49 57 61 65 
MhL044A_00827 
GAAGAAAGAGTGGTG
GCGTTAG/ 
TTGACCGACATATTGA
ATATTGGC 314 Periplasmic - 10 5 9 
MhL044A_00839 
CAGTTTGAACACAACG
AATCC/ 
AACACCGATAAATGAC
ATACCTG 527 Periplasmic 1 3 10 6 
MhL044A_00843 
ATGAATATCTTACAAG
CAGGCG/ 
GCGACCCCGTAGATAA
TCC 155 Periplasmic - - - - 
MhL044A_00855 
GTACCGCCGGAAAAAA
CA/ 
AATTTTACATAGTGAG
TGGTG 197 Unknown 128 90 189 171 
MhL044A_00867 
GGTGAATCCACTTCTG
CGGT/ 
ACGAACACGTAAGACT
TGCC 166 Outer 119 115 150 160 
MhL044A_00869 
GTGAATGCTTCCGGTA
ATAAC/ 
TTTTCTTGGTAAATAAC
GAGCC 426 Outer - - - - 
MhL044A_00870 
ACACCAACTAGCCCAA
GC/ 
GTAAATTTTCCAACCTT
CAGCTT 122 Unknown - - - - 
MhL044A_00876 
CTACTTGAGCGTATAA
ACAACAAA/ 
TTGTACACTAATATCTT
TACCGAA 257 Periplasmic 84 31 40 60 
146 
MhL044A_00931 
ATGTCTAAATGTCCTGT
TACAC/ 
GAGTAAACCCGGTTGA
CCTA 502 Periplasmic - - 127 158 
MhL044A_00964 
ACAACAGAAAGCATTA
ACCAA/ 
TTTACGGGCGTTATAA
ATCTT 251 Unknown 32 49 42 44 
MhL044A_00981 
AGCAATAAATCGACTA
AGAAGCC/ 
ACGAATATTGCGATAT
TTCTCTC 363 Unknown - - 126 153 
MhL044A_00991 
GATATCAAATTTGTGA
TGGAGC/ 
CTTGCCGCCCATCCATT
TAT 238 Periplasmic 16 - 18 21 
MhL044A_00993 
ATGGGAACTAGACTTA
CAACCCT/ 
AGCTGCTCTAGCAAAT
TGAAGAG 953 Cytoplasmic  - - - - 
MhL044A_00993_476A 
ATGGGAACTAGACTTA
CAACC/ 
AATGTTGTTATCCCATT
GCTGC 476 Extracellular - - - - 
MhL044A_00993_477B 
GGTGATTTAGCTGGTA
TTA / 
TCTAGCAAATTGAAGA
GAAGAT 477 Extracellular 31 32 57 43 
MhL044A_01009 
GATCTAAAAATCGGTA
TGTCAATT/ 
TACTGCATCTTTGGTAT
GGAA 333 Periplasmic - - - - 
MhL044A_01030 
ATTGAAACGAAACAAG
CAGAG/ 
AATGACTTTTGCAGTAT
ATTTGAG 102 Unknown 106 94 157 144 
MhL044A_01032 
CAACAGAACAATTTCC
ACACCA/ 
TTCATAGCCAAATTCTT
TCGCCTC 368 Unknown - - - - 
MhL044A_01039 
ACTTCCGTTTACCAAG
GC/ 
TTCCAGCTCAACACCAT
A 219 Periplasmic - - 80 97 
MhL044A_01040 
CATCACGAAATCAAAA
TGTTAGAT/ 
AACTTGCTCTAAATATT
CAAATAAAC 149 Periplasmic - - - - 
MhL044A_01046_490A 
GCAAAAAATTCTGAAA
AAACGACC/ 
TTTCTTGTCGGTTTTGG
CAGTAT 490 Periplasmic 44 - - 46 
MhL044A_01046_491B 
TTTGAAGCAGGTTATT
CGGTG/ 
CTTAATCTCAAACTCTC
GTTGTAG 491 Periplasmic - - - - 
MhL044A_01047 
GATGATAAAAGCAACG
AAAATAAA/ 
GTAAGTATATCCGAAC
GGACTT 548 Periplasmic 74 39 71 71 
MhL044A_01048_330A 
TTGGTAAAACAAGCGA
CGAG/ 
TACTTTATCCAACATAT
AATCCAC 330 Outer - - - - 
MhL044A_01048_330B 
CGTGGGAGAAATAATA
CGGACG/ 330 Outer 22 65 200 113 
147 
GTAAGCCGCACTGAGT
TTCACAT 
MhL044A_01049_281A 
GCAGTGAATGTGCCGG
AT/ 
AATCAAGCTCGAATAA
TCCAAA 281 Outer - - 145 182 
MhL044A_01049_281B 
TTGGATTATTCGAGCTT
GATTG/ 
GAAGGTTTTGATGGCG
GAG 281 Outer 39 - 60 55 
MhL044A_01050_469A 
CAAGGTGAAAGGGTG
CGT/ 
AAAGAATAAACGCCCG
TTTGCG 469 Extracellular 80 126 - 126 
MhL044A_01050_469B 
AACTTGCCGAATGACA
CCGA/ 
TCCGACAATAACTTTA
GCATTGGTA 469 Extracellular - - - - 
MhL044A_01070 
AACGGTTCTTCACAAG
CAAAT/ 
AACATCTAACTCGGTTT
TATTGAAAC 120 Unknown 131 133 165 179 
MhL044A_01074_416A 
ATGGAACTCAATCGTA
GAGA/ 
AATAAATGTACCCACTT
CACGG 416 Periplasmic - - 75 92 
MhL044A_01074_416B 
GAAGTGGGTACATTTA
TTCACC/ 
TTTAACCGCACATTTTT
TGAAG 416 Periplasmic - - 102 122 
MhL044A_01077 
GAAGCCCCTAAGTTAT
CC/ 
TTTAGCTTGAGATTCAC
GTACAG 142 Periplasmic - - 121 147 
MhL044A_01082_405A 
ATGTCTGTGATGGCTG
CCG/ 
ACCGATAGAGCTGTAA
TGGTGAG 405 Periplasmic 14 12 15 14 
MhL044A_01082_405B 
TACGACAACAAAGATT
ACAAAGGCTA/ 
TACCTCAATCGCACCGT
TAAA 405 Periplasmic - - - - 
MhL044A_01086 
GAGTTTCAGCAAGATC
CCAAAG/ 
AAATAGTTTCTCTAAG
GTCATAAAG 464 Outer - - 130 163 
MhL044A_01093 
ACGCAATGGGAGAAA
ATC/ 
GCCTTGTTCAGATAAA
ATCAT 275 Periplasmic 70 51 89 85 
MhL044A_01129 
AATATAACCGCTTCAA
CTGAG/ 
TTGATTTTTCTTAGTGA
GTGCATTT 149 Unknown 126 113 152 164 
MhL044A_01130 
GGCCAAAAAGGCAAA
ACAACC/ 
TAATACCCAAACACGG
CCGTAAT 368 Outer - 100 - 121 
MhL044A_01152_388A 
AAGCAACAATGTTTAC
TTGG/ 
AAAATCAATTTGTGGC
AGAACG 388 Outer - 106 69 104 
MhL044A_01152_389B 
GTTCTGCCACAAATTG
ATTTTAACT/ 
GCTATACGGCTCGGTG
TA 389 Outer - 125 184 191 
148 
MhL044A_01182 
GCATGTAGCAGCTCAT
CAGAT/ 
GTATTCTAATACTGCAC
GACGG 161 Outer - - - - 
MhL044A_01183 
TCTGATGTGCGAATTTC
TATTGA/ 
TTTAGTTAAGTATGGT
GACCATG 428 Periplasmic - - - - 
MhL044A_01192 
AGTGTTAAAACCTCAT
CACTTACT/ 
TTGATGTTTTTGTTTAA
GGCTG 108 Unknown - 117 187 190 
MhL044A_01223_751A 
CTTCAATACTACCGTGA
TTT/ 
AAGTAGCACTTTACCTC
CT 751 Outer 20 23 47 33 
MhL044A_01223_752B 
AGACCGACCCCTCACG
CTTA/ 
GCTATATCCCAGTTTGA
AGCCGG 752 Outer - 14 - 15 
MhL044A_01226 
AAAGAGTATATTGAGG
TGCGTA/ 
TTTCTTACTCAAGAAGA
CCAC 212 Periplasmic 29 7 12 19 
MhL044A_01255_350A 
GTGGCTCAAACTGCTT
CAA/ 
GTTTACGTTTGCACCGT
GG 350 Outer - - 202 215 
MhL044A_01255_350B 
GATTCTGCCCTTCACGA
AAATGT/ 
TCCACGAGCTGATAAT
TGACCAC 350 Outer - - - - 
MhL044A_01263 
AAATCTGATGAAATCG
CTGTGA/ 
GTAAAGAACACCTTTC
GCTT 315 Unknown - - - - 
MhL044A_01272 
GCTGAAACATTTGTGA
CTATC/ 
CTTAATCCAACCTTTCT
CTTTAT 320 Unknown 13 19 14 17 
MhL044A_01284 
GATGAAGGTAATAACA
CACAGG/ 
TAATATCATTGAAGCC
GTTGGTC 212 Unknown - - 171 201 
MhL044A_01319 
GCGGAAGGTTTGCTAC
TTACCC/ 
ATCAATTTCTAACGCCC
CCAAAC 342 Periplasmic - - - - 
MhL044A_01388_291A 
CCAAGTATTCCTCAAG
AGC/ 
AACCACATCACATTCAT
TATTTA 291 Periplasmic 100 98 139 138 
MhL044A_01388_292B 
CCTAGCCAATTATCAGT
GTTA/ 
GTTTCCTTTTTTATGCC
CC 292 Periplasmic 94 86 118 120 
MhL044A_01397 
GGTAACTTAAGTAAAG
TGAGTG/ 
GCCATCATATGCTGGG
GTTTG 284 Outer - - 48 53 
MhL044A_01399 
TCAGATGCAAAACTAA
AAAGCCAG/ 
CTCACTTAACATTTTCG
CTAATTC 227 Periplasmic - - 131 166 
MhL044A_01408 
TTTCTCACCCACATTCA
TTTGTT/ 212 Extracellular - - - - 
149 
ATCGCATATAATCTCCA
CTTTTT 
MhL044A_01413 
GGTATTGAAACCTCTT
GTGATGAA/ 
AATCGGTGGTAATTCG
GTC 343 Extracellular 28 43 134 82 
MhL044A_01414 
AAAGAATTAGAACAAT
CCAACG/ 
GAATTGTTCGCCATACT
TCAG 259 Outer 109 89 97 118 
MhL044A_01424 
TTAAATACCTTGCCTGC
/ 
AAACAACGCCATATAA
AACT 481 Periplasmic 33 35 38 36 
MhL044A_01458 
CAAATTAAGCAATTAC
CGCC/ 
TTCCACTTTCCATTTAC
TG 139 Cytoplasmic 92 102 132 133 
MhL044A_01473 
GCTCCACAAGCTAACA
CTT/ 
CATAGTTACTTCTTTTG
AACCTTG 378 Outer 113 73 84 108 
MhL044A_01477 
ACTTTAGCAGGAAGCC
CGAT/ 
TAATACCGCTAACGCC
GCCT 165 Periplasmic 6 63 50 42 
MhL044A_01479 
CGACCGCAACTGAACA
TTCC/ 
GCTAAATTGACCCATC
GTACCT 474 Periplasmic - - - - 
MhL044A_01483 
GTGATTTTAGGTGCGG
CACT/ 
AATTCTAATCCCAGCA
GTCACAAC 238 Outer 123 124 186 181 
MhL044A_01484_408A 
AGATATTATCCTTCCGC
CAC/ 
AACAACAGAAATCCAA
CCTTTTT 408 Outer - - - - 
MhL044A_01484_408B 
GTAGCAACCAGAACTA
ATCAGGGA/ 
AGCAGTCTCACCTACA
TTATCCA 408 Outer - - 197 212 
MhL044A_01491 
GAGGTAAACATTAAAC
TACTTGGT/ 
ATGAGGACATTCCGGT
GT 353 Periplasmic - - 169 200 
MhL044A_01498 
GATATTGCCGATGTCA
AACCG/ 
TTTAATTAATTTTTCCG
CTTTGGCAA 150 Unknown - - - - 
MhL044A_01531 
AGTGCCGAGCTGATTG
TC/ 
AAGCAGATCATCATCG
TCCTCC 143 Unknown - - - - 
MhL044A_01536 
AATATACCAACTTCCCA
CTAC/ 
ATCCTTTTTAATCCTTA
ATTTACC 225 Periplasmic 112 97 153 146 
MhL044A_01541 
GCTGATTATTTGAGCC
AAGAC/ 
CTTAAAATCCCCCAACT
CA 372 Unknown 40 64 36 51 
MhL044A_01548_276A 
GAAACCCACCAAATCG
GCA/ 
GAGACGAACCCAATCC
AGCAC 276 Cytoplasmic 58 17 24 34 
150 
MhL044A_01548_276B 
CAACAAAAAAGCCTGT
GGGCAA/ 
GAGTAAAAGCACTACC
TTCGCC 276 Cytoplasmic - 59 103 99 
MhL044A_01561 
GATGAAAAAGCACAA
GCACCT/ 
GTTAAATAATTTTAACG
CTTCTTGG 276 Unknown - - - - 
MhL044A_01562 
TGTAATGATAAAGCCG
AAAAGTT/ 
TTTTATCATCGCCCCTT
TAAAC 263 Cytoplasmic - - - - 
MhL044A_01564 
ATGAAAGTTGGATTAG
TGCTG/ 
TTTGGCTAAATATGCCC
TTAAA 280 Extracellular 47 28 112 72 
MhL044A_01566 
AAATTAGTTTCTTTGAT
TGTCGT/ 
GCAATCCATTGGTTGA 237 Periplasmic 37 55 44 48 
MhL044A_01570 
GAAGGTCGTTTAACTG
TTTATTG/ 
GTTTGCTAATTTAATTT
CCGCC 345 Periplasmic 78 58 114 102 
MhL044A_01577 
GTGCAATTAAATCAAG
CATTACCT/ 
TTGCGTTAATGTTTTCA
CCAA 185 Unknown 2 - 11 8 
MhL044A_01631 
ATGTTTTCTTTTTATGG
TAAGA/ 
CCACTCATATCCAACTT
TG 184 Extracellular 48 47 63 61 
MhL044A_01638 
AAATCGCCCGAGTTAA
TGC / 
ATCATTTCTTATTCGCC
AAAACGT 274 Unknown - - - - 
MhL044A_01650 
CAAGAAATTAAACTTTT
TGAACAGA/ 
TTCTTCATTTTTAGCTG
GAGGT 272 Periplasmic 103 66 162 136 
MhL044A_01656 
GAGACTATCGCTCTTG
CAGTA/ 
AATAACCTTTAAATCAA
CCGGAA 292 Periplasmic - - - - 
MhL044A_01672 
ATGTGGCGAATTTTTAT
ATATTTCT/ 
TTTTGATTTTTTGCGGT
TGCT  437 Outer 90 120 77 112 
MhL044A_01681 
CAAGAAACTATCACTTT
TGCG/ 
TTTCCCAGCCATCCAAG
TATTA 241 Periplasmic - - 45 47 
MhL044A_01683 
CTTTTCTCTCAACCCAA
ATTC/ 
AGATTGGCTCATTTCAT
TG 587 Cytoplasmic 107 91 123 130 
MhL044A_01687 
AATCAACTGATTGGGC
AATGG/ 
CTGTTTTATACATTGCC
CTTTAT 166 Unknown - - 19 23 
MhL044A_01700_465A 
GCGACTGAAAATAAAA
AAATAGAAGA/ 
ACAATGCAAGCGATGT
A 465 Outer 61 72 74 84 
MhL044A_01700_465B 
GATTATCCTGTGGTAG
ATAAAAAT/ 
AAACTTCATTTCAAATG 465 Outer 85 87 91 105 
151 
CTAAAC 
MhL044A_01701_292A 
GATGTTCAATCTGCCA
AAGTTC/ 
ATAAGGATCATCGGTA
TTTTTTGCGT 292 Outer 140 - 156 186 
MhL044A_01701_293B 
TTTGGTAAAAGCTCTA
CGACAC/ 
TTCTATTTGACGTTTTC
CGC 293 Outer 21 33 9 25 
MhL044A_01714 
AACTCGCAAGGCGATG
ATCC/ 
TCCATCATAAATCGGTT
TAAGCAC 179 Cytoplasmic - - - - 
MhL044A_01740 
TCAAACAGTTACACCA
CGGAAAC/ 
TTGAGAACTGGATGCC
G 204 Unknown - - 198 213 
MhL044A_01744 
GAGGATATGATTCAGG
AAAATAAA/ 
GTGGCGTTTTTGCTGA
AGTAA 446 Unknown - - - - 
MhL044A_01777 
GATGTATTAACCAGTA
TTAAGCC/ 
TAAACATTGGCTAAAT
TCGTCAG 324 Periplasmic 116 107 160 159 
MhL044A_01802_405A 
CACTGGGTTGATATTA
AAAACTCC/ 
CAAGCGGAACACTTCG
GTTT 405 Periplasmic - - - - 
MhL044A_01802_406B 
TTTGCGGAAGAAGATG
GTTCA/ 
AGCCCCCACAATTTTCT
CAATG 406 Periplasmic - - - - 
MhL044A_01804 
GCACCGCGTGAGTATA
AGC/ 
GATACTCGCTTGGTTG
TCGGT 195 Periplasmic 110 - 191 188 
MhL044A_01831 
CAAGTGCAGGCTGAAA
AAGCAG/ 
TTTCAACCCGGCTTTAA
TCAGATC 117 Unknown - - - - 
MhL044A_01858_294A 
ATGAAAAGTGCAGGA
GGTTATAC/ 
TGCATTTGGAATACGG
AAG 294 Outer 139 - 154 183 
MhL044A_01858_294B 
TTTGATTACCGTGATAA
TGCTGC/ 
GTTACGTCCAGGTTCA
TAATAGC 294 Outer - - 174 203 
MhL044A_01859 
GAAGAAACAACAGCG
GAATTA/ 
CTTCTGAATCAGGAAA
AGCGAG 127 Outer - - 190 208 
MhL044A_01863 
GAAGGAACAACGCTTG
CAGAAAA/ 
TTTCACGATGTAGAGG
TTACGC 544 Periplasmic - - - - 
MhL044A_01901 
AAAGCAGATCCTAAAT
TTGTGG/ 
TTTCTTAGCATCTGCTG
CTTTA 241 Periplasmic - - - - 
MhL044A_01906 
GAAAATAACACTTGGG
TAGACA/ 
GAAGATAGCCTCTAAA
CGTAC 314 Unknown 75 76 53 80 
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MhL044A_01917 
CAAGCAGGTGATGTGA
TATTCC/ 
GAACTTCACCCCGAAA
CCGGC 223 Outer - - - - 
MhL044A_01943 
ACCACCGTTTACGATG
CAGAA/ 
GTATACACGCATACCA
ACAC 372 Outer - - 161 195 
MhL044A_01953 
TCAACAGAGGTGCAAC
AAC/ 
TTTTTCAATGCGGATCT
TCAAC 210 Unknown - - - - 
MhL044A_01967 
ATGCAGAAAAAATCAC
TCATATC/ 
ATACAACACGTCTGCC
AGC 171 Periplasmic 117 - 136 156 
MhL044A_01970 
GCTTGTAGCAGCAATG
AACCG/ 
GAGAAGTAACATACTG
CCCCATT 187 Unknown - 132 - 167 
MhL044A_01972 
GAAACCACACCGGCTC
AACTTC/ 
GAACGTATGTGAAAAC
TCAATATAG 484 Unknown 97 - 113 128 
MhL044A_01978 
ACTATCATTAAGATTG
GTCACT/ 
TTTTGAAATAACATCTT
TAGCC 327 Periplasmic 18 27 22 27 
MhL044A_01987 
GCGACAAAGAATACAA
AAG/ 
ATTCATTACATAAAACT
GATTAGTC 219 Unknown 115 114 151 157 
MhL044A_01988 
AACACTAACTTCAATTT
ATCGG/ 
ATCGAACAAGCTCTTC
ACA 392 Cytoplasmic 19 85 95 78 
MhL044A_01992 
ATCACTGATGTATTAG
GGCGT/ 
TTGCATAAAGAATGTG
CCTTTTG 367 Unknown 36 46 133 87 
MhL044A_02017 
ACAGAACAAGAGCAAT
TAGCC/ 
TTTGCTATAATCATCAC
TTAATGTAC 108 Unknown 138 - 199 199 
MhL044A_02039_635A 
GGTGATAATGGTCAAA
CAATC/ 
TTTATTACCTGCATTGA
TACCATCT 635 Extracellular - - 13 13 
MhL044A_02039_636B 
AATGTTGCGTCTAATCT
GATACC/ 
CTGGTATCCAACGCCT
ACAC 636 Extracellular - - 201 214 
MhL044A_02040 
GTGGATACCGGTTCTA
TCACGGT/ 
GGTGCACCAACAGTTG
CTAAAC 161 Extracellular - - 129 161 
MhL044A_02044 
ATGAACCAATTCTTCCC
TCTAATC/ 
TTTTCTATACCGCTCAT
CCGTC 384 Periplasmic - - 164 197 
MhL044A_02047 
TGTTCATCAAGCATTAA
CCCAG/ 
ATCAATATTCTTCAACT
CTTCTTCCG 251 Outer - 137 188 196 
MhL044A_02068 
ATGATGGCAGAAACCA
CTTCTCG/ 398 Periplasmic 35 41 35 39 
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ATCAAACAACGCTTTG
CCAAGG 
MhL044A_02078 
CAAGATAAAATTCAAA
ATGTAGCA/ 
AGTTTGTTTAGCTTCTT
TGAT 319 Unknown - - - - 
MhL044A_02092 
GCTCCTGTCGGAAATA
CATTTAC/ 
GAAACGATAAGTTGCA
TTCGCG 172 Unknown - - 180 204 
MhL044A_02104 
TGGTTGATTCCATTAAC
TGTCG/ 
GAAGCGTCTTTCAAAT
GGAT 524 Periplasmic - - - - 
MhL044A_02106 
AAAAGGAAAAGCACAC
CACGG/ 
ATCATATTGTCTATACG
GATTTG 291 Periplasmic 108 112 158 154 
MhL044A_02132 
CAAGAGATTACCGTGT
TTGCTG/ 
ATTTACAGGATAAAAC
CCAGCTGC 251 Periplasmic 3 - 6 5 
MhL044A_02137_414A 
ATGAAAAAACAAGACA
ATATTGAC/ 
GTTTGAGTAATGGTAG
CTTAAA 414 Periplasmic 56 50 62 67 
MhL044A_02137_414B 
TTAGGCTCTATCACAG
CAAATC/ 
TTGTGTGTATTTAGGCT
CTTTA 414 Periplasmic - 136 149 176 
MhL044A_02139 
GCCACCAGCTCAACAG
AA/ 
ATGGGAACTGCCTGCT
ACATC 371 Cytoplasmic 53 131 110 116 
MhL044A_02192_691A 
GCAACCTATTCACCAA
CCTAT/ 
ATAGTTAGCACGTTGA
ATGCC 691 Unknown - - 46 49 
MhL044A_02192_692B 
GATAATTCAGGCTCTA
GCGGTGT/ 
TTGATAACCCATGCCA
ATACTACC 692 Unknown - - - - 
MhL044A_02221 
AAAACCATTGTGGCGA
TTGATG/ 
ACCTACCGTGATCTGA
TAAT 398 Outer 99 - 87 111 
MhL044A_02240 
TATCCCCTTTTATTTTC
GCTG/ 
AAATAGCTTTTCTAAA
GTGAAAAAGA 469 Outer 7 4 2 4 
MhL044A_02243 
ACAGGGAATATGAGCA
ATGA/ 
TCTTCTGTATTTACCTG
CC 465 Outer 27 38 25 32 
MhL044A_02244 
GAGCAGAGCCAATACC
AAC/ 
TTTCGGCACAGTTACA
CGATTTA 281 Unknown - - - - 
MhL044A_02245_515A 
GTGAACAATAAACGCA
GAAATC/ 
GATGGCATTGGCTTTA
TGA 515 Periplasmic 76 26 99 79 
MhL044A_02245_516B 
TTTTATACCAGTTGGGC
GATTT/ 
GGCTAATTTCTCTACCT
TCGC 516 Periplasmic - - 51 59 
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MhL044A_02275 
TCGGATTGGGAAATAA
TAGAAG/ 
CTTACAATATCTATTTT
GCATAGC 152 Unknown 89 92 116 119 
MhL044A_02282 
GAATCAATAGAGAATC
CACAAC/ 
GAAACTAAAGCCAACA
TTTACT 954 Cytoplasmic 4 1 1 1 
MhL044A_02282_467A 
ACAGAATCAATAGAGA
ATCCACA/ 
TTTACCGTTTAAGGCCA
AT 467 Outer - - 98 115 
MhL044A_02282_467B 
AAAACAATCAGTAACC
ATGCAA/ 
GAAACTAAAGCCAACA
TTTACT 467 Outer 88 53 58 77 
MhL044A_02291 
CAACAAGCTGAACGTA
AA/ 
GCAATAATAGCAGTAA
CGCCAG 127 Unknown 87 105 115 124 
MhL044A_02292 
GGGACGTTAAGTACAT
CATC/ 
TTTTATATTTTTCTTCGC
CCATTC 202 Unknown 105 61 31 75 
MhL044A_02301 
AACACTAACTTCAATTT
ATCGG/ 
CACACTTCCTGAAGCG 239 Extracellular - - - - 
MhL044A_02304 
GGCAAAATGACCCAAA
CGGT/ 
ATCTAGTTCTTCAAAGA
ATCCATCTT 328 Unknown - - - - 
MhL044A_02332 
AACGAAACTGGAGAA
AGTTG/ 
AAAATGTTTCCACTCTA
ACCC 198 Unknown 104 96 147 140 
MhL044A_02351 
ACCTTTGTTTACTGCTT
AGAGGC/ 
GTAGAAGTTATGTAAG
CTGAACGG 533 Periplasmic 10 - - 12 
MhL044A_02362 
GCCGAACGCCAACTAC
AATG/ 
ATTCCTATTTTTCTGTTC
TTGCCG 222 Unknown - - 196 211 
MhL044A_02372 
AACACATTAACATTCTC
TACC/ 
TTTGAACTGGTGAATT
GCAT 195 Unknown 55 52 55 63 
MhL044A_02386_395A 
GAAAATAACGATGTAG
CGGTG/ 
GCCGTAATCCTGATCTT
TTTTC 395 Outer 134 - 176 192 
MhL044A_02386_395B 
TTCAAAAATCGGGGCA
AAAATAC/ 
TTTCATCTCCATTCCCA
ACATA 395 Outer 125 - 140 168 
MhL044A_02387 
CAAGGTCCATCTATTGT
TGCAGAC/ 
TTTCGCCGCTTTGCTTA
C 485 Outer - - - - 
MhL044A_02388 
ATGAAAAAAATTGCCT
TAC/ 
TTTATCGGTGTAGGCA
TAG 470 Outer - - - - 
MhL044A_02398 
CAAACACCGCCAACTA
CAATGCC/ 
TTCTACCGTTGCTTGCC 112 Cytoplasmic - 2 - 2 
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CAATTCC 
MhL044A_02399 
ATGACACAAAATAATT
TTCGCAAAG/ 
TAACTTATTCAGCCAA
GCTAAAAA 439 Extracellular - - - - 
MhL044A_02400 
GCTTGTAGTACAGTGG
TTACCC/ 
TATGCAATTTGCCGCTA
ACGTTTTT  138 Unknown - - - - 
MhL044A_02410_392A 
ATGAACACAGCATTAG
AAAAAG/ 
ATTGATTGCCCCTAAAC
GAA 392 Periplasmic - - 39 41 
MhL044A_02410_393B 
CCCGATATGCCGTTTTT
CCC/ 
TTCAGGTGCATCTCCCA
CATATT 393 Periplasmic 5 13 29 18 
MhL044A_02413 
CACGCATTATCGGCTC
AATTA/ 
TCTCACACTGATATAAA
TTAACGC 130 Cytoplasmic - - 96 114 
MhL044A_02444 
GATGCTCAATCTGTTG
CAGAAT/ 
TTTTTTCGATTTTTTACC
GCCAC  213 Periplasmic - - - - 
MhL044A_02471 
CAATCTGAAAGCAGAG
TGGG/ 
AGGTAAAAATTGCCCT
AAATTTTCC 330 Periplasmic 26 48 146 88 
MhL044A_02476 
GCACCTAAATCTTTTAC
TTACTGTT/ 
TCTAGGACAGCCCCTA
AAAGT 295 Periplasmic - - - - 
MhL044A_02480 
ATGAAGAAAGCAGTAT
TAAGTGC/ 
TTTTAAAAATTCAGATA
AGTTGTC 329 Periplasmic 34 30 23 30 
MhL044A_02503_329A 
AAAAATAAAGCTGGCT
TGCGTG/ 
TGCTCTACCGTCCACAA
CG 329 Periplasmic - - - - 
MhL044A_02503_329B 
AATACGGAAGAGAAA
AAAGCAAC/ 
TAAATCAATACGGTAA
ACTGCGA 329 Periplasmic - - 34 35 
MhL044A_02512 
GCCGCATTCCAATTAG
CTGAAA/ 
GAATTTGTAGTTTACGT
TTAAACCG 493 Outer - 111 107 134 
MhL044A_02530 
TCGAATAAAAGCGGTT
GGACA/ 
TTTGGTTTTACCTTTAG
ATTGCG 183 Unknown - - - - 
MhL044A_02542 
AGCCCCCTTAAGAAAG
AAGA/ 
AATTAAGTTTTCACTCG
GCAC 126 Unknown 137 139 175 187 
MhL044A_02553 
GGCAAAGAATATATCG
AAGTGC/ 
TAAGAACACAACCGCA
TCAAC 212 Periplasmic 15 15 21 22 
MhL044A_02556_699A 
TCTGTTGTACGTAATG
ATGTGG/ 
AGCAGTAAAATGGCTG
TCTT 699 Outer - - - - 
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MhL044A_02556_699B 
AATATCACGGTAAATA
AAATGGC/ 
ATATCCTAGCTTAACAC
CAGC 699 Outer 46 40 64 56 
MhL044A_02584 
GACGTGTTTAGCGGAA
GCG/ 
AAGCAGAGAAACATTC
AGGTC 154 Outer - - 193 209 
MhL044A_02624 
AATGTAGTGTATTCTTG
CACAAC/ 
GGCTGCAAATCCAGAT
TTTCTC 143 Unknown - 118 168 180 
MhL044A_02625_350A 
AATACCGTTAATGTTG
GCAATAGC/ 
ATTGAGTTGTTCCGGC
GTTAAA 350 Unknown - - 195 210 
MhL044A_02625_350B 
AGTACATCAACGGTCA
GTGTAACAA/ 
GATAATGTAATCGGCT
TCCTGGT 350 Unknown - - - - 
MhL044A_02626 
AGTCCTGCTAATAAAC
CCTC/ 
ATGAGTATGTGTACTTT
TCCAG 92 Unknown 86 104 177 150 
MhL044A_02654 
GGACCAAAAGTAGCTT
ATACCCA/ 
ATAACTTGAATTGACA
ACAACTTC 232 Unknown - - 109 135 
MhL044A_02682 
TCATACTCTGAACATGC
GG/ 
TCGTTTCAAGCCTTGCT
GATA 107 Unknown - - - - 
MhL044A_02713 
GATCATAAAGAAACCG
GTACAC/ 
CCAATATGCTCGTAAG
CCTAC 364 Outer 136 - 143 175 
MhL044A_02723 
AAGAATGTTGATTTTA
AATTAGAAGC/ 
AATTTCCTTTACTTGTA
GCAG  377 Outer 66 78 79 90 
MhL044A_02730 
ATGAGTGAGCCAAACC
ACGCC/ 
TGCTCCGCTAGTTGGT
CTGCC 201 Extracellular 98 - - 117 
MhL044A_02757 
ACTAATACCGTTACTGC
TCAAC/ 
TTGATAAGATGAACCA
TTTGTAGA 256 Extracellular - - 108 131 
MhL044A_02777 
GGTAGCGGAGGTTCGT
CTT/ 
TTTTTTCTCGCTAACCA
TTATTGC 356 Unknown 81 70 82 95 
afor truncated genes  the locus ID is followed by an underscore with the number of amino acids the  product contains followed by a 
letter given serially for each division made. 
bsequence tag added to the 5' end of forward primer: AAAAGCGCTGAAAACCTGATCGAAGGCCGT.  Sequence tag added to the 5' end of 
reverse primer: TGGTGATGGTGGTGACCCCA 
c dashes in columns indicates cases were relative immunoreactivity measured 0. 
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Appendix B 
 
Figure B1 Circular SNP atlas of 11 Mannheimia haemolytica genomes mapped against M. haemolytica 
USDA-ARS-USMARC 183.  The outer circle shows M. haemolytica USDA-ARS-USMARC 183 followed 
inwards by M. haemolytica 587A, M. haemolytica L033A, M. haemolytica T2, M. haemolytica L038A, M. 
haemolytica H23, M. haemolytica 3927A, M. haemolytica T14, M. haemolytica 157-4-1, M. haemolytica 
L044A, M. haemolytica L024A and M. haemolytica 535A. 
 
